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Abstract 
New cardiovascular techniques have been developed to address the unique requirements of 
high risk, elderly, surgical patients with heart valve disease by avoiding both sternotomy and 
cardiopulmonary bypass. However, these techniques pose new challenges in visualization, 
force application, and intracardiac navigation.  Force feedback and augmented reality (AR) 
can be applied to minimally invasive mitral valve repair and transcatheter aortic valve 
implantation (TAVI) techniques to potentially surmount these challenges.  
Our study demonstrated shorter operative times with three dimensional (3D) visualization 
compared to two dimensional (2D) visualization; however, both experts and novices applied 
significantly more force to cardiac tissue during 3D robotics-assisted mitral valve 
annuloplasty than during conventional open mitral valve annuloplasty. This finding suggests 
that 3D visualization does not fully compensate for the absence of haptics, including force 
feedback, in robotics-assisted cardiac surgery. Subsequently, using an innovative robotics-
assisted surgical system design, we determined that direct force feedback may improve both 
expert and trainee performance using robotics-assisted techniques. We determined that 
during robotics-assisted mitral valve annuloplasty the use of either visual or direct force 
feedback resulted in a significant decrease in forces applied to cardiac tissue when compared 
to robotics-assisted mitral valve annuloplasty without force feedback.  
We presented NeoNav, an AR-enhanced echocardiograpy intracardiac guidance system for 
NeoChord off-pump mitral valve repair.  Our study demonstrated superior tool navigation 
accuracy, significantly shorter navigation times, and reduced potential for injury with AR 
enhanced intracardiac navigation for off-pump transapical mitral valve repair with 
neochordae implantation.  In addition, we applied the NeoNav system as a safe and 
inexpensive alternative imaging modality for TAVI guidance.  We found that our proposed 
AR guidance system may achieve similar or better results than the current standard of care, 
contrast enhanced fluoroscopy, while eliminating the use of nephrotoxic contrast and 
ionizing radiation.   
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These results suggest that the addition of both force feedback and augmented reality image 
guidance can improve both surgical performance and safety during minimally invasive 
robotics-assisted and beating heart valve surgery, respectively.  
Keywords 
Mitral Valve Repair, Mitral Valve Regurgitation, Robotics-Assisted Cardiac Surgery, Force 
Feedback, Augmented Reality, Transcatheter Aortic Valve Replacement 
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Chapter 1  
1 Introduction 
Mitral valve regurgitation is the most common valvular heart disease affecting 2-6% of 
the general population [1].  However, in Canada, approximately 40% of patients with 
indications for mitral valve surgery receive no operation due to the perceived risk of 
conventional mitral valve surgery involving median sternotomy and cardiopulmonary 
bypass [2].  A large proportion of these patients are elderly with multiple comorbidities.   
Similarly, degenerative calcific aortic valve stenosis has increased prevalence in the 
elderly and surgical aortic valve replacement is the only treatment for this heart valve 
disease [3-5].  Without aortic valve replacement, the one-year mortality of patients with 
severe symptomatic aortic stenosis is 30%–50% [5-7].  Nevertheless, many patients are 
denied surgery because of the perceived risk of conventional aortic valve replacement.  
Transcatheter aortic valve implantation (TAVI) has emerged as an effective alternative 
treatment to conventional aortic valve surgery in high risk surgical patients with multiple 
comorbidities [7].  Unfortunately, TAVI relies on the use of single-plane fluoroscopy and 
nephrotoxic contrast medium for valve deployment and the use of multiple contrast 
fluoroscopic images can increase a patient’s risk of acute kidney injury [8-11].  In fact, 
the development of acute kidney injury is an independent predictor of prolonged hospital 
stay and impaired early survival following cardiac surgery [11-13].   
Clearly, new cardiovascular techniques must be tailored to address the unique 
requirements of high risk, elderly, surgical patients with mitral valve regurgitation and 
aortic valve stenosis.  This chapter will review mitral valve regurgitation, surgical 
techniques for mitral valve repair, and the challenges posed by innovation in surgical 
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mitral valve repair.  In addition, these challenges will be compared and contrasted with 
those of TAVI for aortic valve stenosis.    
1.1 Mitral Valve Anatomy 
The mitral valve opens to permit the passage of oxygenated blood from the left atrium to 
the left ventricle during diastole.  It closes to ensure efficient flow of oxygenated blood 
through the aortic valve during systole and to prevent backflow of blood into the left 
atrium during systolic ventricular contraction.  Mitral valve regurgitation occurs when the 
anterior and posterior leaflets of the mitral valve fail to coapt or close normally during 
systole.  This allows blood to leak back from the left ventricle to the left atrium during 
systole.  Dysfunction of any part of the mitral valve apparatus may result in mitral valve 
regurgitation; therefore, a thorough knowledge of mitral valve anatomy is necessary for 
the understanding of both mitral valve pathology and surgical repair. 
The mitral valve apparatus consists of the left ventricle, the mitral valve annulus, the 
anterior and posterior mitral valve leaflets, the chordae tendineae, and the anterolateral 
and posteromedial papillary muscles (Figure 1.1).  The left ventricle both encloses and 
supports the mitral valve apparatus.  The mitral valve annulus is divided into an anterior 
fibrous portion and a posterior muscular portion.  The anterior portion is in continuity 
with the left coronary and noncoronary cusps of the aortic valve.  It occupies one third of 
the mitral valve circumference.  The anterior mitral valve annulus is separated from the 
posterior mitral valve annulus by the right and left fibrous trigones.  The posterior portion 
of the annulus is in continuity with both the atrial and ventricular muscle.  It occupies two 
thirds of the mitral valve circumference [14].  As the posterior annulus is primarily 
muscular and not fibrous, it is primarily affected by any enlargement or dilatation of the 
left ventricle.  Critical cardiac structures also lie adjacent to the posterior mitral valve 
annulus.  The circumflex coronary artery is adjacent to the left half of the posterior mitral 
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valve annulus.  The coronary sinus is adjacent to the right half of the posterior mitral 
valve annulus.  Dilatation of the mitral valve annulus may increase the distance between 
the anterior and posterior mitral valve leaflets, and, in turn may prevent leaflet 
coaptation or closure.  This will result in mitral valve regurgitation. 
 
Figure 1.1:  Cardiac anatomy with mitral valve apparatus.  Adapted with 
permission from Heart Pro III, 3D4Medical.com, LLC.  SVC: superior vena cava, 
RA: right atrium, IVC: inferior vena cava, TV: tricuspid valve, RV: right ventricle, 
PA: pulmonary artery, AV: aortic valve, LV: left ventricle. 
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The anterior, or septal, leaflet comprises anterior (A1), middle (A2), and posterior 
segments (A3).  The posterior leaflet comprises anterolateral (P1), middle (P2), and 
posteromedial (P3) scallops (Figure 1.2) [15].  Although leaflets usually have three 
scallops, there can be as many as five or six on a leaflet.  The anterior and posterior mitral 
valve leaflets are separated by anterolateral and posteromedial commissures.   Failure of 
the anterior and posterior leaflets to coapt leads to mitral valve regurgitation.  This may 
be secondary to any component of the mitral valve apparatus, as all these elements have 
an integral role in mitral valve leaflet motion and coaptation. 
Three orders of chordae tendineae insert on the anterior and posterior valve leaflets [15].  
First order chordae tendineae connect the free edge of the leaflets to the anterolateral 
and posteromedial papillary muscles and prevent the leaflet edges from prolapse, or 
displacement into the left atrium, during systole.  The anterolateral papillary muscle is 
supplied by the left anterior descending artery and circumflex artery.  The posteromedial 
papillary muscle is supplied by the right coronary artery or by the dominant circumflex 
artery in ten percent of the population [14].  Second order chordae tendineae insert on the 
ventricular surface of the leaflet.  These thick chordae may attach the leaflet to two 
different papillary muscles or attach one papillary muscle to the ventricular wall.  These 
chordae are required for optimal ventricular motion during systole.  Third order, tertiary 
or basal, chordae tendineae are short and broad fibers that connect the ventricular surface 
of the leaflet to the ventricular wall [15].  In total, 15 to 32 major chordae tendineae 
trunks give rise to over one hundred individual chordeae that attach to the mitral valve 
leaflets.  Elongation and rupture of the papillary muscles or chordae tendineae may also 
lead to mitral valve regurgitation as the corresponding leaflet segment may prolapse into 
the left atrium preventing normal leaflet coaptation. 
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The mitral valve orifice area varies between 5-11.4 cm2 with an average area of 7.6 cm2 
[14].  This area increases in size throughout late systole into diastole and decreases in size 
during atrial contraction at the end of diastole.  The annulus also varies in shape and 
position throughout the cardiac cycle.  The mitral valve forms a hyperbolic paraboloid or 
saddle shape wherein the center of the anterior mitral valve leaflet is furthest away from 
the left ventricular apex.  During systole, the posterior leaflet moves toward the anterior 
leaflet and the annulus moves 3-16 mm toward the left ventricular apex.  During diastole, 
the posterior leaflet moves away from the anterior leaflet and the annulus moves away 
from the left ventricular apex and 2-4 mm into the left atrium.  Changes in left ventricular 
function and shape may alter the normal size, shape, and motion of the mitral valve 
annulus through the cardiac cycle.  This may also result in mitral valve regurgitation.  
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Figure 1.2:  Mitral valve with surrounding critical anatomy. AC: anterior 
commissure, PC: posterior commissure, AV node: atrioventricular node, LC: left 
coronary sinus of aortic valve, NC: noncoronary sinus of aortic valve. 
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1.2 Classification of mitral valve regurgitation 
Normal function of the mitral valve apparatus depends on the proper coordinated 
interaction of all of its components.  Dysfunction of the left ventricle, the mitral valve 
annulus, the anterior and posterior mitral valve leaflets, the chordae tendineae, or the 
anterolateral and posteromedial papillary muscles will result in failure of the mitral valve 
leaflets to coapt during systole, or mitral valve regurgitation.  Mitral valve regurgitation 
can be classified by the etiology, the location of the lesion, and the resulting valve 
dysfunction [16].   
1.2.1 Mitral Valve Regurgitation Classified by Etiology   
A thorough understanding of mitral valve etiology is required as it dictates disease 
prognosis, surgical treatment, and medical therapy.  Firstly, the etiology of mitral valve 
regurgitation may be primary or secondary.  Primary mitral valve regurgitation is the 
result of pathology involving the mitral valve leaflets or chordae; for example, rheumatic 
valve disease, infective endocarditis, or degenerative mitral valve regurgitation.  
Secondary mitral valve regurgitation is the result of pathology involving the myocardium, 
the muscular tissue of the heart, and as a result, affect valve function; for example, 
ischemic mitral valve regurgitation [16].  The underlying etiology of mitral valve 
regurgitation affects the disease prognosis and the medical and surgical management.  
These etiologies may result in lesions in one or multiple components of the mitral valve 
including the annulus, leaflets, commissures, papillary muscles, or left ventricle.   
1.2.2 Mitral Valve Regurgitation Classified by Lesion Location 
Certain lesions are characteristic of specific mitral valve regurgitation etiologies.  For 
example, degenerative mitral valve regurgitation commonly results in excess leaflet 
tissue and thin chordae or chordal rupture. Rheumatic mitral valve regurgitation results in 
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leaflet and chordae thickening with commissure fusion.  Infective endocarditis may result 
in chordal rupture and leaflet vegetations and perforations.  Finally, ischemic mitral valve 
regurgitation may result in a dilated annulus, restricted or tethered chordae tendineae and 
leaflets, and displaced papillary muscles.  Therefore, a thorough understanding of the 
lesions contributing to mitral valve regurgitation is essential for appropriate surgical 
planning.   
1.2.3 Mitral Valve Regurgitation Classified by Function 
To guide surgical planning, Carpentier developed a functional classification of mitral 
valve regurgitation based on leaflet motion [16].  Using this classification, the sum of 
effects from an etiology of mitral valve regurgitation on components of the mitral valve 
apparatus can be summarized based on the resulting leaflet motion.  Type I mitral valve 
regurgitation has normal leaflet motion.  Mitral valve regurgitation is due to lack of 
leaflet coaptation, annular dilatation from a dilated or ischemic left ventricle, or leaflet 
damage in the form of perforation, tear, or vegetation.  Type II mitral valve regurgitation 
involves excessive leaflet motion or prolapse of a leaflet edge into the left atrium.  This 
may be due to elongation or rupture of chordae tendineae or papillary muscles.  The 
degree of prolapse can be measured using echocardiography. Type III mitral valve 
regurgitation involves the limitation or restriction of leaflet motion such that the leaflets 
do not coapt.  This may be further classified into leaflet restriction during diastole (Type 
IIIa) or during systole (Type IIIb).  Rheumatic mitral valve regurgitation typically results 
in Type IIIa valve dysfunction.  Ischemic mitral valve regurgitation typically causes 
papillary muscle displacement and leaflet tethering that results in Type IIIb valve 
dysfunction [16]. 
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1.3 Natural History of Mitral Valve Regurgitation 
The natural history of mitral valve regurgitation depends on the etiology, the acuteness or 
chronicity of the disease, the severity of mitral valve regurgitation, and the patient’s age 
and underlying comorbidities, particularly left ventricular dysfunction.  
1.3.1 Natural History of Rheumatic Mitral Valve Regurgitation 
Rheumatic fever remains a common cause of mitral valve regurgitation in developing 
countries; however, its incidence in Canada and the United States has greatly diminished 
[14, 17-20].  During the first episodes of rheumatic fever in childhood, patients may 
develop acute mitral valve regurgitation.  This occurs as a result of annular dilatation and 
leaflet edema and prolapse with myocarditis or inflammation of cardiac muscle [14, 21, 
22].  Those with posterior leaflet prolapse, not anterior leaflet prolapse, have a less 
favorable outcome and often require early surgical repair [22].  After remission of the 
acute process, myocarditis subsides and annular dilatation regresses leading to reversion 
of mitral valve regurgitation in some cases.   However, in most cases, there is progressive 
leaflet thickening, fusion, prolapse, and chordae shortening or rupture leading to mitral 
valve regurgitation and stenosis [20]. It is unknown why rheumatic fever leads to valvular 
stenosis in some patients and pure regurgitation in others [18]. 
1.3.2 Natural History of Mitral Valve Regurgitation Secondary to 
Infective Endocarditis 
Infective endocarditis is an uncommon cause of pure mitral valve regurgitation.  It may 
occur on a previously abnormal mitral valve or pass from an infected aortic valve to the 
anterior leaflet of the mitral valve to produce perforation and mitral valve regurgitation.  
Further infection may cause destruction of both mitral valve cusps and chordae tendineae 
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[23].  Mortality for mitral valve regurgitation secondary to infective endocarditis is high 
and may be related to uncontrolled systemic infection [23]. 
 
1.3.3 Natural History of Ischemic Mitral Valve Regurgitation   
Mitral valve regurgitation is a frequent complication of an acute myocardial infarction 
and has been detected in up to 39% of patients early after an infarction [24].  There are 
multiple mechanisms wherein ischemic heart disease may produce mitral valve 
regurgitation.  Papillary muscle rupture, altered papillary muscle position and dynamics, 
annular dilatation and shape change, and left ventricular remodeling may all occur 
following a myocardial infarction; and they may all contribute to incomplete leaflet 
coaptation [14, 23, 24].   
Papillary muscle rupture is a rare but potentially fatal complication of an acute 
myocardial infarction, occurring in 1-3% of patients following a myocardial infarction 
[24]. Rupture usually occurs two to seven days after myocardial infarction and accounts 
for approximately half of the acute mitral valve regurgitation in patients following a 
myocardial infarction.  Patients develop acute mitral valve regurgitation with pulmonary 
edema and hypotension.  Without urgent surgery, approximately 50 to 75% of these 
patients may die within 24 hours. Survival after partial papillary rupture is slightly better 
at more than 70% within the first 24 hours, and approximately 50% at one month [25].  
They are then considered to have chronic mitral valve regurgitation. 
Left ventricular systolic dysfunction and remodeling following myocardial ischemia may 
also produce mitral valve regurgitation.  Incomplete mitral coaptation in the mitral valve 
regurgitation in the setting of left ventricular dysfunction and dilatation is called 
functional mitral valve regurgitation [26-28]. Ischemic mitral valve regurgitation is a 
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subset of functional mitral valve regurgitation and occurs in approximately 15% of 
patients with anterior wall involvement and up to 40% of patients with an inferior infarct 
[18, 29]. 
Following a myocardial infarction, left ventricular dysfunction leads to ventricular and 
mitral valve annulus dilatation.  These increased dimensions require the mitral leaflets to 
cover more area prior to coaptation.  Furthermore, remodeling of the left ventricle to a 
more spherical shape leads to loss of the saddle shape of the normal mitral valve annulus 
and lateral displacement of the posteromedial papillary muscle.  This may increase the 
distance from the middle of the anterior annulus to the posteromedial papillary muscle tip 
and affect leaflet coaptation with systolic leaflet tethering [28, 30-33]. Therefore, mitral 
valve regurgitation occurs with failure of leaflet coaptation despite structurally normal 
mitral valve leaflets.   
1.3.4 Natural History of Degenerative Mitral Valve Regurgitation 
Degenerative mitral valve regurgitation encompasses a spectrum of connective tissue 
changes in the mitral valve apparatus that lead to mitral valve prolapse [34].  Mitral valve 
prolapse is a billowing of one or both leaflets into the left atrium during ventricular 
systole.  Mitral valve prolapse may occur in younger patients as a result of fibroelastic 
connective tissue disorders, such as Barlow’s mitral valve disease, or in older patients as 
a result of fibroelastic deficiency.  Regardless of etiology, mitral valve prolapse may 
result in mitral valve regurgitation. 
Barlow’s mitral valve disease occurs as a result of the replacement of mitral valve leaflet 
collagen with dermatan sulfate, a glucosaminoglycan [24].  These leaflets may begin to 
prolapse into the left atrium during systole and fail to coapt.  This places more strain on 
the attached chordae tendineae that, as a result, elongate.  Ultimately, some chordae 
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tendineae rupture.  This further exacerbates both mitral valve prolapse and mitral valve 
regurgitation.  These histologic changes and severe valve redundancy are especially 
pronounced in younger patients.  Barlow’s mitral valve is characterized by myxomatous 
leaflet tissue with bileaflet prolapse and by dilatation of the valve annulus. Barlow’s 
syndrome comprises prolapse of the posterior leaflet, chest pain, palpitations, syncope, 
and dyspnea [14].  
Older patients with degenerative mitral valve regurgitation are more likely to have 
fibroelastic deficiency.  This is characterized by abnormal connective tissue of the mitral 
valve resulting in weakening and rupture of the chordae tendineae [23, 34].  The chordae 
tendineae are one of the supporting structures of the mitral valve; therefore, their 
degeneration hinders valve closure and produces mitral valve regurgitation [35].  With 
degenerative mitral valve disease, the mitral valve leaflets and chordae tendineae become 
thin and pellucid.  The most common cause of severe mitral valve regurgitation is rupture 
of the elongated chordae (Figure 1.3) [35].  Chordal rupture commonly occurs without 
any leaflet pathology.  This results in unsupported leaflets and a flail leaflet tip.  Posterior  
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Figure 1.3:  Etiology of Carpentier Type I Mitral Regurgitation with Normal Leaflet 
Motion.   
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Figure 1.4:  Etiology of Carpentier Type II Mitral Regurgitation with Leaflet 
Prolapse. 
 
 
 
Figure 1.5:  Etiology of Carpentier Type IIIa Mitral Regurgitation with Restricted 
Leaflet Motion During Diastole. 
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Figure 1.6:  Etiology of Carpentier Type IIIb Mitral Regurgitation with Restricted 
Leaflet Motion During Systole. 
chordal rupture is the most commonly seen etiology [18, 36].  Improper closure of the 
mitral valve leaflets is associated with volume overload and subsequent ventricular and 
atrial enlargement with dilatation of the mitral annulus, particularly along the posterior 
aspect of the valve.  This leads to atrial fibrillation, heart failure and death [35].  
Furthermore, mitral annular calcification may occur with or without degeneration and 
prolapse of the mitral leaflets [37].  This is usually the result of degenerative disease, 
seen more commonly in elderly patients, particularly women [17].  The annular 
calcification may be localized or more extensive with rigid bars up to 2 cm in thickness in 
the annulus and leaflets [14].  Calcification commonly extends from the posterior annulus 
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and displaces and immobilizes the posterior leaflet, stretching the attached chordae 
tendineae to produce mitral valve regurgitation.  Ultimately, a rigid bar of calcium may 
surround the entire posterior annulus and, eventually, the entire mitral valve annulus.  
Further extension of calcium into the left ventricular septum may result in conduction 
defects[3].  Finally, systemic embolization of the calcium deposits may occur. Notably, 
the presence of mitral annular calcification appreciably adds to the complexity of any 
surgery on the mitral valve [38].   
Isolated mitral valve prolapse occurs in 1% to 2.5% of the population and it is the most 
common cause of mitral valve regurgitation in patients undergoing mitral valve surgery 
[39-41].   However, not all patients with mitral valve prolapse progress to require surgery.  
The major predictor of cardiac mortality is moderate to severe mitral valve regurgitation, 
but only five to ten percent of patients with mitral valve prolapse develop severe mitral 
valve regurgitation, and rarely before the age of 50 [42, 43].  Severe mitral valve 
regurgitation due to flail leaflets has been reported to have a mortality of 6.3% per year 
[44].  The reported 10-year incidence of atrial fibrillation was 30% and the reported 10-
year incidence of congestive heart failure was 63% [45].   At 10 years, 90% of patients 
with severe mitral valve regurgitation have died or undergone surgery [45].  
1.3.5 Natural History of Acute Mitral Valve Regurgitation 
Acute mitral valve regurgitation may result from partial or complete rupture of chordae 
tendineae secondary to ischemia, infective endocarditis, or trauma. Regurgitation into the 
left atrium increases left atrial pressure and reduces forward cardiac output.  In patients 
with acute mitral valve regurgitation with normal or reduced left atrial compliance, a 
sudden increase in left atrial pressure initially elevates pulmonary vascular resistance and 
results in flash pulmonary edema [17, 46].  Patients experience acute decompensation 
with pulmonary congestion and hypoxia, or insufficient oxygen supply to tissue.  In 
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addition, the fall in cardiac output through the aortic valve results in hypotension and 
cardiogenic shock.  Finally, severe pulmonary venous hypertension may progress to 
right-sided heart failure.   
1.3.6 Natural History of Chronic Mitral Valve Regurgitation 
Chronic mitral valve regurgitation occurs when the gradual progression of mitral valve 
regurgitation leads to compensatory increases in left atrial and pulmonary venous 
compliance.  Enlargement of the left atrium leads to further dilatation of the mitral valve 
annulus and worsening of mitral valve leaflet coaptation.  In addition, atrial enlargement 
leads to atrial fibrillation.  In one longitudinal study of patients with mitral valve 
regurgitation, the incidence of atrial fibrillation among those with severe mitral valve 
regurgitation was over five percent per year [35].  Patients in whom atrial fibrillation 
develops are at increased risk for adverse cardiovascular outcomes, including cerebral 
ischemia or stroke [47].  
The left ventricle also adapts by increasing the left ventricular end-diastolic volume to 
maintain adequate forward output.  Patients with mild to moderate mitral valve 
regurgitation may remain asymptomatic for many years.  However, this higher preload 
eventually leads to left ventricular dilatation and spherical remodeling [48].  Therefore, 
left ventricular size increases as left ventricular contractility decreases.  
After the initial compensatory phase, left ventricular systolic contractility becomes 
progressively impaired [49-51].  However, because the afterload is low as a result of 
ejection of part of the stroke volume into the low-pressure left atrium, the ejection 
fraction can be normal despite depressed systolic function [51-53].  Therefore, left 
ventricular end systolic volume is a better estimate of severity of mitral valve 
regurgitation than ejection fraction, end-diastolic volume, or end-diastolic pressure [54]. 
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A lower afterload and increased preload allows the heart to compensate for chronic mitral 
valve regurgitation for many years before symptoms occur [17].  However, the rate of 
death from cardiovascular causes among asymptomatic patients with at least moderate 
mitral valve regurgitation exceeds three percent per year [35].   
The advanced stage of left ventricular decompensation can result in irreversible left 
ventricle changes.  However, as left ventricular dysfunction progresses, patients may 
exhibit symptoms of heart failure including dyspnea.  Without intervention, the rate of 
death among symptomatic patients with at least moderate mitral valve regurgitation 
exceeds five percent [55-57].  
1.4 Role of Imaging in Mitral Valve Regurgitation 
The presence of symptoms is a crucial, but subjective determinant of mitral valve 
regurgitation severity; therefore, multiple cardiac imaging modalities are used to provide 
a more objective assessment.  Cardiac imaging is used to determine the etiology, the 
severity, and the surgical timing and approach in patients with mitral valve regurgitation.  
The roles of transthoracic echocardiography, transesophageal echocardiography, cardiac 
angiography, and magnetic resonance imaging will be discussed. 
1.4.1 Role of Transthoracic Echocardiography 
Transthoracic echocardiographic (TTE) images are used to determine the etiology and 
severity of chronic primary mitral valve regurgitation.  These images are two-
dimensional and demonstrate the details of leaflet pathology.  Firstly, the degree and 
location of mitral valve prolapse can be ascertained.  Echocardiographic diagnosis of 
mitral valve prolapse requires prolapse of 2 mm or more above the annulus in the long-
axis parasternal view [58, 59].  Furthermore, Doppler color flow imaging can identify the 
location and magnitude of the mitral regurgitant flow.  Secondly, TTE can demonstrate 
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valve disruption or perforation from infective endocarditis, chordal rupture, and papillary 
muscle rupture.  This is especially useful when there are no obvious signs of mitral valve 
regurgitation on physical examination; for example, in acute mitral valve regurgitation, 
when the rapid rise in left atrial pressure and fall in left ventricular pressure limit both the 
pressure gradient and the audible murmur in systole [24].   
There is no single transthoracic echocardiographic parameter to quantify mitral valve 
regurgitation [60, 61].  Therefore, as stated in the 2003 American Society of 
Echocardiography's consensus statement on echocardiographic quantification of valvular 
regurgitation, it is essential to consider the entire echocardiographic image for an 
accurate assessment of valve severity [61]. This includes the assessment of mitral valve 
structure and the measurement of chamber dimensions, Doppler flow, Proximal 
Isovelocity Surface Area (PISA), and vena contracta width (Table 1.1) [61]. 
Structural abnormalities, such as an enlarged left atrium or left ventricle and the 
appearance of the mitral apparatus, can be used to assess the severity of mitral valve 
regurgitation.  As previously mentioned, the onset of left ventricular dysfunction and 
presence of pulmonary artery hypertension both portend advanced mitral valve 
regurgitation and poor patient outcomes.  Furthermore, increased preload and normal to 
decreased afterload in chronic mitral regurgitation enable left ventricular ejection fraction 
to remain above 60%, despite progressive valvular and ventricular dysfunction.  
Therefore, chamber volumes are used to determine a more accurate measure of left 
ventricular dysfunction [45].  Mild mitral regurgitation is usually associated with normal 
or near-normal left atrial size, left ventricular size, and intact mitral apparatus.  Moderate 
mitral regurgitation is frequently associated with some degree of left atrial enlargement, 
normal or mildly dilated left ventricle, and varying degrees of mitral apparatus 
abnormalities.   Severe chronic mitral regurgitation is usually associated with moderate to 
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severe left atrial enlargement and some degree of left ventricular dilatation.  In addition, 
it is often associated with flail mitral leaflet, ruptured papillary muscle, or malcoaptation 
of the mitral leaflets [45]. 
Colour Doppler flow, illustrating the regurgitation of blood as a jet into the left atrium, is 
considered to be a qualitative or semi-quantitative measure of mitral valve regurgitation 
severity.  A small jet occupying less than 20% of the left atrial area is graded as mild 
mitral valve regurgitation. A large jet occupying more than 40% of the left atrial area and 
extending into the pulmonary veins is graded as severe mitral valve regurgitation [62].   
Proximal flow acceleration or proximal isovelocity surface area (PISA) is seen as a 
concentric series of hemispheric shells of alternating colors, each shell denoting an 
isovelocity of aliasing [62].  After the color jet crosses the mitral valve, the width of the 
jet increases. At a given aliasing velocity, the radius of PISA increases with increasing 
regurgitant volume. In the parasternal long-axis view, the narrowest portion of the 
regurgitant jet across the valve is defined as the vena contracta. Mild mitral regurgitation 
is usually associated with a vena contracta less than 0.3 cm, while severe mitral 
regurgitation is usually associated with a vena contracta of 0.7 cm or more [63, 64]. 
The effective regurgitant orifice area (EROA) can be calculated by dividing the flow rate 
through the regurgitant orifice, that is, the product of the surface area of the hemisphere 
(2πr2) and aliasing velocity (Va), by the peak velocity of the regurgitant jet (PkVreg):  
EROA = (2πr2 * Va)/PkVreg [65].  Mild mitral regurgitation is associated with an EROA 
of less than less than 0.2 cm.  Moderate mitral regurgitation is associated with an EROA 
of 0.2 to 0.39 cm.  Severe mitral regurgitation is associated with an EROA of at least 0.4 
cm [45].  
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Table 1.1: Mitral Regurgitation Severity Assessment by Echocardiography [66]. 
Measurement Mild Moderate Severe 
Regurgitant Volume (mL) <30 30-60 
 
>60 
 
PISA radius (mm) <4 4-10 
 
>10 
 
Vena Contracta (mm) <3 4-6 
 
>7 
 
1.4.2 Role of Transesophageal Echocardiography 
Whereas TTE is generally sufficient to determine the etiology and severity of mitral 
valve regurgitation, transesophageal echocardiography (TEE) provides excellent imaging 
of the mitral valve apparatus and may provide additional information.  Firstly, TEE is 
indicated when two-dimensional TTE does not provide adequate information regarding 
the etiology and severity of mitral valve regurgitation.  This is particularly important in 
cases of acute severe mitral valve regurgitation when neither physical examination nor 
TEE provide a clear diagnosis.  As previously noted, acute mitral valve regurgitation may 
create early equalization of left atrial and ventricular pressures with only narrow eccentric 
jets that may not be readily seen with TTE.  Secondly, TEE is especially useful in cases 
of mitral valve regurgitation due to infective endocarditis to visualize vegetations and to 
ascertain if additional adjacent cardiac structures are infected.  Thirdly, TEE allows more 
precise quantitation of mitral valve regurgitation severity and provides more anatomical 
information for surgical planning and for determining the likelihood of successful valve 
repair.  In particular, three-dimensional TEE provides an enhanced understanding of the 
mitral valve anatomy for surgical planning.  Finally, following repair, an intraoperative 
transesophageal echocardiogram is used to determine the adequacy of repair.  Even mild 
residual mitral valve regurgitation after repair increases the likelihood of later repair 
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failure necessitating reoperation.  Therefore, recognizing any residual mitral valve 
regurgitation is critical and often an indication that the repair should be revised.   
Furthermore, any observed left ventricular inflow or outflow obstruction secondary to the 
repair should be rectified [67, 68]. 
However, as TEE is more invasive than TTE, it is not recommended for routine 
evaluation of patients with mitral valve regurgitation.  Furthermore, TEE, which requires 
sedation, can downgrade the severity of mitral valve regurgitation [69].  Therefore, 
although TEE is helpful in examining leaflet anatomy it can be misleading due to the 
nonphysiological conditions under sedation. 
1.4.3 Role of Cardiac Angiography 
Although not as critical as echocardiography in diagnosis and surgical planning, 
angiography with a left ventriculogram will also demonstrate mitral valve regurgitation.  
Whereas Doppler interrogation of the mitral valve with echocardiography measures flow 
velocity, left ventriculography uses the density of contrast to estimate the amount of 
blood flow from the left ventricle to the left atrium with mitral valve regurgitation.  
Firstly, this can be used to estimate the severity of mitral valve regurgitation and left 
ventricular function.  Secondly, any underlying coronary artery disease contributing to 
ischemic mitral valve regurgitation can be defined by coronary angiography.  Thirdly, 
hemodynamic measurements from cardiac angiography can be used when there is a 
clinical discrepancy between symptomatic status and noninvasive testing. For example, a 
normal hemodynamic examination in a symptomatic patient with less than severe mitral 
valve regurgitation suggests a noncardiac cause for the symptoms.  In patients with 
concomitant lung disease, a normal left atrial pressure and a large transpulmonary 
gradient suggest pulmonary hypertension due to lung disease rather than mitral valve 
disease [70].  Finally, all patients older than 40 years should undergo coronary 
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angiography to detect the presence of concomitant coronary artery disease for 
revascularization. 
1.4.4 Role of Cardiac Magnetic Resonance Imaging 
Cardiac magnetic resonance imaging may also be used to assess left and right ventricular 
volume and function if these values cannot be adequately assessed with TTE.  However, 
this imaging modality is less helpful in establishing the etiology of mitral valve 
regurgitation [71-73].  
1.5 Indications for Surgery in Patients with Mitral Valve 
Regurgitation 
1.5.1 Rheumatic Mitral Valve Regurgitation 
As previously mentioned, symptoms such as dyspnea, or shortness of breath, on exertion, 
orthopnea, or shortness of breath in the recumbent position, and declining exercise are the 
culmination of the pathophysiology of mitral valve regurgitation.  The onset of symptoms 
may indicate changes in left ventricular function, left atrial compliance, increases in 
pulmonary artery pressure, and decreases right ventricular pressure. Therefore, once 
symptoms have occurred, the patient should be considered for mitral valve operation 
even if medication has led to improvement [23, 74, 75].  
Mitral valve repair and mitral valve replacement with preservation of the subvalvular 
apparatus are the main surgical options for mitral valve regurgitation.  As surgical results 
improve, the indications for surgery are broadening.  Improved myocardial protection, 
cardiopulmonary bypass technology and minimally invasive incisions, coupled with 
enhanced intensive care unit support have all contributed to improved patient outcomes 
[14]. 
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The Canadian Cardiovascular Society, the American Heart Association and the American 
College of Cardiology recommendations for surgical intervention in mitral valve 
regurgitation are assigned classes of support based on clinical evidence.  A Class I 
indication denotes a condition for which there is evidence and/or general agreement that a 
given procedure or treatment is beneficial, useful, and effective.  Whereas, a Class II 
indication denotes a condition for which there is conflicting evidence and/or a divergence 
of opinion about the usefulness and efficacy of a procedure or treatment.  
Recommendations for which the weight of evidence is in favor of the usefulness and 
efficacy of a procedure or treatment are classified as Class IIa.  Recommendations for 
which the usefulness and efficacy of a procedure or treatment are less well established by 
evidence are classified as Class IIb [23, 45, 69]. 
Prior to surgical management of mitral valve regurgitation, the indications for surgery, 
surgical timing, and operative approach must be carefully planned. Operative candidacy, 
timing, and surgical approach must take into consideration not only mitral valve 
regurgitation etiology and severity, but also patients’ comorbidities including left 
ventricular dysfunction.  The following section will outline the indications for surgery, 
surgical management, and surgical outcomes for rheumatic, acute ischemic, chronic 
ischemic, and degenerative mitral valve regurgitation.   
1.5.2 Acute Ischemic Mitral Valve Regurgitation 
Acute ischemic mitral valve regurgitation due to complete papillary muscle rupture is a 
rare but potentially fatal complication following a myocardial infarction.  Only 25% of 
patients are expected to survive if treated nonsurgically.  Clearly, acute ischemic mitral 
valve regurgitation accompanied by hemodynamic instability is a Class I indication for 
emergent mitral valve replacement [56, 69, 74, 76-79].     
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1.5.3 Chronic ischemic mitral valve regurgitation 
 
The surgical management of chronic ischemic mitral valve regurgitation requires 
consideration of not only the etiology and severity of mitral regurgitation, but also the 
availability of valve repair and operative mortality risk.  Furthermore, the literature does 
not offer strict guidelines for the surgical management of chronic ischemic mitral valve 
regurgitation. 
Both the AHA and CCC state that revascularization alone may be sufficient to reverse 
less than moderate ischemic mitral valve regurgitation [23, 45].  However, no reported 
randomized trials have compared coronary revascularization alone versus coronary 
revascularization with mitral valve repair or replacement in patients with mild or 
moderate mitral regurgitation. 
It is a Class IIb recommendation for patients with chronic moderate ischemic mitral 
valve regurgitation who are undergoing other cardiac surgery to undergo concomitant 
mitral valve surgery [23].   It is a Class IIa recommendation for patients with chronic 
severe ischemic mitral valve regurgitation who are undergoing other cardiac surgery to 
undergo concomitant mitral valve surgery [23].  It is a Class IIb recommendation for 
patients with chronic severe ischemic mitral valve regurgitation with symptoms of heart 
failure to undergo mitral valve surgery [23].   
Chronic moderate to severe ischemic mitral regurgitation adds volume overload to a 
decompensated left ventricle and worsens prognosis in patients with ischemic heart 
disease.  Small randomized controlled trials have demonstrated that mitral valve surgery 
reduces chamber size and improves peak oxygen consumption in chronic severe ischemic 
mitral valve regurgitation [57, 80-93].  However, there are sparse data that this surgery 
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prolongs life or even improves symptoms over an extended time [93-95].  In fact, there is 
accumulating evidence that in patients with severe functional ischemic mitral 
regurgitation and left ventricular ejection fraction less than 45%, long-term survival and 
functional status are not improved by adding mitral valve annuloplasty to coronary 
revascularization [86, 87, 91, 96-98].  
1.5.4 Degenerative Mitral Valve Regurgitation 
It is a Class I recommendation for patients with chronic severe degenerative mitral valve 
regurgitation, with or without symptoms of heart failure and a left ventricular ejection 
fraction greater than 30%, to undergo mitral valve surgery.  Mitral repair is recommended 
over replacement if a successful and durable repair can be accomplished [23].  It is also a 
Class I recommendation for patients with chronic severe degenerative mitral valve 
regurgitation who are undergoing other cardiac surgery to undergo concomitant mitral 
valve repair or replacement [23].  It is also a Class IIa recommendation for patients with 
chronic moderate degenerative mitral valve regurgitation who are undergoing other 
cardiac surgery to undergo concomitant mitral valve repair or replacement [23].    
 For asymptomatic patients, it is a Class IIa recommendation for patients with chronic 
severe degenerative mitral valve regurgitation and preserved left ventricular function to 
undergo mitral valve repair if the likelihood of successful repair is greater than 95% and 
the mortality rate is less than 1% [23].  It is also a Class IIa recommendation for 
asymptomatic patients with chronic severe degenerative mitral valve regurgitation, with 
preserved left ventricular function and recent onset atrial fibrillation or pulmonary 
hypertension, to undergo mitral valve surgery if a successful mitral valve repair is highly 
likely [23]. 
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Excellent surgical outcomes in these patients are due to the low postoperative incidence 
of congestive heart failure.  In fact, the survival of these patients at ten years is equivalent 
to that expected for a matched population [99-101].  There is recent evidence that 
asymptomatic patients have better long-term survival than symptomatic patients with the 
same risk of reoperation if low risk reparative surgery is possible.  Furthermore, early 
surgery improves morbidity and long-term survival [41, 44, 102-108].  Therefore, 
delaying surgery may lead to the development of left ventricular dysfunction and impair 
long-term survival and quality of life [109-114].  
When patients with chronic severe mitral regurgitation decompensate to the extent that 
their left ventricular ejection fraction is 30% or less, mitral valve surgery is recommended, 
but only as a Class IIb recommendation [23].  The onset of symptoms, ventricular 
dysfunction, and pulmonary hypertension all worsen prognosis for mitral valve 
regurgitation. Therefore, some advocate mitral valve repair in patients with chronic 
severe degenerative mitral valve disease prior to the onset of symptoms or physiologic 
sequelae.  Reduction annuloplasty may be beneficial in these patients with operative 
mortality below 10% [115]; however, if mitral valve replacement is required, there is 
unlikely to be a benefit in symptoms or mortality [116-119]. 
1.6 Surgical Management of Mitral Valve Regurgitation 
As previously stated, there is no proven therapy for the treatment of mitral valve 
regurgitation; and, in addition, mitral valve replacement with preservation of the 
subvalvular apparatus and mitral valve repair are the main surgical options.  Surgical 
mitral valve replacement with either a biologic or mechanical prosthesis was the standard 
treatment for patients with mitral valve disease until effective techniques for valve repair 
were developed, reducing the risk of complications associated with prosthetic valves. 
Moreover, current mitral valve repair techniques are associated with lower rates of 
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operative mortality than mitral valve replacement (1-3% for valve repair versus 5-9% for 
valve replacement) [120-123].  Therefore, mitral valve repair represents the procedure of 
choice by current North American and European guidelines for treatment of degenerative 
mitral valve regurgitation [122, 124].  Certain mitral valve repair techniques can be 
employed for the treatment of ischemic and rheumatic mitral valve regurgitation; 
however, often due to the nature and extent of the mitral valve pathology, repair is not 
possible and the valve is replaced.  Mitral valve replacement and repair techniques for 
specific valve etiologies and their outcomes will be reviewed in this section. 
1.6.1 Mitral Valve Replacement   
Prior to the onset of mitral valve repair procedures, surgical mitral valve replacement 
with either a biological or mechanical prosthesis was the standard treatment for patients 
with mitral valve disease.  The first successful mitral valve mechanical prosthesis was 
developed by Starr and Edwards in 1961 [125].  Over a decade later, St. Jude Medical 
developed a bileaflet mechanical prosthesis that has remained similar in design and 
remains widely used today [126-129].  Although bioprosthetic valves were first 
developed in the 1950s, they did not become available commercially until 1970 [24, 130]. 
Rheumatic mitral valve regurgitation is a complex, progressive mitral valve disease that 
may result in concomitant mitral valve regurgitation and stenosis.  Therefore, this disease 
is more suitable for mitral valve replacement because the durability of a repair is limited 
by disease progression with further thickening and calcification of leaflets and chordal 
fusion [131-133].  According to ACC/AHA guidelines, mitral valve repair for rheumatic 
mitral valve regurgitation should only be considered if a durable and successful repair is 
likely or if long-term anticoagulation for a prosthetic valve is not possible.  Additionally, 
the Canadian Cardiovascular Society’s recommended management of acute ischemic 
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mitral regurgitation is coronary artery revascularization followed by mitral valve 
replacement with preservation of the subvalvular apparatus [45].   
The mitral valve may be approached through either a left or right atrial incision.  As the 
mitral valve apparatus has an integral role in left ventricular contraction, its preservation 
during mitral valve surgery results in better left ventricular function postoperatively [134-
145]. The anterior and posterior chordae tendineae may be preserved by splitting the 
anterior leaflet centrally and folding the anterior and posterior leaflets laterally prior to 
prosthesis insertion [146]. 
 The mechanical or biologic prosthesis is sewn into place with pledgeted horizontal 
mattress sutures on the atrial or ventricular side.  Excessive force should be avoided 
during placement of these annular sutures, as the tissue may be very friable and 
postoperative ventricular rupture should be avoided.  Further care should be taken in 
avoiding the circumflex artery that is in close proximity to the mitral valve annulus. 
1.6.2 Mitral Valve Repair 
Prior to the development of the cardiopulmonary bypass machine, closed repair 
techniques for mitral valve regurgitation were performed by Bailey, Davila, Nichols, and 
their colleagues [147-149].  In 1957, Lillehei, Merendino, and Bruce and their colleagues 
were the first to report open repair of mitral valve regurgitation using cardiopulmonary 
bypass [150, 151].  In subsequent years, a number of surgeons have contributed technical 
advances in the repair of mitral regurgitation, particularly Carpentier, Duran, Frater, 
Reed, and their colleagues [152-155]. 
The goals of mitral valve repair for mitral regurgitation are: to restore physiological 
leaflet motion, to recreate leaflet coaptation or closure, and to stabilize the mitral annulus, 
correcting annular dilatation.   Many techniques have been proposed to attain these goals 
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of mitral reconstruction.  However, the technique and operative results of mitral valve 
repair are highly dependent on both the etiology of mitral valve regurgitation and the 
anatomy of the valvular apparatus. 
1.6.2.1 Repair in Ischemic Mitral Valve Regurgitation 
Mitral valve repair techniques may be employed in ischemic mitral valve regurgitation if 
only one papillary muscle head is ruptured or if both the papillary muscles and chordae 
tendineae are intact [156, 157].  Mitral valve repair for ischemic mitral valve 
regurgitation must restore the elements of the mitral valve apparatus that were distorted 
with left ventricular dilatation and remodeling [158].  These surgical interventions 
include: coronary revascularization, narrowing the mitral valve annulus, reducing the left 
ventricular volume and restoring the elliptical shape of the left ventricle from its distorted 
spherical shape.  
In the presence of mild ischemic mitral valve regurgitation, coronary revascularization 
alone is sufficient.  However, if there is at least moderate mitral valve regurgitation, 
coronary revasculization should be accompanied by concomitant mitral valve surgery, 
unless the patient has prohibitive operative risk [82, 159-161].  Conventional mitral valve 
repair is performed through a median sternotomy incision and requires aortic cross-
clamping with cardiac arrest and cardiopulmonary bypass.   
In order to narrow or to reduce the size of an enlarged mitral annulus and restore leaflet 
coaptation, an annuloplasty band or ring can be placed [162-165].  Flexible or rigid 
posterior annuloplasty bands and complete flexible, semi-rigid, rigid, flat, or shaped 
annuloplasty rings are all available for use.  There is no large trial comparing the relative 
efficacy of these annuloplasty devices.  The most important aspect of ring or band 
selection is to find a size and shape that adequately stabilizes the area between the trigone 
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of the anterior leaflet of the mitral valve [14].  Eight to twelve sutures deep mattress 
sutures are used to secure the annuloplasty band or ring.  The sutures themselves serve to 
reinforce the mitral valve repair.  For example, sutures at the commissures flatten and 
narrow the commissure to further annular dilation.  Although these sutures reinforce the 
repair, they may injure cardiac muscle and adjacent cardiac structures.  Possible 
complications during annuloplasty suturing include circumflex coronary artery 
compromise, atrioventricular dissociation, and dehiscence, or tearing, of the annuloplasty 
band or ring from the mitral valve annulus [166].  
In addition, some recommend left ventricular volume reduction and restoration of the left 
ventricular elliptical shape.  This surgery not only reduces the posterior mitral annulus, 
but also aims to exclude any noncontracting akinetic or dyskinetic ventricular muscle.   
Other techniques used in repair of acute ischemic mitral valve regurgitation include: 
division of secondary chordae tendineae, and posterior mitral leaflet extension.  Division 
or cutting of secondary chordae tendineae may be used to decrease leaflet tethering [167, 
168].  Posterior mitral leaflet extension involves enlarging the posterior half of the 
posterior leaflet with pericardium [169].  These techniques are also commonly 
accompanied by mitral valve annuloplasty. 
1.6.2.2 Repair in Degenerative Mitral Valve Regurgitation 
The surgical techniques used for repair of degenerative mitral valve regurgitation are:  
posterior leaflet quadrangular resection with or without sliding plasty, triangular resection 
of the anterior leaflet, chordal transfer, chordal shortening, papillary muscle 
repositioning, edge to edge repair, and chordal replacement with artificial expanded 
polytetrafluoroethylene sutures [45].   
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Following median sternotomy and establishment of cardiopulmonary bypass, the mitral 
valve is exposed.  Each element of the mitral valve apparatus is examined and areas of 
prolapse and regurgitation are identified. Normal chordae tendineae are distinguished 
from the abnormal or ruptured chordae.  The middle segment of the posterior leaflet, P2, 
is the most commonly affected part of the valve in degenerative mitral valve disease 
[170].  The P2 portion of the posterior leaflet is severely prolapsed in approximately 80% 
of patients with mitral regurgitation.  The most critical element in repair of P2 prolapse is 
to decrease the height of the posterior leaflet. 
Several techniques have been developed to repair P2 prolapse.  The most commonly used 
technique is resection of the redundant posterior leaflet tissue to reduce the height of the 
posterior leaflet and to eliminate mitral regurgitation. This can be accomplished with 
quadrangular resection with or without sliding plasty, when there is a more extensive 
leaflet segment prolapsing (Figure 1.5) [166].   A rectangular section of the prolapsed 
leaflet is excised. The resulting gap is bridged with interrupted nonabsorbable sutures 
from the base of the resected leaflet. Alternatively, with a sliding plasty, adjacent normal 
portions of the posterior leaflet are incised at their bases and moved centrally to obliterate 
the gap [24].  An annuloplasty band or ring is usually sutured in place to prevent further 
annular dilatation. In the case of bileaflet prolapse without anterior chordal pathology, 
posterior leaflet quadrangular resection and annuloplasty alone may be sufficient to 
resolve any mitral valve regurgitation [171].  Annular plication can be used in extensive 
posterior leaflet prolapse to reduce tension of the suture line of the reconstructed leaflet 
by imbricating the annulus back into the left atrium.  In cases with short segments of 
redundant posterior leaflet, repair can be accomplished by completing a folding plasty.  
Folding plasty involves tacking the leading edge of the posterior leaflet to the underside 
of the leaflet at the annulus, decreasing the height by fifty percent [166]. 
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Anterior leaflet pathology is more challenging and less often successful than posterior 
leaflet repair.  For triangular resection of a prolapsed anterior leaflet, a triangular wedge, 
extending no more than one third of the diameter of the involved anterior leaflet, is 
resected [172, 173].  Finally, an annuloplasty band or ring is usually sutured in place to 
prevent further annular dilatation.   
In addition, more technically challenging techniques have been developed for the 
resolution of anterior leaflet mitral valve prolapse.  Chordal transfer involves excising the 
leaflet insertion of a normal intact chord from the posterior leaflet and attaching it to the 
anterior prolapsing sectorn [174].  Chordal shortening involves embedding the elongated 
anterior chordae tendineae in an incised papillary muscle [175, 176].  Papillary muscle 
repositioning was also developed to eliminate anterior leaflet prolapse.  With A1 to A2 
prolapse, the anterior head of the anterolateral papillary muscle can be repositioned.  
With A2 to A3 prolapse, the anterior head of the posteromedial papillary can be 
repositioned [177].  Finally, a simple technique for treatment of anterior leaflet prolapse 
was developed by Alferi and colleagues [178, 179].  This technique involves 
approximating the free edge of the anterior and posterior leaflets with one or two mattress 
sutures to create a double mitral valve orifice [180].  The resultant orifices should be at 
least 2 cm in diameter [181].  However, mitral valve stenosis is a possible complication 
of this technique if the resulting mitral valve orifices are too small.  This technique can be 
used for anterior leaflet prolapse, bileaflet prolapse, posterior leaﬂet prolapse with severe 
annular calciﬁcation, or when other surgical repair techniques have failed [166].    
More recently, polytetrafluoroethylene (PTFE) neochordae have been used to replace 
diseased chordae tendineae causing anterior or posterior mitral valve prolapse.  These 
size 5-0 PTFE chords are used support the free edge of the prolapsing leaflet and to 
displace abnormal excess tissue into the ventricle, ensuring a good surface of coaptation 
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instead of resection of leaflet tissue [182, 183]. The neochordae are made short enough to 
displace the prolapsing segment into the left ventricle and to ensure a large surface of 
coaptation for the anterior leaflet while preventing anterior leaflet displacement in the 
outflow tract [166].  A double-armed suture is passed twice through the usually fibrous 
tip of the papillary muscle; each arm is then passed through the area of the leaflet where 
the native chordae are inserted and then tied.  
This technique is associated with low operative mortality, high freedom from re-
operation, and long-term survival similar to the general population [176, 182, 183].  
Artificial chordae tendinae, or neochordae, do not shrink or break and become covered by 
an intimal tissue like native chordae [184]. Moreover, this technique is simple and 
reproducible [182].  Therefore, since 1985, implantation of artificial chordae tendineae 
has become a well established repair technique for the correction of both posterior and 
anterior leaflet prolapse with excellent postoperative outcomes [176, 182, 183].   
The final step in contemporary repair of mitral valve regurgitation is the insertion of an 
annuloplasty band or ring. The aim of mitral valve annuloplasty is to restore a normal 
ratio between the annular size and leaflet surface area in order to restore the normal 
circumference and shape of the mitral valve to match the available leaflet tissue [185]. In 
addition, this technique may adjust the shape of the annulus to restore normal geometry. 
Undersized annuloplasty has been associated with left ventricular reverse remodeling and 
improvement of symptoms in the majority of patients.  Several investigators have 
concluded that mitral valve annuloplasty as essential to a complete and long-lasting repair 
[170, 186].    
If all this is satisfactory, the left atrium is closed and cardiopulmonary bypass is 
discontinued. At this point, competence of the valve is assessed by TEE and if more than 
mild regurgitation is present, the repair is revised or the mitral valve is replaced [187].   
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1.6.3 Outcomes of Mitral Valve Repair and Replacement 
The decision to repair or replace the mitral valve for mitral regurgitation depends on the 
feasibility of a successful repair and the possibility of survival benefit if a repair is done. 
As previously indicated, not all cases of mitral valve regurgitation are amenable to valve 
repair and, therefore, mitral valve replacement is required.  For example, rheumatic mitral 
valve regurgitation is more suitable for replacement than repair because the durability of 
any repair is limited by disease progression.  Therefore, the ACC/AHA recommends 
repair of rheumatic mitral valve regurgitation only in patients with less advanced disease 
in whom a durable repair can be accomplished or in patients for whom a mechanical 
prosthesis cannot be used because of anticoagulation management concerns [80, 188].  
Similarly, mitral valve repair may not be feasible in patients with acute ischemic mitral 
regurgitation with complete papillary muscle rupture and hemodynamic instability.  
The benefits of performing mitral valve repair over mitral valve replacement with 
preservation of the subvalvular apparatus are unclear in patients with chronic ischemic 
mitral valve regurgitation [93-95].  No reported randomized controlled trials have 
compared mitral valve repair and mitral valve replacement in patients with severe 
ischemic mitral regurgitation, with or without concomitant coronary revasculization.  In 
fact, current studies show the two surgical approaches provide equally poor results [189-
192].  This may be due to the fact that the durability of any mitral valve repair is 
dependent on any progression of ventricular dilation [57, 80, 83-87, 89-91, 188, 189, 
191].  As ischemic left ventricular remodeling is a progressive process, mitral valve 
repair with annuloplasty may recur as the left ventricle gradually dilates and impairs 
leaflet coaptation. In an effort to curb this remodeling, surgeons may undertake 
ventricular restoration surgery; however, the results of this surgery are limited [193-195]. 
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On the other hand, repair of degenerative mitral disease limited to the posterior leaflet has 
superior mortality and morbidity results as compared to biological or mechanical mitral 
valve replacement.  The reparability of ruptured posterior chordae should be 85% to 90% 
in degenerative disease [102].  In this case, the operative mortality is less than one 
percent and long-term survival is equivalent to that of age-matched general population 
with approximately 95% freedom from reoperation and greater than 80% freedom from 
recurrent moderate or severe regurgitation at 15 to 20 years after operation [124, 196-
198].  Therefore, the AHA guidelines state that mitral valve replacement should not be 
performed for the treatment of chronic severe degenerative mitral valve regurgitation 
limited to less than one half of the posterior leaflet unless mitral valve repair has been 
attempted and was unsuccessful.    
In summary, these repair techniques have demonstrated excellent outcomes with a high 
durability and high freedom from reoperation rate with minimal perioperative mortality. 
If successful, mitral valve repair enables better preservation of the subvalvular apparatus 
than mitral valve replacement and, in turn, improved postoperative left ventricular 
function.  Furthermore, mitral valve repair avoids the risk associated with prosthetic heart 
valves including thromboembolism, anticoagulant related hemorrhage, and structural 
deterioration [199-101]. 
1.7 Emerging Challenges in Mitral Valve Repair 
Despite these favorable outcomes, a lack of adherence to guidelines addressing the timely 
referral of patients with indications for mitral valve repair can be observed.  Several 
studies have found that numerous patients with indications for surgery received no 
operation.  For example, Toledano and colleagues [2] surveyed Canadian cardiologists 
and found nearly 40% of those cardiologists indicated that they delay surgical referral of 
an asymptomatic patient with severe mitral valve regurgitation until the ejection fraction 
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fell below 40% or symptoms occur.  Furthermore, Mirabel and colleagues found that 
49% of patients with symptomatic mitral valve regurgitation from the Euro Heart Survey 
were not referred for surgery due to advanced age, co-morbidities and a decreased 
ejection fraction [202].   Patients are either not referred for surgery or denied surgery due 
to the perceived risk of conventional mitral valve surgery involving median sternotomy 
for surgical access and cardiopulmonary bypass for exposure of the surgical site.  
Median sternotomy is associated with postoperative infection, risk of blood transfusion, 
prolonged ventilation time, and pain, which may all increase recovery time and stay in 
hospital.  Firstly, sternotomy site infection is the most common postoperative infection 
following cardiac surgery [203].  Sternotomy infections can range from a superficial skin 
infection to a deep sternal wound infection, or mediastinitis. Although the most serious 
wound infection, mediastinitis, has a reported incidence of 0.6-2.65% following cardiac 
surgery, the mortality rate associated with this infection is 14-23% [203].  Moreover, the 
proportion of cardiac surgery patients at increased risk of postoperative infection is 
increasing [204].   This patient population includes the obese, diabetic, elderly, patients 
with chronic obstructive pulmonary disease, and patients with a history of smoking or 
previous vascular surgery. All of these patient characteristics are reported as independent 
predictors of postoperative infections [203, 204].   
Secondly, administration of blood products and prolonged ventilation times associated 
with sternotomy have both been linked to an increased risk of postoperative infections in 
cardiac surgery patients [203, 205-207]. One study reported that the risk of postoperative 
infection increases 30% for every day on mechanical ventilation [203]. In addition, 
patients treated with mechanical ventilation for over 48 hours have a 5.4 times higher risk 
for developing a severe postoperative infection, a four times higher risk for pneumonia, 
and a four times increased risk for postoperative sepsis [205].   
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Cardiopulmonary bypass is employed to remove blood from an arrested heart, to 
oxygenate the blood, and to maintain oxygenated blood circulation to the remainder of 
the body during cardiac surgery.  Blood is removed through cannulas in the superior and 
inferior vena cava such that blood does not reach the right atrium.  Additional blood is 
removed using cannulas that pass from the aortic root or through the right upper 
pulmonary vein into the left atrium and left ventricle.  This blood is oxygenated by a 
membrane oxygenator in the cardiopulmonary pulmonary bypass machine [3].  The 
oxygenated blood passes to the ascending aorta beyond an aortic cross-clamp.  In order to 
decrease the metabolic demand of the heart during cardiac surgery, the heart is cooled 
and arrested with a solution called cardioplegia.  This solution is infused from the 
cardiopulmonary bypass machine to the aortic root and coronary arteries through a 
cardioplegia cannula placed below the aortic cross-clamp.  In this way, mitral valve 
surgery can take place in an arrested, relatively bloodless heart while the remainder of the 
body is supplied with oxygenated blood.      
However, cardiopulmonary bypass has been related to perioperative morbidity and 
mortality [208, 209]. This is because cardiopulmonary bypass is associated with a 
generalized systemic inflammatory response, cerebral dysfunction, myocardial 
depression, and hemodynamic instability [210-212].  The inflammatory response is 
believed to be caused by exposure of blood to abnormal shear forces from the 
cardiopulmonary bypass circuit pumps and its contact with the artificial surface of bypass 
circuit [213-215]. This trauma activates the coagulation and fibrinolytic systems [216] 
and, as a result, cytotoxic enzymes and inflammatory mediators are released [217, 218].  
Therefore, the longer the duration of cardiopulmonary bypass, the longer the exposure to 
its detrimental effects.  Several studies have shown a significant correlation between 
prolonged cardiopulmonary bypass time and postoperative blood loss and blood product 
transfusions [219-221], postoperative prolonged mechanical ventilation, pulmonary 
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edema, or acute respiratory distress syndrome [209, 222, 223], and renal dysfunction 
[224]. 
Furthermore, the use of cardiopulmonary bypass has been linked to permanent neurologic 
dysfunction and postoperative decreases cognition and motor abilities.  Application of the 
aortic cross-clamp may dislodge aortic atheromatous plaque into the aortic arch and 
carotid arteries to the brain causing a stroke.  In addition, decreases in pressure during 
cardiopulmonary bypass may cause brain ischemia, particularly in patients with narrowed 
carotid arteries.  Artificial oxygenation, microemboli, tissue microaggregates, and 
gaseous microbubbles from the cardiopulmonary bypass circuit may also occlude the 
microvessels in the cerebral cortical region, leading to edema and stroke [209].  There is 
a correlation between prolonged cardiopulmonary bypass time and neurologic 
complications, such as stroke [225].  Elderly patients with multiple comorbidities are 
particularly vulnerable to cognitive deficits including stroke [212, 226-232]. 
Therefore, the two main challenges of conventional cardiac surgery are the sternotomy 
incision for surgical access and cardiopulmonary bypass for exposure of the surgical site.  
Both these procedures are associated with risk of longer recovery periods, which may not 
be as well tolerated in elderly patients with multiple co-morbidities.  In Canada, the 
fastest growing population group is among seniors 65 years and over [233]. In addition, 
the fastest growth in the senior population is occurring among the most elderly, those 
seniors 80 years or older [234].  Within this group, cardiovascular disease is the leading 
cause of death [234].  Clearly, new cardiovascular techniques must be tailored to address 
the unique requirements of high risk, elderly, surgical patients with mitral valve disease. 
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1.8 New Surgical Techniques for Mitral Valve Repair 
Minimally invasive mitral valve surgery encompasses a spectrum of new operative 
techniques that aim to minimize surgical trauma by reducing incision size [3].   In order 
to avoid sternotomy and use smaller incisions, innovative strategies for surgical site 
access have been developed, including hemisternotomy, minithoracotomy, and totally 
endoscopic access. Furthermore, these smaller incisions require advanced visualization 
systems and customized instruments for surgery and cardiopulmonary bypass.   
Fortunately, simultaneous advances in biomedical engineering have facilitated the use of 
minimally invasive access for mitral valve repair. 
The ascending levels of minimally invasive cardiac surgery are defined in Table 1.2 [3].   
Table 1.2: Levels of Ascent in Minimally Invasive Cardiac Surgery [3] 
Level 1 Direct Vision 10-12 cm incisions 
Level 2 Direct vision/Video Assisted 4-6 cm incisions 
Level 3 Video-directed and Robotics-assisted 1.2-4 cm incisions 
Level 4 Robotic (computer telemanipulation) <1.2 cm port sites 
Level 1 includes cardiac surgery, including mitral valve repair and replacement, under 
direct vision using a10-12 cm limited incision that is slightly smaller than the typical 
median sternotomy.  Level 2 includes more complex surgery through a 4 to 6 cm mini 
incision that requires both direct and video assisted visualization.  Level 3 includes 
surgery through a micro incision measuring 1.2 to 4 cm in size.  This smaller incision 
requires either video or robotics assisted visualization and instrumentation.  Finally, 
Level 4 includes surgery through port sites under 1.2 cm in size.  These surgeries are 
performed using robotic computer telemanipulation [3].  The evolution of minimally 
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invasive mitral valve repair from Level 1 to Level 4 robotics-assisted mitral valve surgery 
will be outlined in the next section.    
1.8.1 Robotics-Assisted Mitral Valve Repair   
The first minimally invasive mitral valve repair operations were performed under direct 
vision in 1996 using ministernal or parasternal incisions [235-237].  Surgeons reported 
low surgical mortality (1-3%), low morbidity, and shorter stay in hospital for patients 
following these minimally invasive mitral valve repairs [235, 238, 239].    
Concurrently, arterial and venous cannulation for cardiopulmonary bypass were modified 
to accommodate minimally invasive valve surgery.  Arterial access could be obtained via 
femoral cannulation, direct aortic cannulation either through the incision, or right axillary 
artery cannulation.  Venous cannulation and drainage of the right atrium could be 
established from direct access through the incision, from the right internal jugular vein, or 
from the femoral vein.   Furthermore, a retrograde coronary sinus cardioplegia catheter 
can be inserted directly into the right atrium through the incision for myocardial 
preservation during cardiopulmonary bypass.  Echocardographic guidance of both arterial 
and venous cannulas is essential for safe and effective cardiopulmonary bypass using 
minimally invasive access.   
In order to accommodate aortic cross clamping for minimally invasive valve surgery, an 
intra-aortic balloon occlusion and cardioplegia device called Port-access was developed 
in 1996 [237, 239-241].   This device is advanced retrograde through the femoral artery 
and positioned above the sinotubular junction under echocardiographic guidance.  The 
balloon is inflated to obstruct aortic blood flow and antegrade cardioplegia is given via 
the catheter central lumen and a percutaneous retrograde cardioplegia is introduced via 
the internal jugular vein preoperatively under echocardiographic guidance.  Aortic 
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occlusion for minimally invasive valve surgery can also be completed using a standard 
cross-clamp placed through the incision or using a flexible-handle aortic clamp to 
increase exposure through the hemi-sternotomy.    
Subsequently, Carpentier performed the first video assisted mitral valve repair through a 
minithoracotomy using hypothermic ventricular fibrillation [242].  Two-dimensional (2D) 
video-assistance was used for intracardiac visualization.  From this experience, 
Carpentier concluded that 2D visualization was inadequate for detailed repairs [243]. 
However, other surgeons have successfully completed complex repairs including 
quadrangular resections, chordal transfers, and synthetic chordal replacements using only 
2D visualization.  
In 1997, the Aesop 3000 voice-activated camera robot (Intuitive Surgical, Inc., 
Sunnyvale, CA, USA) was used for minimally invasive videoscopic mitral valve repair.  
This device provides automatic vision control [244].  The surgeon directs the movement 
of the 2D endoscopic camera by voice activation and continues to operate with long 
instruments.   
Performance of surgical tasks with 2D vision requires the use of indirect monocular cues 
to compensate for the lack of depth perception [245]. These cues include the relative 
position of instruments, anatomic structure size, shading of light and dark, and texture 
grading [246]. Therefore, performance of detailed skills such as intracorporeal suturing, 
tying, and fine dissection with 2D visualization requires practice and experience.  
Previous studies have suggested that because 3D visualization provides more binocular 
depth cues, depth perception with binocular 3D systems is superior to that achieved with 
monocular 2D systems [247, 248]. Furthermore, compared to 3D binocular vision, 2D 
performance with monocular vision affects the kinematics and pattern of human motions. 
2D visualization increases movement time and lowers peak velocity. In addition, with 3D 
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vision, reach and grab tasks are performed faster than with 2D visualization [246, 248-
251]. 
In 1997, minimally invasive mitral valve repair using time three-dimensional (3D) 
videoscopy was first reported [252].  Despite 3D visualization, simple reconstructions in a 
series of patients were significantly more difficult than those done through a sternotomy.  
In June 1998, Carpentier and Mohr reported the first robotic mitral valve operations using 
the da Vinci surgical system (Intuitive Surgical, Inc., Sunnyvale, CA, USA) [253, 254].  
The surgeon operates from a console through end-affecter instruments that are mounted 
on robotic arms inserted through port hole incisions in the thorax. These devices emulate 
human wrist motion with seven full degrees of freedom: x, y, z, pitch, yaw, rotation, and 
grasp. Additionally, arm insertion and rotation, as well as variable grip strength, give 
additional freedom to the operating wrist [254, 255].  Lange and associates in Munich 
were the first to perform a totally robotic mitral valve repair using the da Vinci surgical 
system [256].  
1.8.2 Robotics-Assisted Mitral Valve Repair Outcomes 
Currently, minimally invasive techniques, including robotics-assisted surgery, are used 
for simple to complex mitral valve repairs [255, 257]. Reported outcomes following 
minimally invasive mitral valve repair show no significant difference in overall mortality 
between minimally-invasive and conventional approaches.  Specialized centres have 
reported thirty day operative mortality between 0.3% and 2% following robotics-assisted 
mitral valve repair.   
Furthermore, favourable outcomes of patients undergoing cardiac surgery without 
sternotomy have been reported [238, 239, 258-270]. For example, reductions in mortality 
among high-risk patients and obese patients have been reported with minimally invasive 
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cardiac surgery as opposed to cardiac surgery with sternotomy [258]. In addition, patients 
undergoing minimally invasive cardiac surgery have reduced blood loss, reduced need for 
reoperation for bleeding, reduced pain, reduced ventilation time, and improved 
postoperative respiratory function [238, 239, 259-271]. Avoidance of sternotomy incision 
with minimally invasive techniques has also been reported to significantly decrease 
patients’ postoperative length of stay in the hospital and the intensive care unit [259, 264, 
266]. In one study, patients undergoing minimally invasive cardiac surgery had less than 
half the length of stay in hospital than patients who had undergone cardiac surgery with 
sternotomy [266]. These patients experience more rapid return to functional activity and 
higher levels of satisfaction. Furthermore, minimally invasive surgeries have been shown 
to decrease health care costs [238]. 
These results suggest that the potential benefits of minimally invasive cardiac surgery can 
be attained without compromising the proven efficacy of conventional approaches.  
On the other hand, this may come at an expense of increased cardiopulmonary bypass 
time and longer cross-clamp and procedure times. Although these techniques employ 
small access incisions, they still require the use of aortic cross clamping and 
cardiopulmonary bypass.   
Furthermore, these outcomes are generated from high-volume and single-center 
prospective cohort studies.  A randomized, prospective trial comparing minimally 
invasive mitral valve repair to conventional mitral valve repair is required to adequately 
assess the relative risks and benefits of minimally invasive versus conventional mitral 
valve repair in patients with degenerative mitral regurgitation.     
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1.9 Challenges of Robotics-Assisted Mitral Valve 
Repair 
Avoidance of sternotomy for minimally invasive mitral valve repair presents unique 
challenges for the surgeon. Acceptance of this technology has been limited as a result of 
the risk of intraoperative conversion to sternotomy, procedure complexity, steep learning 
curves, and prolonged cardiopulmonary bypass and operative times.  
Due to new challenges in preoperative planning and limited surgical access, minimally 
invasive techniques are technically more demanding. Surgeons’ learning curves for 
robotics-assisted coronary artery bypass grafting (CABG) and mitral valve repair have 
been reported. Novick et al. reported the learning curve for 90 beating heart robotics-
assisted coronary artery bypass grafting (CABG) surgeries [272]. Operating time reduced 
from a mean of 537 ± 119 min in first quintile to 307 ± 56 min in last quintile. Chitwood 
reported lower rates of reoperation and failure of mitral valve repair in the last 200 of 300 
patients [273]. Therefore, innovative training platforms for complex minimally invasive 
surgery, such as mitral valve repair, are of growing interest for surgery training programs. 
Minimally invasive surgeries have the potential to be not only more complex, but also 
longer. Limited incision size, incomplete or inadequate exposure, and tissue manipulation 
using robotic or long- shafted instruments all have the potential to increase operative 
times.  Increased operative times may be due to the use of indirect visualization through 
an endoscope and remote manipulation of tissue through a master-slave configuration 
[257].  In conventional or open heart surgery, sensory input is derived from both vision 
and haptic feedback [274, 275].  Haptics is the combination of kinesthetic, tactile, and 
proprioceptive information. Kinesthetic feedback provides position, force, and movement 
information and can be acquired using a force/torque sensor. Tactile feedback includes 
the sensation of vibration, shape, and texture. Proprioception provides the sense of 
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position and movement of body segments [276]. For a complete depiction of haptic 
interactions between surgical instruments and tissue, feedback from kinesthetics, tactile, 
and proprioception must be acquired  [276-278]. 
During robotics-assisted surgery, the indirect manipulation of tissue through the master-
slave configuration of the robotic system prevents realistic interaction forces between the 
surgeon, the therapeutic instruments, and the tissue [277]. This may be particularly 
deleterious in dexterous fine movements such as intracorporeal suturing and knot tying, 
which require accurate control of applied forces and instrument positions [277-279]. 
Without haptic feedback, insufficient forces might be applied when grasping tissue or 
sutures, resulting in loose knots [276, 277]. Conversely, excessive forces may be applied 
to tissue leading to increased trauma and damage to tissue. This is particularly important 
in robotics-assisted mitral valve repair, which requires fine motor skill to suture an 
annuloplasty band to the cardiac tissue surrounding the mitral valve annulus.  Therefore, 
improved training methods and tissue manipulation with the addition of haptic feedback 
are both means of potentially decreasing minimally invasive operating times. 
Furthermore, although robotics-assisted mitral valve repair avoids the use of sternotomy 
incision, aortic cross-clamping and cardiopulmonary bypass are required for access to the 
mitral valve.  Therefore, compared to conventional surgery with sternotomy, minimally 
invasive surgeries have significantly longer cross-clamp, bypass, and operative times. 
Results from a multicentre phase II FDA trial of the da Vinci robotic system for mitral 
valve repair in 112 patients reported total operative, aortic cross-clamp, and 
cardiopulmonary bypass times were: 2.8 ± 0.1 hours, 1.3± 0.01 hours, and 2.1 ± 0.1 
hours, respectively [255].   A further comparison of robotics-assisted mitral valve repair 
to conventional techniques with sternotomy reported significantly longer operative times 
(186 ± 61 versus 169 ± 59 minutes, p<0.01), cardiopulmonary bypass (142 ± 54 versus 
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102 ± 45 minutes, p<0.000), and cross-clamp times (74 ± 44 versus 64 ± 28 minutes, p 
<0.015) using robotics-assisted techniques [266].  Previous studies have shown 
prolonged cross-clamp and cardiopulmonary bypass time are independent predictors of 
mortality with a linear relationship between cross-clamp time and mortality rates [280]. 
Moreover, because cardiopulmonary bypass is associated with an increased risk of 
perioperative stroke and ischemia, particularly in an elderly population with multiple 
comorbidities, innovative minimally invasive techniques that avoid cardiopulmonary 
bypass and aortic cross-clamping are an area of growing interest.  As a consequence of 
this challenge, minimally invasive techniques have been developed for beating heart 
surgery.  
1.10 Beating Heart Mitral Valve Repair 
Although robotics-assisted mitral valve repair avoids the use of sternotomy incision, 
aortic cross-clamping and cardiopulmonary bypass are required for access to the mitral 
valve.  Cardiopulmonary bypass is associated with an increased risk of perioperative 
stroke and ischemia, particularly in an elderly population with multiple 
comorbidities.  As a result of this challenge, there is renewed interest in minimally 
invasive beating heart mitral valve repair.  In order to avoid aortic cross-clamping and 
cardiopulmonary bypass, minimally invasive techniques have been developed for beating 
heart surgery.  
In fact, beating heart mitral valve repairs were first performed prior to the development of 
the cardiopulmonary bypass machine to repair mitral valve stenosis [281-286].  However, 
the development of the cardiopulmonary bypass machine enabled surgeons to perform 
more complex mitral valve repair [287].  More recently, beating heart mitral valve repair 
techniques have been developed for: edge-to-edge leaflet repair, leaflet ablation repair, 
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repair of leaflet coaptation, direct annuloplasty repair, indirect annuloplasty repair, 
subannular repair, and chordae tendineae replacement.   
This chapter provides a description of beating heart mitral valve repair techniques, an 
evaluation of the published outcomes following the use of these techniques, and a 
discussion of the main challenges encountered in the implementation of these techniques.   
1.10.1  Edge-to-Edge Repair 
The edge-to-edge repair was first performed by Alfieri in 1991 for anterior leaflet 
prolapsed [190, 299, 300].  The procedure was first performed through a median 
sternotomy with cardiopulmonary bypass and cardiac arrest.  Since that time, this 
technique has been successfully used in the minimally invasive repair of both 
degenerative and functional mitral regurgitation. 
The Mitraclip (Evalve Inc, Redwood City, Calif; MitraClip Inc., Abbott Vascular, USA) 
device is a 4 mm wide cobalt-chromium clip housed in a catheter, and it is advanced 
through the femoral vein to the right atrium under 3D TEE and fluoroscopy guidance [94, 
290, 291].  Trans-septal puncture is performed in the mid-superior and posterior aspect of 
the fossa ovalis.  The clip is advanced through the left atrium to the left ventricle below 
and perpendicular to the line of coaptation.  The leaflets are grasped by retraction of the 
clip and the leaflet edges clipped together when the device is closed.  The clip can be 
reopened and repositioned if required.  Also, a second or third clip may be added to 
improve the result.  MitraClip has been implanted in over five thousand patients with 
degenerative and functional mitral regurgitation worldwide.   
Although both the EVEREST I and EVEREST II trials have demonstrated the safety of 
MitraClip implantation, the efficacy of this device to repair mitral valve regurgitation is 
not clear cut [94, 290, 291].  The safety advantage of MitraClip over conventional mitral 
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valve repair is derived from a higher rate of transfusions with conventional mitral valve 
repair.   
Both randomized controlled trials demonstrate that conventional mitral valve repair is 
more effective than MitraClip implantation at reducing mitral regurgitation.  Despite 
these outcomes, patients in the MitraClip cohort reported better quality of life and 
symptomatic relief than conventional surgery patients.  Therefore, MitraClip emerges as 
an option for those patients who are elderly higher risk surgical candidates in whom a 
decreased reduction in mitral regurgitation may afford a better quality of life following 
the procedure.       
With this patient cohort in mind, the ACCESS-EU trial was initiated.  ACCESS-EU is a 
prospective, observational study at 14 European centres [93].  Compared to the 
EVEREST trial patient cohort, patients enrolled in this study are older (mean age 74 ± 10 
years), with more comorbidities, and depressed left ventricular function.  The thirty day 
mortality in MitraClip patients was 2.3% and one year mortality 17.3%.  Mitral valve 
regurgitation improved to grade 2 or less in 79% of 327 patients with matched 
echocardiographic data, and NYHA class to II or less in 72% of 343 patients with 
matched clinical data.  At one year, the results from MitraClip patients are as follows: 
freedom from death was 82%, freedom from mitral valve regurgitation greater than 2+ 
was 79%, and freedom from mitral valve surgery was 94% [93].  
Similarly, the MOBIUS Leaflet Repair System (Edwards Lifesciences Corp., USA) was 
developed to achieve an edge-to-edge repair; however, this system uses a suture secured 
by nitinol clips to create a double mitral valve orifice.  The MOBIUS catheter is 
advanced through the femoral vein to the right atrium, and requires transeptal puncture to 
allow it to enter the left atrium.  The mitral valve leaflets are grasped sequentially under 
transesophageal echocardiographic guidance.  Following needle penetration of the 
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leaflets, the suture is exteriorized and fastened with a nitinol suture clip to create a double 
orifice.  Although initial animal trials showed feasibility of this device, poor outcomes 
were reported in human trials [292, 293].  Insufficient tissue penetration of the suture and 
asymmetric deployment of the sutures led to unsuccessful deployment and limited device 
durability [292, 293]. 
The main limitations of edge-to-edge techniques are their limited applicability to mitral 
valve pathology and the lack of annuloplasty repair.   Candidacy for the MitraClip is 
determined according to strict anatomical features including a flail segment width less 
than 1.5 cm and a regurgitant jet origin from within the central two-thirds of the line of 
leaflet coaptation [290].  Conventional edge-to-edge mitral valve repair can be applied to 
a larger number of patients because annuloplasty repair and other required procedures can 
be performed concurrently through a median sternotomy with cardiopulmonary bypass.  
Moreover, the addition of mitral valve annuloplasty is an important component of mitral 
valve repair and the absence of an annuloplasty band or ring has been associated with 
shorter durability in some studies [289, 294-296].  In the future, a combination of both 
percutaneous edge-to-edge leaflet repair and annuloplasty repair may expand the 
indications and improve efficacy and durability of these devices.   
1.10.2 Leaflet Ablation 
Radiofrequency ablation has been proposed as a treatment of mitral valve regurgitation.  
In myxomatous mitral valve regurgitation, redundant leaflet tissue prevents the valve 
from coapting during systole.  Radiofrequency ablation generates thermal lesions by 
denaturing collagen and disrupting the tissue architecture.  As a result, the leaflet size can 
be reduced and coaptation is improved.  The Thermocool irrigation ablation electrode 
(Biosense Webster, Inc., Diamond Bar, California) is a radiofrequency ablation catheter 
that is advanced through the femoral artery to the left ventricle.  Radiofrequency ablation 
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is delivered to the anterior leaflet of the mitral valve to induce scarring, fibrosis, and 
reduced leaflet motion [297].   
At this time, there is little evidence of efficacy of this device.  Only animal studies have 
been reported that require median sternotomy access to the mitral valve leaflets.  
Unfortunately, the resulting fibrosis is difficult to predict; therefore, there may be residual 
or worsening mitral valve regurgitation.  Furthermore, damage to the leaflets and adjacent 
cardiac structures may be induced [297].   
1.10.3 Direct Annuloplasty Repair 
The aim of mitral valve annuloplasty is to restore a normal ratio between the annular size 
and leaflet surface area in order to increase the surface of coaptation [298]. In addition, 
this technique may adjust the shape of the annulus to restore normal geometry.  
Annuloplasty is usually performed after leaflet lesion correction.  Different annuloplasty 
methods and devices are available.  Typically, annuloplasty repair involves the 
implantation of a ring or band surrounding the mitral annulus that brings the leaflets 
together to facilitate coaptation.  While several devices have been developed for 
minimally invasive direct annuloplasty repair, these technologies are at an early phase of 
development.   
The Mitralign device (Mitralign Inc, Tewksbury, Mass, USA) is advanced through 
transfemoral arterial access to the left ventricle.  Plegetted anchors connected by a suture 
are placed at the base of the posterior mitral valve leaflet along the posterior mitral valve 
annulus.  The resulting purse-string suture is tightened to reduce the annular dimensions.  
The first human trial of this technique achieved success; however, no further results are 
reported [298].   
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Similarly, the AccuCinch (Guided Delivery Systems, Santa Clara, CA, USA) device is 
advanced transapically to the left ventricle where multiple anchors are deployed below 
the leaflets from commissure to commissure [298, 299].  The anchors are joined by a 
contracting wire, with the resulting cinching device being adjusted to reduce the annular 
dimensions.  The first human trial of this technique achieved success [299]; however, no 
further results are reported. 
Cardioband (ValtechCardio, OrYehuda, Israel) is advanced through a left mini-
thoracotomy to the left atrium [300, 301].  The steerable device carrying a Dacron band 
and metallic anchors are advanced to the mitral valve under echocardiographic guidance.  
Next, up to fifteen metallic helical anchors are implanted in the base of the mitral valve 
annulus under echocardiographic guidance and tactile feedback.  Once deployment of the 
implant is completed, the implant is disconnected from the delivery system and 
connected to an adjustment roller used to contract or expand the band under 
echocardiographic guidance.  Once the desired contraction is obtained, the implant is 
released from the adjustment tool.  The delivery system is removed through an 18F 
sheath in the left atrium and the access incision is closed using a purse string stitch.  
Animal trials of this device were successful off pump; however, human trials of this 
device require implantation on cardiopulmonary bypass [300, 301].  The annuloplasty 
band is adjusted under beating heart conditions.  Therefore, although this technique is 
considered minimally invasive, all human trials have required cardiopulmonary bypass 
for implantation of the annuloplasty band. 
1.10.4 Indirect Annuloplasty Repair 
Due to the close location of the coronary sinus to the mitral valve annulus, devices have 
been developed for deployment in the coronary sinus to decrease the annular diameter by 
forcing the posterior annulus anteriorly and reducing the anterior-posterior dimension. 
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The MiCardia DYANA annuloplasty system (MiCardia Corp, Irvine, Calif) is a nitinol-
based annuloplasty ring that decreases the anterior-posterior diameter of the mitral valve 
by radiofrequency ablation via detachable activation wires, under TEE guidance [302-
306].  Without radiofrequency activation, it functions as a standard complete 
annuloplasty ring. The nitinol support is encapsulated in silicone and covered with a 
polyester cloth to allow for suture attachment.  The annuloplasty ring is sutured to the 
mitral valve annulus under cardiopulmonary bypass, as in conventional surgery.  The 
distal ends of activation wires are attached to the annuloplasty ring, and the proximal 
ends are attached to a radiofrequency generator. After surgical implantation of the 
annuloplasty ring, the proximal ends of the activation wires are passed through the 
atriotomy, the left atrium is closed, and the patient is weaned from cardiopulmonary 
bypass.   The size of the annulus is adjusted using TEE guidance.  Finally, the activation 
wires are disengaged and removed through the atriotomy suture line at the end of the 
procedure in all patients before closure of the sternum.  Human implantation of this 
annulplasty ring has successful outcomes [306]; however, cardiopulmonary bypass is 
required for ring implantation.  
The PS3 system (Ample Medical Inc, Foster City, CA, USA) deploys an anchor in the 
coronary sinus and attaches a cord traversing the left atrium to be anchored in the fossa 
ovalis [307, 308]. This tether is then tensioned to diminish the anterior-posterior 
dimension of the mitral annulus.  In an unpublished report, the PS3 system was implanted 
in two patients before open heart surgery and then removed during the surgical procedure 
[307, 308].  Mitral valve regurgitation was significantly reduced by the device alone.  No 
further trials have been reported.   
The MONARC device (previously Viking device; Edwards Lifesciences, Irvine, 
California, USA) consists of proximal and distal self-expanding nitinol stents connected 
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by a strut [309].  The strut consists of a spring with an absorbable suture holding the 
spring in a partially open position.  The device is advanced through the internal jugular 
vein to the coronary sinus.   After the coronary sinus diameters and length have been 
carefully measured before the procedure, the device is advanced into the coronary sinus 
in an introducer.  The distal stent is deployed by extruding the device out of the 
introducer, and it becomes fixed in place by the radial force the stent applies on the 
coronary sinus wall. The remainder of the device is then deployed, with placement of the 
proximal stent in the proximal coronary sinus. Over a period of weeks, the suture 
dissolves, allowing the spring to compress between the fixed proximal and distal stents.  
Shortening the device reduces the anterior-posterior dimension of the mitral valve, 
thereby improving leaflet coaptation.  As a result, the annulus size is reduced leading to a 
reduction in mitral regurgitation.   
The first-generation MONARC device developed a fracture in the bridge segment that 
resulted in device separation during follow-up in 3 of 5 patients.  Bridge separation did 
not cause adverse events but may have reduced the efficacy of the device. Therefore, a 
non-biodegradable suture was added to reinforce the bridge segment and reduce the 
likelihood of separation of the device following implantation.  The human trial of this 
new device is reported in the EVOLUTION trial [309].  Despite the new design, device 
fracture continues to occur following MONARC implantation.     
CARILLON Mitral Contour System (Cardiac Dimensions Inc., Kikland, Washington) 
uses two self-expanding nitinol hoop-shaped helical anchors connected by a nitinol 
bridge [310-312].  The device is advanced through the internal jugular vein to the 
coronary sinus.  The distal anchor is deployed in the coronary sinus anchor, then manual 
tension is applied to the connecting wire and the proximal anchor is deployed, obtaining a 
shortening of the mitral annular dimension.  The tension on the device can be adjusted 
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before the final release, with the degree of traction being guided by both fluoroscopic and 
echocardiographic assessments.  Once tissue plication is optimized, the proximal anchor 
was deployed near the coronary sinus ostium.  Despite reports of reverse left ventricular 
remodeling and significant clinical improvements following implantation, the safety of 
this device has yet to meet the standard of conventional mitral valve repair [310-312]. 
The Viacor device (Viacor, Inc., Wilmington, Massachusetts) is based on placing a 
multilumen delivery catheter through the right internal jugular vein into the coronary 
sinus, and then introducing one or more nitinol rods of different lengths and extensibility 
into the lumens to reshape the annulus [313-317].  The device consists of a composite 
nitinol (nickel titanium alloy) and stainless steel construct and is coated with medical-
grade teflon and polyethylene plastic.  In addition, this device is comprised of a 
substantially straight and rigid element that is connected to a flexible push rod to 
facilitate delivery.  When passed through the internal lumen of a guiding catheter 
positioned in the coronary sinus, the rods maintain their straight shape.  This exerts 
outward force on the mitral valve annulus resulting in anterior displacement of the 
posterior annulus and increases leaflet coaptation.  The guide catheter and annuloplasty 
device are designed with radiopaque components to enable visualization under 
fluoroscopy.  However, results from in-human trials were disappointing due to difficult 
device delivery and device fracture [316, 317].   
Clearly, although initial animal trials of indirect annuloplasty devices were promising, 
human trials proved more challenging [316, 317].  There are several reasons for this 
discrepancy.  In patients with chronic mitral valve regurgitation, the distance between the 
coronary sinus and the posterior mitral valve annulus increases with left ventricular 
remodeling; therefore, the effectiveness of the device is potentially decreased.  
Furthermore, the anatomic location of the coronary sinus does not consistently lie in 
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plane with the mitral valve annulus.  In some patients, force is applied to the left atrial 
wall and not the mitral valve annulus; therefore, the annulus may continue to dilate, 
reducing device effectiveness. 
Moreover, coronary arteries may lie between the mitral annulus and the coronary sinus.  
In fact, the diagonal or intermediate ramus coronary vessel crosses between the coronary 
sinus and the mitral valve annulus in 16% of patients; and the circumflex artery crosses 
between these two structures in 64-80% of patients [318-322]. Furthermore, the friable 
coronary sinus can be dissected with advancement of these devices.  In addition, several 
studies have reported device fracture after implantation into the coronary sinus. 
Finally, other limitations include significant mitral valve calcification, the presence of 
coronary sinus pacing leads, coronary venous branch point variability, coronary venous 
system size constraints as a risk for coronary sinus perforation, and structural mitral valve 
leaflet abnormalities.  In addition, these devices may prevent future attempts at 
implanting cardiac resynchronization devices.   
1.10.5 Subvalvular repair 
Coapsys device (Myocor Inc, Minneapolis, Minn) employs a transventricular splint with 
pads on the anterior and posterior epicardial surfaces of the left ventricle connected by a 
subvalvular cord [323-336]. In an open chest, this device is placed on a beating heart 
under direct echocardiographic guidance. A suction cup-stabilized c-clamp with anterior 
and posterior locators is placed around the left ventricle.  The posterior locator is 
positioned externally between the papillary muscle insertions, about 2 cm below the 
insertion of the posterior leaflet. The anterior locator is placed on the right ventricle side 
of the left anterior descending coronary artery, halfway down the longitudinal axis of the 
ventricle. Verification of these locations is determined by handheld epicardial 
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echocardiography. The jig guides a thin blunt-tipped needle through the left ventricle 
from one locator to the other. The needle is followed by the Coapsys cord. The Coapsys 
device, with pads attached to either end, is initially placed without tension. Sizing is then 
conducted under real-time colour flow Doppler imaging to quantify mitral valve 
regurgitation. Pads attached to each end of the splint are tightened to pull the ventricle 
into the region of the papillary muscles and also to move the posterior leaflet to better 
coapt with the anterior leaflet. 
The i-Coapsys (Myocor Inc, Minneapolis, Minn) device performs the same role but can 
be delivered by transcatheter implantation system with fluoscopic guidance [336].   The 
device consists of two epicardial pads (anterior and posterior) connected by a load-
bearing transventricular chord.  Pericardial access is gained through a right anterolateral 
intercostal incision through which the device is advanced into the pericardial space.  
Three vacuum stabilized catheters are used to identify the appropriate anterior and 
posterior pad implantation sites and anterior and posterior pads are advanced under 
fluoroscopic guidance.   
1.10.6 Chordae tendineae replacement 
Replacement of the diseased chordae tendineae with PTFE neochordae for conventional 
repair of mitral valve regurgitation is associated with low operative mortality, high 
freedom from re-operation, and long-term survival similar to the general population [187, 
193, 194].  The NeoChord DS1000 (NeoChord Inc., Eden Prairie, MN USA) was 
developed as an off-pump device that uses transapical access to deliver PTFE sutures to 
flail segments of the mitral valve [337-340].  This device is introduced into the left 
ventricle and left atrium through transapical access.  Using the center thumb ring shaft 
(Figure 1.7), the surgeon opens the gripper at the distal end of the tool and then closes the 
gripper on the prolapsed portion of the mitral leaflet by releasing the thumb ring.  Correct 
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leaflet capture is verified using a fiber-optic-based detection mechanism.  After leaflet 
capture has been verified, a needle and an exchangeable cartridge for loading the 
NeoChord suture are installed within the tool.  The needle is used to puncture the leaflet 
and a PTFE suture is pulled through the leaflet; then the tool is retracted outside the apex 
of the heart with both ends of the suture.  The suture is fixed at the leaflet with a girth 
hitch knot, adjusted under Doppler ultrasound to ensure minimum mitral regurgitation 
and then secured at the apex using a pledget.  Multiple neochordae are typically used to 
ensure optimal valvular function. 
 
Figure 1.7:  The NeoChord DS1000 (A) has the following features: A tip with 
expandable jaws to grasp the leaflet and 4 fiber-optic channels (B) each of which 
corresponds to an indicator light on the device monitor (C) to confirm proper leaflet 
capture. The needle (D) is also included in the device to deploy the suture after 
confirmation of leaflet capture [340]. 
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After extensive acute and chronic animal studies throughout Europe, Canada, and the 
United States, the NeoChord is undergoing human trials for the repair of degenerative 
mitral valve regurgitation [337-340].  Initial results confirm the safety and efficacy of this 
surgical tool for mitral valve repair in patients with degenerative mitral valve 
regurgitation.  However, the limited visualization during tool navigation to the mitral 
valve leaflets and neochord dehiscence, or tearing, from the mitral leaflet following 
deployment are ongoing challenges with this procedure. 
 
1.11 Challenges of Beating Mitral Valve Repair 
Beating heart cardiac surgery alone is technically challenging and requires superior 
visualization of cardiac structures; however, minimally invasive techniques are even 
more challenging due to the absence of direct vision. 
Transcatheter valve techniques have been developed to enable beating heart mitral valve 
repair. Although these techniques have shown positive results in animal and human trials, 
beating heart mitral valve repair is challenging due to the limitations of currently 
available medical imaging techniques.  
Mitral valve repair using beating heart minimally invasive procedures requires adequate 
visualization of the mitral valve apparatus and critical cardiac structures adjacent to the 
mitral valve.  At this time, fluoroscopy and echocardiography are used for intraoperative 
guidance of beating heart mitral valve procedures.   
Although fluoroscopy provides 2D imaging of these gross anatomical structures, their 3D 
context is lost [341].   Echocardiography lacks the spatial and temporal resolution to view 
intracardiac instruments and critical cardiac structures simultaneously; therefore, there is 
a risk of potential injury to intracardiac structures during instrument navigation.   
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For example, use of the NeoChord DS1000 tool relies exclusively on TEE guidance in 
the form of 2D single plane, biplane, and 3D imaging for tool navigation and neochordae 
deployment [342, 343].  The tool is identified in 2D biplane ultrasound (mitral valve 
commissural, midesophageal long-axis view), and navigated into the commissure of the 
mitral valve leaflets, while the surgeon and echocardiographer attempt to maintain tool 
tip, tool profile, and final target site in the ultrasound image planes at all times. Correct 
position and orientation of the grasping tool are then achieved using a 3D zoomed view. 
Returning to biplane ultrasound for higher temporal and spatial resolution, the prolapsing 
leaflet is grasped by the jaws of the NeoChord device.  
A major challenge in navigating the NeoChord device to the mitral valve target region is 
that ultrasound imaging must simultaneously keep the target region (mitral valve line of 
coaptation) and the tool tip in view.  While TEE has so far proven adequate for the final 
positioning of the tool and grasping the leaflet, there have been safety concerns relating 
to the navigation of the tool from the apex to the target mitral valve leaflet.   
Echocardiography lacks the spatial and temporal resolution to view intracardiac 
instruments and critical cardiac structures simultaneously; therefore, there is a risk of 
potential injury to intracardiac structures during instrument navigation.   TEE guidance is 
problematic since it is not always possible to maintain appropriate spatial and temporal 
resolution in 3D, and it is not always possible using 2D and 2D bi-plane views to 
simultaneously maintain both the tool tip and the target site in the field of view.  Due to 
these navigation challenges, the tool can be caught in the subvalvar apparatus risking 
chordal rupture or leaflet perforation.  Clearly, novel imaging modalities are required 
for superior tool guidance and improved patient safety and outcomes.  
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1.12 Aortic Valve Anatomy 
The aortic valve opens to permit the passage of oxygenated blood from the left ventricle 
to the aorta and systemic circulation during systole.  It closes to ensure efficient flow of 
oxygenated blood from the aortic root to the coronary arteries during diastole and to 
prevent backflow of blood into the left ventricle.  The aortic root extends from the basal 
attatchment of the aortic valve leaflets within the left ventricle to the leaflet attachments 
at the sinotubular junction [344, 345].  The sinotubular junction is demarcated by the top 
attachments of the aortic valve leaflets and it forms an outlet of the aortic root into the 
ascending aorta [344, 345]. The sinus of Valsalva is the dilated portion of the aortic just 
above the aortic valve annulus from which the coronary arteries originate.  The aortic 
valve comprises three leaflets, or cusps:  the left coronary cusp, the right coronary cusp, 
and the noncoronary cusp.  The left coronary artery originates from the aortic root above 
the left coronary cusp.  The right coronary artery originates from the aortic root above the 
right coronary cusp.   
1.13 Aortic Valve Stenosis Etiology and Classification 
Aortic valve stenosis occurs when there is incomplete opening of the aortic valve orifice 
that obstructs the normal flow of blood from the left ventricle during systole.  Thickening 
and fusion of aortic valve leaflets may occur secondary to degenerative calcification in 
tricuspid or bicuspid aortic valves or to rheumatic heart disease [3, 346].    
1.13.1 Degenerative Aortic Valve Stenosis 
The most common cause of aortic valve stenosis is degenerative calcification of the aortic 
valve leaflets.  With aging, cumulative mechanical stress generates proliferative and 
inflammatory changes with lipid accumulation and calcium deposits on the leaflets 
making them thick and immobile [348-352]. As a result, they are prevented from opening 
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properly during systole.  This generally culminates in septuagenarians and octogenarians.  
In fact, the prevalence of moderate to severe aortic valve stenosis in the population over 
the age of 75 is between 3-9 % [353].   
Calcium may also deposit cephalad through the ascending aorta.  As this process is 
similar to atherosclerosis, the risk factors for the development of degenerative calcific 
aortic valve stenosis also include elevated serum levels of low-density lipoprotein 
cholesterol, diabetes, smoking, and hypertension [351].   
1.13.2 Bicuspid Aortic Valve Stenosis 
Bicuspid aortic valves are more prone to developing calcified aortic valves.  These valves 
have two fused leaflets that result in a bicuspid conformation, rather than the normal 
tricuspid aortic valve conformation. Bicuspid aortic valves are present in approximately 
2% of the general population [354].  The bicuspid conformation induces more turbulent 
blood flow across the aortic valve; therefore, buildup of calcification becomes significant 
earlier and is seen in the fifth and sixth decades of life [355]. 
1.14  Rheumatic Aortic Valve Stenosis 
Furthermore, rheumatic deposits on the aortic valve may also cause aortic valve stenosis.  
Rheumatic aortic valve disease is characterized by lymphocytic infiltration to the aortic 
valve leaflets.  As a result, the leaflets become thickened with scarred and fused leaflet 
[356].  Rheumatic valve disease is rarely isolated to the aortic valve, as it commonly 
involves the mitral valve [357]. 
1.15 Natural history of aortic valve stenosis 
The average area of the aortic valve orifice is 3-4 cm2 [3].  As the aortic valve leaflets 
become thickened and fused, the left ventricular outflow tract is narrowed.  Once the 
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aortic valve area decreases to below 1.5 cm2, there is increased pressure and wall stress 
within the left ventricle [3, 346].  As a result, the left ventricle adapts by increasing wall 
thickness.  This is called left ventricular hypertrophy.  The hypertrophied left ventricle is 
less compliant during diastole and requires increased myocardial oxygen consumption.  
Furthermore, diastolic dysfunction and increased diastolic pressures compresses coronary 
arteries and decreases coronary flow to the left ventricle [358].   
In summary, there is increased myocardial oxygen demand and decreased myocardial 
oxygen supply.  Therefore, the heart is more susceptible to ischemic injury.  At this point, 
patients with aortic valve stenosis may develop angina.  In the late stages of severe aortic 
valve stenosis, the left ventricle gradually decompensates, resulting in heart failure.  With 
progressive left ventricular outflow obstruction and left ventricular dysfunction, there is 
inadequate cardiac output to the systemic circulation.  Patients develop symptoms of 
syncope, or loss of consciousness, from cerebral hypoperfusion [359].  Furthermore, as 
cardiac output declines, there is an increase in pulmonary congestion leading to 
pulmonary hypertension.  Patients may present with dyspnea as a result of congestive 
heart failure [360].  
Initially, patients may be asymptomatic for a long period of time; however, as the aortic 
valve narrowing becomes more hemodynamically significant and symptoms develop, 
prompt surgical intervention is required, as patient mortality increases dramatically [69].  
The mean survival of patients with angina is five years.  The mean survival of patients 
that present with syncope is three years, and the mean survival of patients who present 
with symptoms of congestive heart failure is less than one year [361].  
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1.16 Role of imaging in aortic valve stenosis 
1.16.1 Role of Echocardiography 
Echocardiography is the most common diagnostic tool for diagnosis and grading of aortic 
valve stenosis.  Both TTE and TEE are used to diagnose and grade the severity of aortic 
valve stenosis, to diagnose any concomitant cardiac disease, and to evaluate ventricular 
function.  Grading the severity of aortic valve stenosis is based primarily on 
echocardiographic measurements of pressure gradients across the aortic valve and peak 
jet velocity across the aortic valve, and on the calculation of aortic valve area [Table 1.3; 
69].  As aortic valve stenosis is a progressive disease, the AHA recommends periodic 
TTE every five and two years for mild and moderate aortic valve stenosis, respectively 
[69].  
Table 1.3: Aortic Valve Stenosis Severity Assessment by Echocardiography [3]. 
Measurement Mild Moderate Severe 
Aortic valve area (cm2) >1.5 1.0-1.5 <1.0 
 
Mean pressure gradient 
(mmHg) <25 25-40 
 
 
>40 
 
Peak jet velocity (m/s) <3 3-4 
 
>4 
 
1.16.2 Role of Cardiac Angiography 
Cardiac angiography is the gold standard for measuring the gradient across the aortic 
valve [3].  Therefore, cardiac angiography is used to determine both the severity of aortic 
valve stenosis and any concomitant coronary artery disease.  Ventricular function and the 
presence of additional cardiac disease can also be elucidated from angiography.   
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1.16.3 Role of Computed Tomography (CT) 
Although CT is not used routinely for diagnosis of aortic valve stenosis, it may be used 
for preoperative assessment of ascending aortic calcification prior to aortic valve surgery.  
The presence of extensive aortic calcification may preclude aortic cross clamping 
required for cardiopulmonary bypass.  In addition, CT can be used to assess the caliber of 
the ascending aorta.  A dilated ascending aorta that may be prone to dissection or rupture 
should be identified prior to aortic valve surgery for appropriate operative planning.   
1.16.4 Role of Magnetic Resonance Imaging (MRI) 
Similarly, MRI is not used routinely for diagnosis of aortic valve stenosis; however, it is 
an alternative noninvasive imaging modality for assessment of aortic valve stenosis 
[362].  Cardiac MRI uses a range of pulse sequences to assess structural heart disease, 
including aortic valve leaflet pathology and left ventricular hypertrophy [363-366].   
1.17 Indications for surgery in aortic valve stenosis 
Aortic valve replacement is the only definitive treatment for aortic valve stenosis.  No 
effective medical therapy for aortic valve stenosis exists.  As the onset of symptoms and 
ventricular dysfunction herald a dramatic increase in mortality, both symptom onset and 
left ventricular dysfunction are Class I indications for aortic valve replacement in 
patients with severe aortic valve stenosis [23].  It is also a Class I indication to replace 
the aortic valve in asymptomatic patients with severe aortic valve stenosis who require 
concomitant coronary revascularization or aortic surgery [69].    
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1.18 Surgical management of aortic valve stenosis 
1.18.1 Aortic valve replacement 
1.18.1.1 Aortic valve prostheses 
Currently, mechanical or bioprosthetic aortic valve replacement is the only established 
treatment for aortic valve stenosis [3].  The first orthotopic mechanical prosthetic aortic 
valves were a ball and cage design; however, their poor hemodynamic performance 
prompted the development of tilting disc prosthetic aortic valves [3, 367, 368].  In 1977, 
St. Jude Medical developed a bileaflet tilting disc valve with a lower postoperative aortic 
gradient and a lower rate of thromboembolism than previously developed models [369- 
373].  This is the most commonly implanted type of mechanical prosthesis in the world 
[374].     
There are several different types of bioprosthetic valves available: stented, homografts, 
stentless, and pulmonary autografts.  Stented biologic prostheses are constructed from 
either porcine aortic valves or bovine pericardium fixed with glutaraldehyde to reduce 
calcium deposition and to antigenicity [375].  Over the years, the design of stented 
bioprosthetic valves has been ameliorated with newer fixation methods to reduce material 
fatigue and calcification and with thinner stents and lower profiles.   
However, the stents, large sewing rings, and supporting structures of mechanical and 
stented bioprosthetic valves may impinge on the left ventricular outflow tract.  In 
contrast, homografts, stentless valves, and pulmonary autografts are free of these support 
structures.  Therefore, larger prostheses can be implanted to produce superior aortic valve 
hemodynamics.  In fact, the first valve used for aortic valve replacement was an aortic 
homograft valve in the descending aorta [376, 377].   Subsequently, orthotopic aortic 
homograft implantation was completed using subcoronary placement [378-380].  
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Homograft valves can be obtained from donors whose beating hearts are not suitable for 
transplantation or from nonbeating heart donors and cryopreserved until use [3].  In 
addition to an excellent hemodynamic profile, aortic homografts have a low risk of 
thromboembolism and do not require anticoagulation and they have a low risk of valve 
infection.  Unfortunately, these valves are also subject to structural deterioration that is 
directly related to donor age and inversely related to recipient age [3].  In addition, 
homograft availability is limited.  Therefore, their use is usually reserved for challenging 
cases of aortic valve endocarditis or for younger patients requiring both aortic valve and 
root replacement who cannot be anticoagulated [381]. 
Pulmonary autografts were first implanted in the aortic position in 1967 [382].  They are 
the only autologous valve replacement option.  In addition to an excellent hemodynamic 
profile, aortic homografts have a low risk of thromboembolism and do not require 
anticoagulation and they have a low risk of valve infection [383].  However, aortic valve 
replacement with a pulmonary homograft is technically demanding [3].   
Stentless xenograft aortic valves were developed to offer the excellent hemodynamics of 
homografts and autografts, but with improved availability and lower cost [384-386].  
However, implantation of stentless aortic valves is technically challenging and has the 
potential for increased operative risk and higher operative mortality stented aortic valve 
replacement [387].  Therefore, the use of stentless aortic bioprostheses is contentious.   
1.18.1.2 Surgical procedure for aortic valve replacement 
In conventional aortic valve replacement with a mechanical or stented bioprosthetic 
valve, the aortic valve is accessed though a midline sternotomy. The pericardium is 
opened and the patient is placed on cardiopulmonary bypass using an aortic cannula in 
the ascending aorta and a venous cannula through the right atrial appendage.  The aorta is 
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cross-clamped and an aortotomy incision is made below the cross-clamp and 
approximately 1 cm above the takeoff of the right coronary artery.  This is extended 
approximately three-quarters of the way around the aorta and the native aortic valve 
leaflets are excised along with any calcium.  Braided 2-0 stitches are sutured in an 
interrupted mattress fashion around the annulus, then passed through the sewing ring of 
the prosthesis.  The prosthetic valve is lowered into the annulus. After proper leaflet 
motion and coronary artery patency are assured, and the aortotomy is sutured closed.  
1.18.2 Outcomes of aortic valve replacement 
The mortality rate for isolated aortic valve replacement at both high and low volume 
centres, as reported by the Society of Thoracic Surgeons’ is 3.2% [69].  The expected 
survival after aortic valve replacement is approximately 80 to 85% at five years, 65 to 
75% at ten years, and 45 to 55% at fifteen years [388-390].  Longitudinal analysis 
demonstrates no difference in survival up to ten years between patients of the same age 
receiving mechanical and bioprosthetic valves [391].  However, at fifteen years, there is a 
survival benefit for patients with mechanical valves as bioprosthetic valves fail due to 
structural valve deterioration.  In one trial, the fifteen year mortality was 79 and 66% for 
bioprosthetic and mechanical valves, respectively [392]. 
In the early follow-up period, anticoagulation related hemorrhage is the most common 
untoward event for mechanical valve prostheses. Thus, over the first ten years of follow-
up there is a higher incidence of valve related complications in patients with mechanical 
prostheses as opposed to those with biologic valves [393].  Whereas from ten to twenty 
years following surgery, this ratio is reversed because of incidence of bioprosthetic valve 
failure.  Furthermore, biological valves have a higher failure rate in younger patients.  
Burdon and colleagues found that after 15 years of follow up only a third of patients who 
had received a bioprosthesis for aortic valve replacement between the ages of 16–39 
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years remained free of structural valve deterioration, compared with more than 90% of 
those over 70 at the time of implantation [394]. These findings have been corroborated by 
others [395].   
For this reason and to avoid the bleeding risks of anticoagulation, many surgeons have 
recommend a bioprosthetic aortic valve for patients age 70 and over. In patients younger 
than 60 years of age, most opt for a mechanical prosthesis based on prosthesis durability.   
1.18.3 Challenges in aortic valve replacement 
Conventional aortic valve replacement drastically improves the mortality of patients with 
symptomatic aortic stenosis.  However, it requires sternotomy and cardiopulmonary 
bypass that are particularly detrimental in elderly or frail patient with comorbidities.  
Therefore, these high risk patients may not be offered surgery and managed 
conservatively with medical therapy.  Unfortunately these patients have an extremely 
poor prognosis [396, 397].   Transcatheter aortic valve implantation (TAVI) has emerged 
as an therapeutic option for these high-risk patients [8, 398, 399]. 
1.18.4 TAVI 
TAVI is a minimally invasive aortic valve replacement technique involves the delivery of 
a bioprosthetic valve within an expandable stent to the beating heart via a catheter.  
Guidewires and sheaths are placed through a vascular access site to reach the level of the 
aortic valve.  TAVI access has been described through the left ventricular apex using a 
left anterior minithoracotomy incision, or through femoral, subclavian, axillary, and 
carotid arteries [400-402].  Some cases of ascending aortic access have also been 
reported. Balloon valvuloplasty may be performed to relieve the stenosis of the native 
aortic valve. The prosthesis is then guided up to the level of the aortic annulus and 
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implanted under rapid ventricular pacing to temporarily reduce cardiac output [403, 404].  
The deployed valve relies on radial traction forces to remain within the native aortic 
annulus. This procedure was first reported in human patients in 2008 [405].   
The Placement of AoRTic TraNscathetER Valve (PARTNER) trial has demonstrated 
significantly better survival in TAVI treatment compared to medical therapy in non-
surgical patients up to five years postoperatively [8, 398].  However, the second arm of 
the PARTNER trial comparing TAVI treatment to high risk patients who underwent 
conventional aortic valve replacement found no significant difference in mortality and 
higher morbidity in the TAVI group [399].  
Currently, there are many commercially available TAVI stent designs.  The SAPIEN TM 
valve (Edwards Lifesciences, Irvine, CA,) and the CoreValve TM (Medtronic Inc., 
Minneapolis, MN) received Food and Drug administration approval for use.  The 
JenaValve (JenaValve, Munich, Germany) was awarded CE mark in 2011.  Medtronic’s 
Engager valve, Boston Scientific’s Lotus valve, St Jude Medical’s Portico valve, and 
Direct Flow Medical’s Direct Flow valve were awarded European CE mark in 2013.  
Symetis’ AcurateTM valve (Symetis, Lausanne, Switzerland) was awarded European CE 
mark in 2014.   
The SAPIEN bovine pericardial valve on a balloon-expandable stent, while the 
CoreValve is a porcine pericardial valve on a self-expanding nitinol frame.  The 
JenaValve is a porcine root valve within a nitinol self-expanding stent.  The Engager is a 
bovine pericardial valve on a self-expanding nitinol frame.  The Lotus is a bovine 
pericardial valve on a nitinol frame that requires controlled mechanical expansion for 
deployment.  The Portico valve is a bovine pericardial valve on a self-expanding nitinol 
frame.  The Direct Flow valve is a bovine pericardial tissue valve mounted between two 
inflatable polyester rings that adapt to the native aortic annulus and the left-ventricular 
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outflow tract fill with contrast dye for optimal positioning under fluoroscopy.  The 
Acurate valve is a porcine valve mounted within a self-expanding nitinol stent [406]. 
1.19 Emerging challenges in TAVI 
As the use of TAVI has expanded, the risks and challenges associated with this 
technology have been reported.  Postoperative mortality, stroke, and nephrotoxicity from 
contrast use have been reported [407].   Moreover, several additional postoperative 
complications have been reported that are directly linked to improper valve positioning 
and deployment.  These include prosthetic valve embolism, coronary obstruction, heart 
block requiring permanent pacemaker, and paravalvular leak and secondary [407].  
Optimal positioning and safe deployment of TAVI valved-stent is integral to the success 
of the procedure.  The PARTNER Trials demonstrated a 30-day mortality of 3.4-5% for 
TAVI patients [8, 399].   The majority of these complications may be related to 
inadequate image guidance and suboptimal valve positioning.  Implantation of the 
valved-stent too far above the aortic valve annulus may result in embolism of the valved-
stent or coronary occlusion by the valved-stent; whereas, positioning the valved-stent too 
far below the aortic valve annulus may cause atrioventricular block requiring a permanent 
pacemaker or retrograde embolization [341].  Some cases of paravalvular leak may also 
be related to poor positioning of the stent with respect to calcium on the native leaets, 
which prevents the stent from deploying fully [27]. 
Currently, many imaging modalities may be used intraoperatively to guide valve 
deployment.  However, most centres use fluoroscopy for positioning and deployment of 
the transcatheter valve.  Ideal valve positioning depends on the type of valve being 
deployed.  Ideally, the Edwards Sapien Valve rim should be positioned 2/3rd above and 
1/3rd below the native aortic valvular annular plane.  Whereas, the Medtronic CoreValve 
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rim should be placed 5-10 mm below the aortic valve annular plane. 
Although single-plane fluoroscopy provides good visualization of guidewires, this 
imaging modality has several limitations.  Fluoroscopic images are only able to display 
gross anatomic structures; therefore, to improve visualization, nephrotoxic contrast 
medium is required to obtain contrast-enhanced images.  However, the use of multiple 
contrast fluoroscopic images can increase a patient’s risk of acute kidney injury [401-
404].  Many TAVI patients have underlying renal dysfunction and are therefore more 
vulnerable to acute kidney injury.  The reported incidence of acute kidney injury 
following TAVI is between 12 and 57% [408, 409, 411, 412].  One registry of TAVI 
patients reported that up to 6.7% of patients required acute hemodialysis was required in 
the post-procedural period [413].  Furthermore, the development of acute kidney injury is 
an independent predictor of prolonged hospital stay and impaired early survival following 
cardiac surgery [411, 414, 415].  In fact, one study reported an 11.7% incidence of acute 
kidney injury following TAVI and a greater than four-fold increase in the risk of 
postoperative mortality among those patients [417].  Finally, fluoroscopic imaging 
exposes both patients and health care professionals to ionizing radiation.   
As a result of these challenges, image guidance systems have been developed for TAVI 
that provide visualization of the critical structures within the aortic root and the valve 
stent prosthesis. For example, the DynaCT system is an intra-operative cone-beam CT 
overlaid onto a fluoroscopy image. The DynaCT C-arm system constructs a segmented 
aortic root from rotational angiography, and automatically detects landmarks, such as the 
coronary ostia [416-418]. The static segmented CT image is superimposed onto the real-
time fluoroscopy image, to be employed to select an optimal C-arm angulation for 
fluoroscopy. Recent results from Kempfert et al. in 50 patients demonstrate a positional 
accuracy of the coronary ostia, as displayed on the fluoroscopy image, of 4.8mm [417]. 
  
 
 
 
 
75 
Although this technique represents an improvement, the CT aortic root image remains 
static and does not allow for real-time intraoperative guidance.  Furthermore, this system 
requires fluoroscopy and contrast dye therefore exposing both patients and health care 
professionals to ionizing radiation.   
Others have proposed intraoperative MRI to guide TAVI placement [419, 420].  
Although this technique avoids ionizing radiation, this imaging modality is not only very 
expensive, but also scarce.  Furthermore, many TAVI valves and surgical tools required 
for the procedure are not MRI compatible [420]. 
TEE is an imaging modality that is currently used throughout both conventional and 
transcatheter aortic valve implantation.  During TEE procedural guidance, both the 2D 
short axis and long axis views of the aortic valve are used individually or simultaneously 
to align and center the prosthesis.  Live 3D images may also be used for prosthetic valve 
alignment.  Following valve deployment, TEE is used to assess valve function and to 
identify any procedural complications including perivalvular leak or vascular injury 
[422].  In fact, TEE has been successfully utilized as an alternative primary imaging 
modality for TAVI guidance.  In fact, a study by Bagur et al. [423] demonstrated similar 
results when using fluoroscopy and echocardiography as the primary intra-operative 
image guidance modality for TAVI. However, TEE alone has limited resolution and does 
not provide satisfactory imaging of the TAVI catheter [424].  
Integrating AR with TEE would enable virtual representations of both the TAVI valved-
stent and critical aortic valve anatomy to be registered to biplane TEE.   
1.20 Thesis Statement, Objectives, and Hypothesis 
Clearly, although minimally invasive and beating heart surgery provide both improved 
postoperative morbidity and quality of life, they are technically demanding and require 
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additional surgical training and expertise.  My thesis is that innovative strategies 
developed by our research team in medical imaging, force feedback, and electromagnetic 
tracking can be applied to minimally invasive mitral valve repair and transcatheter aortic 
valve implantation techniques to surmount the current challenges in minimally invasive 
cardiac surgery and to make these techniques more facile and safe.  
We have also developed a robotics-assisted surgical test bed with force reflection that can 
be used to determine the effect of stereoscopic visualization and force feedback on 
operative performances [425, 426]. This information can be applied to robotics-assisted 
mitral valve repair training systems for training and skill evaluation. In addition, we have 
developed an augmented reality enhanced TEE guidance system that can be used to 
facilitate more direct and safe intracardiac navigation during beating heart cardiac 
surgery [342, 343].  The working hypothesis for this work was that the addition of force 
feedback to robotics-assisted mitral valve repair and the addition of augmented reality to 
beating heart valve procedures would improve both the ease and safety of these 
techniques. 
The primary objective of this thesis is to evaluate the usefulness of 3D visualization, 
force feedback, and augmented reality technologies to surgeons as they are applied in a 
clinical setting.  Specifically, the aims of this thesis are:  
1. To determine the effect of 3D stereoscopic vision on the amount of force applied 
to cardiac tissue during robotics-assisted cardiac surgery.  
2. To determine the effects of force feedback on the amount of force applied to 
cardiac tissue during robotics-assisted cardiac surgery and to determine is these 
effects are consistent between novices and experts in robotics-assisted cardiac 
surgery.  
  
 
 
 
 
77 
3. To evaluate the use of an augmented reality guidance system for successful 
NeoChord navigation to the mitral valve annulus.  
4. To determine what factors contribute to NeoChord suture dehiscence from the 
miral valve leaflet.  
5. To apply the innovative augmented reality guidance system for valve implantation 
in transcatheter aortic valve replacement. 
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Chapter 2  
2 Evaluating the effect of three dimensional visualization 
on force application and performance time during 
robotics-assisted mitral valve repair  
 
In this chapter, the effect of three-dimensional (3D) binocular (stereoscopic) and two-
dimensional (2D) monocular visualization on robotics-assisted mitral valve annuloplasty 
versus conventional techniques is examined in an ex vivo animal model. In addition, these 
effects are compared between novices and experts in robotics-assisted cardiac surgery. 
____________________________________________________________________ 
This chapter is adapted from the following work: 
 Currie ME, Trejos AL, Rayman R, Chu MWA, Patel R, Peters TM, Kiaii B.  The 
role of three-dimensional visualization in robotics-assisted cardiac surgery.  Proc 
SPIE 2012; 8316: 83160F1-10.   
 Currie ME, Romsa J, Fox S, Vezina WC, Akincioglu C, Warrington JC, McClure 
RS, Stitt LW, Menkis AH, Boyd WD, Kiaii B. Long-term angiographic follow-up 
of robotic-assisted coronary artery revascularization. Ann Thorac Surg 
2012;93:1426-1431.   
 Currie ME, Trejos AL, Rayman R, Chu MWA, Patel R, Peters TM, Kiaii B.  
Evaluating the effect of three dimensional visualization on force application and 
performance time during robotics-assisted mitral valve repair.  Innovations (Phila) 
2013; 8(3): 199-205. 
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My contribution to this chapter involved designing and conducting experiments and 
analyzing data.    
2.1 Challenges of Robotics-Assisted Cardiac Surgery 
Robotic surgical systems assist surgeons in performing minimally invasive procedures, 
through their provision of high-definition stereoscopic imaging and wristed suturing 
capability through smaller endoscopic ports. As a result of these engineering advances, 
the surgical robot reduces tremor at the instrument and increases surgeons’ dexterity [1, 
2].  However, robotic surgical systems present new and unique challenges resulting from 
the use of indirect visualization through an endoscope and remote manipulation of tissue 
through a master-slave configuration  [3]. 
It is well established that in conventional or open surgery, sensory input is derived from 
both vision and haptic feedback [4, 5]. Haptics is the combination of kinesthetic, tactile, 
and proprioceptive information. Kinesthetic feedback provides position, force, and 
movement information and can be measured using a force/torque sensor. Tactile feedback 
includes the sensation of vibration, shape, and texture. Proprioception provides the sense 
of position and movement of body segments [6]. For a complete depiction of haptic 
interactions between surgical instruments and tissue kinesthetic, tactile, and 
proprioception feedback must be acquired [6-8].  
During robotics-assisted surgery, the indirect manipulation of tissue through the master-
slave configuration of the robotic system prevents realistic interaction forces between the 
surgeon, the therapeutic instruments, and the tissue [3]. This may be particularly 
deleterious in dexterous fine movements such as intracorporeal suturing and knot tying, 
which require accurate control of applied forces and instrument positions [6, 9-11]. 
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Without haptic feedback, insufficient forces might be applied when grasping tissue or 
sutures, resulting in loose knots  [3, 6].  Conversely, excessive forces may be applied to 
tissue leading to increased trauma and damage to tissue [3, 6].  This is particularly 
important in robotics-assisted mitral valve repair, which requires fine motor skill to 
suture an annuloplasty band to the cardiac tissue surrounding the mitral valve annulus.  
Without tactile and force information, surgeons must rely on visual cues to estimate the 
force being applied [4-6, 12]. 
 
2.2 Visualization in Robotics-Assisted Mitral Valve 
Repair 
Two-dimensional (2D) visualization was used in the first minimally invasive mitral valve 
surgeries [13-15]. Performance of surgical tasks with 2D vision requires the use of 
indirect monocular cues to compensate for the lack of depth perception [16]. These cues 
include the relative position of instruments, anatomic structure size, shading of light and 
dark, and texture grading [17]. Therefore, performance of detailed skills such as 
intracorporeal suturing, tying, and fine dissection with 2D visualization requires practice 
and experience. Chitwood and colleagues [13-15] reported successful complex mitral 
valve repairs including quadrangular resections, sliding valvuloplasties, chordal transfers, 
and synthetic chordal replacements using 2D visualization. 
However, others have suggested that 2D visualization was inadequate for detailed repairs 
[18].  Advanced surgical skills require fine-motor skills and depth perception. 
Minimizing tissue trauma while using these skills can ultimately affect patient outcome. 
As a result, fine-motor skills and depth perception may directly affect surgical 
performance, operative time, and morbidity. 
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Previous studies have suggested that because 3D visualization provides more binocular 
depth cues, depth perception with binocular 3D systems is superior to that achieved with 
monocular 2D systems [17, 19]. Furthermore, compared to 3D binocular vision, 2D 
performance with monocular vision affects the kinematics and pattern of human motions. 
2D visualization increases movement time and lowers peak velocity. In addition, with 3D 
vision, reach and grab tasks are performed faster than with 2D visualization [17, 20-23]. 
Intuitive Surgical Incorporated, (Sunnyvale, CA) has developed the da Vinci surgical 
system with a very high quality three-dimensional (3D) stereoscopic visualization system 
to enhance the performance of robotics-assisted surgical procedures [8, 13, 24]. 
Throughout this chapter, stereoscopic and monoscopic visualization modes are referred to 
as 3D and 2D, respectively.  While some have argued that the da Vinci’s superior 3D 
visualization capabilities compensates for lack of haptic feedback, others assert that 
visualization alone cannot replace the value of force feedback.  
The objective of the study outlined in this chapter is to determine the effect of three-
dimensional visualization on the amount of force applied to mitral valve tissue and the 
time to perform ex vivo mitral valve annuloplasty using robotics-assisted and 
conventional techniques. In addition, our aim is to determine whether these effects are 
consistent between novices and experts in robotics-assisted cardiac surgery. Finally, to 
add further clinical relevance, we compare these results with those of conventional open 
mitral valve annuloplasty to examine differences in forces applied and times required to 
complete surgical tasks between robotics-assisted and conventional open surgery. 
2.3 Mitral valve annuloplasty test-bed 
A cardiac surgery test bed was constructed to measure forces applied by test subjects 
performing either conventional or robotics-assisted mitral valve annuloplasty. The tissue 
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test bed consisted of a porcine mitral valve mounted on a six-axis force/torque sensor 
(ATI Industrial Automation, Apex, NC) to measure applied forces in the x, y, and z 
directions (Figure 2.1). The porcine mitral valve annulus and attached leaflets were 
dissected from the porcine chordae tendinae attachments and left ventricle. A disc to 
mount the mitral valve on the force/torque sensor and expose the valve annulus and 
leaflets was designed and constructed using SolidWorks (Dessault Systèmes SolidWorks 
Corporation, Waltham, Massachusetts). The disc was printed from ABSplus™ 
production-grade thermoplastic (Dimension Incorporated, Eden Prairie, MN) using an 
Elite 3D printer (Dimension Incorporated, Eden Prairie, MN). The excised mitral valve 
was mounted between the two custom designed plates that firmly clamp the cardiac tissue 
along the outer edge of the annulus (Figure 2.1).  Custom software was written in C++ to 
record forces applied to the porcine mitral valve and measured by the force/torque sensor 
every 1ms.  Multiple studies have employed porcine mitral valves as a model of the 
human mitral valve for force modeling, pathology modeling, surgical techniques, surgical 
skills training and surgical outcomes  [25-33].  In fact, a recent study compared the 
biomechanical properties of the human mitral valve to the porcine mitral valve and found 
that the annular and leaflet geometry of the porcine and human mitral valves are very 
close in dimensions; however, porcine mitral valves are more compliant than human 
valves [32].   
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Figure 2.1:  A, Mitral valve annuloplasty test bed.  The tissue test bed consists of an 
excised porcine mitral valve mounted between two custom designed plates that 
firmly clamp the cardiac tissue along the outer edge of the annulus.  The plates and 
valve are mounted on a six-axis force/torque sensor (ATI Industrial Automation, 
Apex, NC).  B, Mitral valve annuloplasty test bed within the operative field of the da 
Vinci robot.  C, Mitral valve annuloplasty test used for conventional valve repair.   
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2.4 Selection of Subjects 
Following approval from the Western University Ethics Review Board, cardiac surgeons 
with experience in both conventional and robotics-assisted cardiac surgery, along with 
medical trainees with no experience in robotics-assisted surgery, were contacted to 
participate in this study.  Nine study participants completed both conventional and 
robotics-assisted mitral valve annuloplasty trials. Three participants were surgeons with 
training in both conventional and robotics-assisted cardiac surgery, while six were 
trainees with no experience in robotics-assisted procedures.  The three expert participants 
had each completed over five hundred robotics-assisted cardiac operations as part of their 
specialized training and surgical practice prior to the study.  One of the three experts was 
left handed.  The novice group consisted of cardiac surgery residents from postgraduate 
year one to postgraduate year six.  None of the residents had completed a robotics-
assisted cardiac surgery prior to the study.  However, all residents had experience in 
conventional suturing and knot tying in cardiac surgery.  One of the six trainees was left 
handed.  All other participants were right handed.   
2.5 Assessment of forces and time required for 
conventional mitral valve annuloplasty tasks 
Study subjects completed conventional mitral valve annuloplasty within the mitral valve 
annuloplasty test bed. Each subject passed sixteen 75 cm 2-0 (V-5) Ethibond sutures 
(Ethicon Incorporated, Somerville, NJ) through the porcine mitral valve annulus in a 
transverse mattress fashion at predetermined points using the same six inch Crile-Wood 
needle driver and eight inch DeBakey tissue forceps (Pilling, Canada Teleflex Medical, 
Markham, ON). The sutures were then passed through a Cosgrove-Edwards flexible 
annuloplasty band (Edwards Lifesciences Corporation, Irvine, CA) and tied in place. The 
entire stitch length was not pulled through the annulus.  Force and time were recorded; 1. 
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from contact of the needle with the mitral valve annulus to complete withdrawal of the 
needle from the mitral valve annlulus, 2; from contact of the needle to the annuloplasty 
band to complete withdrawal of the needle from the annuloplasty band, and 3; from 
initiating the first loop for tying two forehand surgeon’s knots and one backhand knot to 
tightening the last knot before the surgeon removed their instruments from the suture.  
There was no surgical assistant for any of the trials.  All surgeons completed suture 
placement at standardized demarcated points along the posterior annulus of the mitral 
valve.   
 
2.6 Assessment of Forces and Time Required for 
Robotics-Assisted Mitral Valve Annuloplasty with 2D 
and 3D Visualization 
Mitral valve annuloplasty was completed by study subjects as described above, using 
robotics-assisted techniques and the da Vinci Surgical System (Intuitive Surgical 
Incorporated, Sunnyvale, CA). The da Vinci was randomly switched between 2D and 3D 
visualization modes. Eight sutures and four ties were completed by study subjects for 
both 2D and 3D visualization modes. The forces applied by the study subjects during 
three different force actions (inserting the needle into the mitral valve annulus, inserting 
the needle into the annuloplasty band, and suture tying) were measured by the 
force/torque sensor and recorded by the customized software.  In addition, the time taken 
to execute three instrument ties was recorded. The maximum force measurement acquired 
by the force/torque sensor during each suturing or tying task was recorded for each 
surgeon. The average of these maximum forces was calculated for experts and novices 
using 2D visualization, 3D visualization, or conventional techniques. 
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2.7 Statistical Analysis 
All statistical analyses were performed using SPSS (International Business Machines 
Corporation, Armonk, NY). Univariate analysis of variance was employed to compare 
force and time measurements completed by subjects using conventional mitral valve 
annuloplasty and robotics-assisted mitral valve annuloplasty with either 2D or 3D 
visualization. Continuous variables are expressed as mean with standard deviation (SD). 
A p value < 0.05 was considered statistically significant. 
2.8 Results 
2.8.1 Assessment of Time Required for Robotics-Assisted Mitral 
Valve Annuloplasty with 2D and 3D Visualization 
The mean time required to suture the mitral valve annulus using 3D visualization was 
significantly less than that required to suture the mitral valve annulus using 2D vision (p 
< 0.001, Table 2.1). This finding was consistent between experts and novices (p = 0.5).  
In addition, there was no significant difference in suture times between experts and 
novices  
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Table 2.1: Comparison of the time required by experts and novices during robotics-
assisted ex vivo mitral valve annuloplasty with 2D and 3D visualization and with 
robotics-assisted and conventional surgical techniques. 
Measurement 2D 3D p 
value 
Robotics-
assisted 
surgery 
with 3D 
visualization 
Conventional 
surgery 
p 
value 
 
Mitral valve 
suture time (s) 
      
Expert 49.4 ± 4.1 25 ± 3.2 <0.001 25 ± 3.2 12.4 ± 1.8 <0.001 
Novice 45 ± 2 26.8 ± 1.9 <0.001 26.8 ± 1.9 19.4 ± 1.4 <0.001 
Expert versus 
Novice (p 
value) 
  0.8   0.004 
 
Mitral valve 
tie time (s) 
      
Expert 105 ± 15.2 63.5 ± 
11.2 
<0.001 63.5 ± 11.1 17.6 ± 8.2 <0.001 
Novice 145.5 ± 9.5 97.7 ± 9.5 <0.001 97.7 ± 9.5 19.3 ± 6.4 <0.001 
Expert versus 
Novice (p 
value) 
  0.03   0.002 
with either 2D or 3D visualization (p = 0.8).  Similarly, the mean time required to tie a 
suture to the mitral valve annulus using 3D visualization was significantly less than the 
mean time required to tie using 2D vision (p < 0.001, Table 2.1). This finding was 
consistent between experts and novices (p = 0.9).  However, experts required 
significantly less time than novices to tie sutures using either 2D or 3D visualization (p = 
0.03).   
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2.8.2 Assessment of Time Required for Mitral Valve Annuloplasty 
with Robotics-Assisted and Conventional Cardiac Surgery 
Techniques 
The time required to complete suturing and tying tasks during ex vivo mitral valve 
annuloplasty using conventional techniques was compared to that required to complete 
these tasks using robotics-assisted techniques with 3D visualization. The mean time 
required to suture the mitral valve annulus using conventional surgical technique was 
significantly less than that needed to suture using robotics-assisted assistance and 3D 
vision (p < 0.001, Table 2.2). This finding was consistent between both experts and 
novices (p = 0.1).  However, experts required significantly less time than novices to 
suture using either 3D visualization or conventional surgical technique (p = 0.004).      
The mean time required to tie a suture to the mitral valve annulus using conventional 
surgical techniques was significantly less than that needed to perform the same task using 
robotics-assisted techniques with 3D vision (p < 0.001, Table 2.2). This finding was 
consistent between both experts and novices (p = 0.1).  However, experts required 
significantly less time than novices to tie sutures using either robotics-assisted techniques 
with 3D vision or conventional surgical technique (p = 0.002).    
2.8.3 Assessment of Forces Applied During Robotics-Assisted 
Mitral Valve Annuloplasty with 2D and 3D Visualization 
Mean forces applied by the study subjects were measured and recorded during three 
different force actions: 1. Inserting the needle into the mitral valve annulus, 2. Inserting 
the needle into the annuloplasty band, and 3. Suture tying.  The mean maximum force 
applied during suturing of the mitral valve annulus using 3D visualization was 
significantly less than that applied to suture using 2D vision in experts; however, there 
was no significant difference in the mean maximum force applied by novices using either  
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Table 2.2: Comparison of the force applied by experts and novices during robotics-
assisted ex vivo mitral valve annuloplasty with 2D and 3D visualization and with 
robotics-assisted and conventional surgical techniques. 
Measurement 2D 3D p 
value 
Robotics-
assisted 
surgery 
with 3D 
visualization 
Conventional 
surgery 
p 
value 
Mitral valve annulus force (N)    
Expert 4.6 ± 1.2 5.1 ± 0.9 0.7 5.1 ± 0.8 2.6 ± 0.5 <0.001 
Novice 6.8 ± 0.6 4.8 ± 0.6 0.1 4.8 ± 0.6 2.8 ± 0.4 0.06 
Expert versus 
Novice (p value) 
  0.5   0.9 
Annulopasty band force (N)     
Expert 4.5 ± 0.5 4.2 ± 0.4 0.7 4.2 ± 0.4 1.6 ± 0.3 <0.001 
Novice 4.8 ± 0.4 4.3 ± 0.4 0.7 4.3 ± 0.4 1.9± 0.3 <0.001 
Expert versus 
Novice (p value) 
  0.8   0.6 
Suture tie force (N)    
Expert 5.8 ± 1.9 4.1 ± 1.5 0.006 4.1 ± 1.5 2.9 ± 1.2 0.02 
Novice 13.9 ± 1.3 11.5 ± 1.3 0.6 11.5± 1.3 3.6 ± 0.9 <0.001 
Expert versus 
Novice (p value) 
  0.001   <0.001 
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3D or 2D visualization (Table 2.2).  This finding was consistent between both experts and 
novices (p = 0.3).   In addition, there was no significant difference in force applied by 
experts or novices using 2D or 3D visualization (p = 0.5).   
There was no significant difference in the mean maximum force applied to mitral valve 
tissue during suturing of the mitral valve annuloplasty band with either 3D visualization 
or 2D visualization (Table 2.2). This finding was consistent between both experts and 
novices (p = 0.8).  In addition, there was no significant difference in force applied by 
experts or novices using 2D or 3D visualization (p = 0.8).   
Finally, the mean maximum force applied during suture tying using 3D visualization was 
significantly less than the mean maximum force applied using 2D vision in experts (p = 
0.006).  However, there was no significant difference in the mean maximum force 
applied by novices using either 3D or 2D visualization (Table 2.2).  In addition, experts 
applied significantly less force than novices during suture tying using either 2D or 3D 
visualization (p = 0.001). 
2.8.4 Assessment of Forces Applied During Mitral Valve 
Annuloplasty with Robotics-Assisted and Conventional 
Cardiac Surgery Techniques  
The mean maximum force applied when suturing the mitral valve annulus using the 
conventional surgical technique was significantly less than the mean force applied to the 
suture using robotics-assisted techniques with 3D vision (Table 2.2). This finding was 
consistent between both experts and novices (p = 0.5).  In addition, there was no 
significant difference in the force applied by experts or novices using robotics-assisted 
techniques with 3D vision or conventional techniques (p = 0.9).   
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The mean maximum force applied when suturing the mitral valve annuloplasty band 
during conventional surgery was significantly less than the mean suturing force applied 
during robotics-assisted techniques with 3D vision (Table 2.2). This finding was 
consistent between both experts and novices (p = 0.6).  In addition, there was no 
significant difference in the force applied by experts or novices using robotics-assisted 
techniques with 3D vision or conventional techniques (p = 0.6).   
The mean maximum force applied when tying the suture to the mitral valve annulus using 
the conventional surgical approach was significantly less than that applied to the suture 
using robotics-assisted techniques with 3D vision (Table 2.2). Experts applied 
significantly less force than novices using either robotics-assisted techniques with 3D 
vision or conventional techniques (p < 0.001).  However, the decrease in force applied to 
cardiac tissue was significantly greater in novices compared to experts (p = 0.001).   
2.9 Discussion 
Our results suggest that, when comparing 2D and 3D visualization when performing the 
use of the latter mode results in significantly shorter robotics-assisted suturing and tying 
times. In addition, both experts and novices had significantly shorter suturing and suture 
tying times with 3D compared to 2D visualization. This is consistent with previous 
studies that demonstrate that 3D visualization is associated with shorter movement times 
and higher movement velocities than 2D visualization [16, 20-22]. In addition, binocular, 
3D visualization provides more depth cues than monocular 2D visualization [16, 19]. As 
a result, performance of surgical tasks with 2D vision requires the use of indirect 
monocular cues to compensate for the lack of depth perception  [16]. These cues include 
the relative position of instruments, anatomic structure size, shading of light and dark, 
and texture grading [17]. There is no significant difference in the amount of time required 
by novices or experts to suture using robotics-assisted techniques on the da Vinci surgical 
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system.  This point illustrates how intuitive the da Vinci system is for novice surgeons to 
conduct suturing. However, robotics-assisted suture tying is a more complex task and 
novices required significantly more time than experts to complete this task. Therefore, 
performance of detailed skills such as intracorporeal suturing, tying, and fine dissection 
with 2D visualization requires practice and experience.  
Previous studies have illustrated the improvement in operative performance times by 
surgeons with increased experience [34, 35].  One center reported a 95% decrease in 
operative times each time the case number for a surgeon doubled [36].  Although learning 
curves differ between centers, this is reflected in the faster tying times for experts, who 
have completed over five hundred robotics-assisted procedures, versus novices.  As our 
results show, on average, experts sutured each stitch 12.6 seconds faster and tied each 
knot 45.9 seconds faster with conventional techniques versus robotics-assisted techniques 
with 3D vision.  Moreover, on average, novices sutured each stitch 4.4 seconds faster and 
tied each knot 78.4 seconds faster with conventional techniques versus robotics-assisted 
techniques with 3D vision.   
On an annuloplasty band with ten double-armed stitches, the above results translate to a 
mean difference between conventional and robotics-assisted techniques with 3D vision 
for suturing and tying of 11.9 minutes in experts and 14.5 minutes in novices.     
Our data also show that suture time with conventional open surgery required significantly 
less time than that required when employing a robotics-assisted procedure, with either 2D 
or 3D visualization. Therefore, although the da Vinci surgical system provides true 
stereoscopic vision, there are other effects associated with the robotics-assisted approach 
that still create an increase in the task completion time.  This conclusion is consistent 
with previous clinical studies that have reported longer operative times in robotics-
assisted surgeries compared to conventional or open surgeries [37-39].    
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Although previous studies have demonstrated superior performance curves and operative 
efficiency with 3D visualization, no previous studies have examined the effect of 3D 
visualization on force application on surgical tissue. These data suggest that there is no 
significant difference in the maximum force applied by novices to the mitral valve during 
insertion of needle in the annulus, insertion of needle in the annuloplasty band, or during 
suture tying using either 2D or 3D visualization. However, there is a significant decrease 
in the force applied by experts to the mitral valve tissue during suture tying with 3D 
visualization versus the corresponding forces with 2D visualization. Experts’ mean 
maximum forces were also more consistent with 3D visualization, reflected as a smaller 
SE. In addition, novices consistently applied significantly more force to the mitral valve 
tissue than experts using 2D or 3D visualization. One possible explanation for this is that 
novices are less perceptive of visual cues to indicate the force applied to tissue. They may 
not have adapted to the lack of haptic feedback, while experts have more experience 
using visual cues to guide the force applied to tissue. 
The force applied to cardiac tissue by novices was consistently greater than that applied 
by experts, particularly during suture tying.  Previous studies employing porcine tissue 
have reported visible tissue damage with the application of an 11 N force over an area of 
2.4 cm² [40].  In this study, novices applied potentially damaging forces to cardiac tissue 
using robotics-assisted techniques without force feedback. This suggests that force 
feedback may be particularly useful to novices employing robotics-assisted techniques. 
Moreover, force application could potentially be used as a measure of surgical 
performance or expertise in evaluating trainees on robotics-assisted procedures; however, 
further validity testing is required to support such a hypothesis. 
This study and others have demonstrated shorter operative times with 3D visualization; 
however, despite high quality binocular images, both experts and novices applied 
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significantly more force to cardiac tissue during 3D robotics-assisted mitral valve 
annuloplasty than during conventional open mitral valve annuloplasty.  The highest 
forces applied by experts were still less than the force required to inflict any damage on 
the cardiac tissue; however, novices applied potentially damaging force to the cardiac 
tissue using robotics-assisted techniques without haptic feedback.  This finding suggests 
that 3D visualization does not fully compensate for the absence of haptic feedback in 
robotics-assisted cardiac surgery, particularly in novices. Therefore, although 3D 
visualization may provide more information regarding object depth to facilitate complex 
tissue grasping, 3D visualization may not provide adequate visual cues to reflect the force 
applied to cardiac tissue.  We have demonstrated that although robotics-assisted mitral 
valve repair provides many benefits to the patient, this technique poses further challenges 
to the surgeon and surgical trainee. Robotics-assisted surgical tasks require additional 
time and may apply potentially damaging forces to cardiac tissue, a factor that is more 
prominent in novice surgeons. A simulation system providing force feedback may 
improve both expert and trainee performance using robotics-assisted techniques. We plan 
to test this hypothesis in future studies. Our results demonstrate that robotics-assisted 
mitral valve repair requires more time and surgeons apply more force to cardiac tissue 
using robotics-assisted techniques compared to conventional mitral valve repair.  
Conventional or open mitral valve repair is technically challenging and investigators have 
reported the improvement in trainee performance following simulation training for open 
or conventional mitral valve surgery [33].  
Due to this repeated measures study design, results may have been limited by subject 
fatigue after several trials, carry over effects from one technique to the next, and the order 
of technique presentation. To minimize these effects, the order of trials with 2D and 3D 
visualization was randomized for each subject. In addition, the accuracy of suturing and 
quality of suture tying by novice study subjects was not assessed in this trial. 
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Furthermore, our sample size was limited by the number of experts in robotics-assisted 
cardiac surgery. If we had included more participants to increase the power of the study, 
we may have been able to detect a significant decrease in the amount of force applied to 
cardiac tissue with 3D visualization. We plan to address this limitation in future work. 
In conclusion, although 3D visualization increases the control and consistency of the 
interaction forces on cardiac tissue, it does not prevent the application of damaging 
forces.  The implication of these findings is that to achieve better control of the 
interaction forces on cardiac tissue haptics, including force feedback, may be required. 
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Chapter 3  
3 The Role of Visual and Direct Force Feedback in 
Robotics-Assisted Mitral Valve Annuloplasty 
Robotics-assisted cardiac surgery involves the indirect manipulation of cardiac tissue and 
prevents realistic interaction forces among the surgeon, the instruments, and the 
tissue [1]. This absence of haptic feedback may be detrimental, as excessive forces may 
be applied to cardiac tissue leading to increased trauma and damage to tissue during 
suturing and tying [1, 2].  Minimizing tissue trauma during robotics-assisted surgery can 
ultimately affect patient outcome.   
A force feedback-enabled master-slave surgical system was constructed to provide both 
visual and direct force feedback to the surgeon during robotics-assisted cardiac surgery 
with three-dimensional visualization.  This novel robotics system was used to measure 
the amount of force applied to cardiac tissue during ex vivo mitral valve annuloplasty 
repair.   
This chapter outlines the effect of both direct force feedback and visual force feedback on 
the amount of force applied to mitral valve tissue during ex vivo mitral valve annuloplasty 
using robotics-assisted techniques.   
____________________________________________________________________ 
This chapter is adapted from the following work: 
 M. E. Currie, A. L. Trejos, R. Rayman, M. W. A. Chu, R. Patel, T. M. Peters, B. 
Kiaii.  The role of haptics in robotics-assisted mitral valve annuloplasty.  Hamlyn 
Symposium on Medical Robotics, July 2012, London, England.   
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 Visual and Direct Haptic Feedback in Robotics-Assisted Cardiac Surgery. M. E. 
Currie, A. Talasaz, A. L. Trejos, R. Rayman, M. W. A. Chu, B. Kiaii, T. M. 
Peters, R. Patel.   Minimally Invasive Robotic Association International Congress, 
September 2012, Boston, USA.  
 M. E. Currie, A. Talasaz, A. L. Trejos, R. Rayman, M. W. A. Chu, B. Kiaii, R. 
Patel, T. M. Peters.  The Role of Visual and Direct Haptics in Robotics-Assisted 
Mitral Valve Annuloplasty. Journal of Medical Robotics and Computer Assisted 
Surgery (Submitted) 
My contribution to this chapter involved designing and conducting experiments and 
analyzing data.    
3.1 Introduction 
Haptics is the combination of kinesthetic, tactile, and proprioceptive information. 
Kinesthetic feedback provides position, force, and movement information and can be 
measured using a force/torque sensor. Tactile feedback includes the sensation of 
vibration, shape, and texture. Proprioception provides the sense of position and 
movement of body segments [1]. For a complete depiction of haptic interactions between 
surgical instruments and tissue, kinesthetic, tactile, and proprioception feedback must be 
acquired [1-3].    
During robotics-assisted surgery, the indirect manipulation of tissue through the master–
slave configuration of the robotic system prevents realistic interaction forces among the 
surgeon, the therapeutic instruments, and the tissue [4]. This absence of haptic feedback 
may be detrimental in dexterous fine movements such as intracorporeal suturing and knot 
tying, which require accurate control of applied forces and instrument positions [1, 5–
7].  Furthermore, without haptic feedback, insufficient forces might be applied when 
grasping tissue or sutures, resulting in loose knots [1, 4].  Conversely, excessive forces 
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may be applied to tissue leading to increased trauma and damage [1, 4].  This is 
particularly important in robotics-assisted mitral valve repair, which requires fine motor 
skill to suture an annuloplasty band to the cardiac tissue surrounding the mitral valve 
annulus.  Without tactile and force information, surgeons must rely on visual cues to 
estimate the force being applied [1, 8–10].  Advanced surgical skills require not only fine 
motor skills but also depth perception. Minimizing tissue trauma while performing 
surgery may ultimately affect surgical performance, operative time, and morbidity. 
In the currently used minimally invasive surgical robotic system (the da Vinci from 
Intuitive Surgical Inc.), the master–slave configuration and the absence of haptic 
feedback prevent the transmission of tool–tissue interaction forces to the surgeon 
[11].  Some have argued that the da Vinci’s superior three-dimensional (3D) visualization 
capabilities compensate for lack of haptic feedback, others assert that visualization alone 
cannot replace the value of haptic feedback [12].  
 
In fact, we have previously found that despite high-quality binocular images, both the 
experts and the novices applied significantly more force to the cardiac tissue during 3D 
robotics-assisted mitral valve annuloplasty than during conventional open mitral valve 
annuloplasty. This finding suggests that 3D visualization does not fully compensate for 
the absence of haptic feedback in robotics-assisted cardiac surgery [13].  Furthermore, 
although a complete depiction of haptic interactions has not been integrated into robotics-
assisted surgical systems, other researchers have investigated the potential benefits of the 
addition of either direct force feedback or visual force feedback into robotics-assisted 
surgical systems [14–18].   
 
Direct force feedback involves the kinesthetic perception of reflected weight and 
resistance to motion by muscles, tendons and joint sensory receptors [19].  For example, 
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Wagner and colleagues found that direct force feedback for a minimally invasive 
cannulation task using endoscopic visualization reduces applied forces [14].  Another 
study by Wagner and colleagues examined the effects of direct force feedback on blunt 
dissection of an artery in a synthetic model using endoscopic visualization [15].  The 
absence of direct force feedback increased the average force magnitude applied to the 
tissue by at least fifty percent, increased the peak force magnitude by at least 100%, and 
increased the number of errors that damage tissue by over a factor of three.  Kazi and 
colleagues also showed that using direct force feedback during minimally invasive 
catheter insertion into a vessel could lower the magnitude of the force applied to tissue 
during a procedure [16].  
 
Visual force feedback involves sensory substitution and provides force feedback by using 
size and/or color to represent the magnitude of forces applied by a surgical instrument 
[12].  For example, Reiley and colleagues examined the effects of visual force feedback 
during surgical knot tying using a modified da Vinci robotic system equipped with force-
sensing instrument tips [17].   They found no differences in measured performance 
parameters between robotics-assisted knot ties executed with and without visual force 
feedback among surgeons with robotics-assisted surgical experience. However, visual 
force feedback was associated with lower suture breakage rates, peak applied forces, and 
standard deviations of applied forces among surgeons without robotics-assisted surgery 
experience.  These results suggested that visual force feedback primarily benefits novice 
robotics-assisted surgeons.  Finally, Tholey and colleagues developed an automated 
laparoscopic grasper with both direct force and visual feedback to help surgeons 
differentiate tissue stiffness [18].  These investigators found that the addition of both 
visual and direct force feedback led to better tissue stiffness characterization than either 
visual or direct force feedback alone.       
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Despite this evidence for the benefits of direct force or visual force feedback in robotics-
assisted and laparoscopic surgery, many robotics-assisted mitral valve repair surgeries are 
performed in the absence of any haptic feedback with excellent results [20–24].  
Furthermore, some have suggested that the addition of additional stimuli during task 
learning made the process more difficult, as novice trainees may have less attentional 
resources to attend to force feedback while learning a skill [25].   
 
Therefore, the objective of this study is to determine the effect of both direct force 
feedback and visual force feedback on the amount of force applied to mitral valve tissue 
during ex vivo mitral valve annuloplasty using robotics-assisted techniques.  In addition, 
our aim is to determine whether these effects are consistent between novices and experts 
in robotics-assisted cardiac surgery.  We expect that the addition of either direct or visual 
force feedback will decrease the magnitude of force applied to cardiac tissue during 
robotics-assisted mitral valve annuloplasty.  Furthermore, we expect that these 
differences will be more pronounced in novices, as they have less experience using visual 
cues to estimate the amount of force applied to tissue during robotics-assisted cardiac 
surgery. 
3.2 Materials and Methods 
3.2.1 Mitral valve annuloplasty test-bed  
A cardiac surgery test bed was developed to measure forces applied by test subjects 
performing robotics-assisted mitral valve annuloplasty. The tissue test bed consisted of a 
porcine mitral valve mounted on a six-axis force/torque sensor (ATI Industrial 
Automation, Apex, NC) to measure applied forces in the x, y, and z directions (Figure 
3.1). The porcine mitral valve annulus and attached leaflets were dissected from the 
porcine chordae tendineae attachments and left ventricle. A disc to mount the mitral valve 
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on the force/torque sensor and expose the valve annulus and leaflets was designed and 
constructed using SolidWorks (Dessault Systèmes SolidWorks Corporation, Waltham, 
Massachusetts). The disc was printed from ABSplus™ production-grade thermoplastic 
(Dimension Incorporated, Eden Prairie, MN) using an Elite 3D printer (Dimension 
Incorporated, Eden Prairie, MN). The excised mitral valve was mounted between the two 
custom designed plates that firmly clamp the cardiac tissue along the outer edge of the 
annulus (Figure 3.1).  Custom software was written in C++ to record forces applied to the 
porcine mitral valve and measured by the force/torque sensor every 1ms.  
 
Figure 3.1: Mitral valve annuloplasty test bed.  The tissue test bed consists of an 
excised porcine mitral valve mounted between two custom designed plates that 
firmly clamp the cardiac tissue along the outer edge of the annulus.  The plates and 
valve are mounted on a six-axis force/torque sensor (ATI Industrial Automation, 
Apex, NC). 
3.2.2 Force feedback-enabled robotic surgery system  
The force feedback-enabled master-slave surgical system used for trials is shown in 
Figures 3.2 and 3.3. This setup consists of two Mitsubishi PA10-7C robots as the slave 
system controlled remotely over a dedicated network through two customized Quanser 
Haptic Wands as the master interface [2]. The structure of the Haptic Wand, its 
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workspace and force reflection capability have been described in a previous publication 
[3]. Stereoscopic visualization was provided by a zero-degree endoscope (Intuitive 
Surgical, Sunnyvale, CA) and a ProView XL50 head-mounted display (Kaiser Electro-
Optics Inc, Carlsbad, CA).  
3.2.3 Selection of subjects 
Following approval from the Western University Ethics Review Board, three cardiac 
surgeons with experience in both conventional and robotics-assisted cardiac surgery, 
along with nine students with no experience in robotics-assisted surgery, agreed to 
participate in this study. Prior to the study, the three expert participants had each 
completed over 500 robotics-assisted cardiac operations as part of their specialized 
training and surgical practice.  One of the three experts was left-handed. The novice 
group consisted of students and trainees with no previous experience in robotics-assisted 
surgery. Two of the nine trainees were left-handed. All other participants were right-
handed.   
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Figure 3.2: Force feedback-enabled robotics-assisted surgery system with sensorized 
DaVinci instruments mounted on Mitsubishi robotic arms [19].   
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Figure 3.3: Experimental test bed for force feedback-enabled robotics-assisted 
mitral valve annuloplasty showing both the master control side (a) and the robotic 
slave side (b) [19]. 
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3.2.4 Assessment of forces applied during robotics-assisted mitral 
valve annuloplasty tasks 
Study subjects completed robotics-assisted mitral valve annuloplasty within the mitral 
valve annuloplasty test bed (Figure 3.3).  The tasks used for measurement of time and 
force involved pulling the suture through the annuloplasty band and tightening the stitch 
holding the annuloplasty band to the mitral valve annulus.    
For force measurement during suturing, two double-armed 75 cm 2-0 (V-5) Ethibond 
sutures (Ethicon Incorporated, Somerville, NJ) were passed through the porcine mitral 
valve annulus at predetermined points.  The sutures were then passed through a 
Cosgrove-Edwards flexible annuloplasty band (Edwards Lifesciences Corporation, 
Irvine, CA) in a horizontal mattress fashion.  The force required to pull each stitch a 
distance of 8 cm from the annuloplasty band was recorded.  This was repeated four times, 
once for each end of two double-armed sutures, that is, a suture with a needle attached at 
each end.  Next, the force required for study subjects to tighten two surgical knots and to 
secure the annuloplasty band to the mitral valve annulus was recorded.  Subjects 
performed tasks with or without force feedback.   
Force feedback was provided as visual force feedback, direct force feedback, or both 
visual and direct force feedback.  Three levels were considered for both direct and visual 
force feedback.  Direct force feedback was provided at the same, half, or double the 
intensity of the actual force applied to tissue.  The main objective of showing visual force 
feedback in different levels was to assure the user that the force being applied on the 
tissue was safe and that there was sufficient force to tie a secure knot (Figure 3.4). Both 
colour and size denoted the magnitude of force applied by both the right and left arms.  
Green denoted the range of force below the threshold required for a tight knot, which was 
less than 4 N.  Yellow denoted the range sufficient for a tight knot, which was between 4 
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N and 6 N.  Red denoted force that could damage the tissue or break the suture, which 
was greater than 6 N [19]. In order to prevent sliding between the grippers and the suture 
when the subject tightened the suture knot, the grippers were commanded to maintain a 2 
N grasping force with the grippers closed. 
The order in which force feedback was presented was randomized.  Randomization was 
performed by a statistical program (Design Expert®, Stat-Ease, Inc., Minneapolis, MN).  
Throughout all trials, all actions of the surgical instruments were captured on video and 
the positions of the master (Haptic Wand, Quanser, Inc., Markham, ON) and the slave 
robot were also recorded.  All test subjects completed suture placement at standardized 
demarcated points along the posterior annulus of the mitral valve.  There was no surgical 
assistant for any of the trials. 
 
Figure 3.4: Visual force feedback, as shown to subjects.  This figure shows the visual 
force feedback for the left surgical arm.  Both colour and size denote the magnitude 
of the force applied by both the right and left arms.  Green denotes the range of 
force/tension below the threshold required for a tight knot (under 4N).  Yellow 
denotes the range sufficient for a tight knot (4-6 N).  Red denotes force that may 
damage the tissue or break the suture (above 6N). 
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3.2.5 Statistical Analysis 
Statistical analysis was performed using a multi-level linear regression model for this 
repeated-measures study design.  Analysis of variance was employed to compare force 
measurements completed by subjects using robotics-assisted mitral valve annuloplasty 
with or without force feedback. The three options for providing force feedback included 
visual force feedback, direct force feedback, and both visual and direct force feedback.  
All statistical analyses were performed using RStudio (RStudio, Inc., Boston, MA).   
Continuous variables were expressed as the mean and standard deviation (SD).  For 
purposes of data analysis, a p value of less than 0.05 was considered statistically 
significant.   
3.3 Results 
3.3.1 Amount of maximum force applied during suturing by novices 
and experts during robotics-assisted ex vivo mitral valve 
annuloplasty 
Figure 3.5 illustrates the variability in the maximum force (N) applied to mitral valve 
tissue by novices and experts during four trials of robotics-assisted suturing.  Novices are 
Subjects 1–9 and experts are Subjects 10–12.  
The dependent variable, maximum force applied to cardiac tissue, was right or positively 
skewed.  Therefore, a logarithmic transformation of maximum force score was applied to 
the data to bring the outlying data closer to the center in order to achieve a normal 
distribution for further statistical analysis.   
The mean maximum force applied to cardiac tissue by experts (n = 3) and novices (n = 9) 
during suturing for all trials was 3.02 ± 2.12 N and 2.33 ± 1.39 N, respectively. There 
appeared to be a trend toward higher force applied by experts; however, this difference 
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was not statistically significant (p = 0.1609; Figure 3.6).  This was likely due to the low 
number of experts included in the study.   
Interestingly, the mean amount of force applied by both experts and novices gradually 
decreased after each trial.  The mean amount of force applied by experts and novices 
during suturing for the first, second, third, and fourth trials were 2.86 ± 1.80 N, 2.57 ± 
1.68 N, 2.35 ± 1.52 N, and 2.23 ± 1.48 N, respectively (Figure 3.7).  In fact, there was a 
statistically significant decrease in the mean amount of force applied between the first 
and fourth trials (p = 0.0019).  This also held true for novices alone, indicating a learning 
curve.  The mean amount of force applied by novices alone during suturing for the first, 
second, third, and fourth trials were 2.64 ± 1.59 N, 2.37 ± 1.41 N, 2.21 ± 1.29 N, and 
2.09 ± 1.22 N, respectively (p = 0.0009, Figure 3.8).   
 
Figure 3.5: Variability in maximum force (N) applied to mitral valve tissue by 
novices and experts during robotics-assisted suturing.  
  
 
 
 
 
177 
The dependent variable, maximum force applied to cardiac tissue, was right or positively 
skewed.  Therefore, a logarithmic transformation of maximum force score was applied to 
the data to bring the outlying data closer to the center in order to achieve a normal 
distribution for further statistical analysis.   
The mean maximum force applied to cardiac tissue by experts (n = 3) and novices (n = 9) 
during suturing for all trials was 3.02 ± 0.22 N and 2.33 ± 0.08 N, respectively.  This is 
not significantly different (p = 0.1609; Figure 3.5).  In fact, there appeared to be a trend 
toward higher force applied by experts; however, likely to due to the low number of 
experts included in the study, this difference was not statistically significant.   
Interestingly, the mean amount of force applied by both experts and novices gradually 
decreased after each trial.  The mean amount of force applied by experts and novices 
during suturing for the first, second, third, and fourth trials were 2.86 ± 0.18 N, 2.57 ± 
0.17 N, 2.35 ± 0.15 N, and 2.23 ± 0.15 N, respectively.  This also held true for novices 
alone, indicating a learning curve.  The mean amount of force applied by novices alone 
during suturing for the first, second, third, and fourth trials were 2.64 ± 0.19 N, 2.37 ± 
0.17 N, 2.21 ± 0.15 N, and 2.09 ± 0.14 N, respectively.   
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Figure 3.6: Mean maximum force applied to mitral valve tissue by experts (n = 3) 
and novices (n = 9) during robotics-assisted mitral valve annuloplasty suturing.   
There was no statistically significant difference in the mean maximum force applied 
to mitral valve tissue by experts (n = 3) and novices during robotics-assisted 
suturing (n = 9; p = 0.1609). 
 
3.3.2 The effect of visual force feedback on the amount of force 
applied during suturing by novices during robotics-assisted 
ex vivo mitral valve annuloplasty 
The mean maximum force applied to cardiac tissue by novices with visual force feedback 
(2.18 ± 1.30 N) was significantly lower than the mean maximum force applied to cardiac 
tissue by subjects without visual feedback  (2.47 ± 1.47; p = 0.018; Figure 3.9).   
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Figure 3.7: Mean maximum force applied to mitral valve tissue by experts (n = 3) 
and novices (n = 9) during robotics-assisted mitral valve annuloplasty suturing 
decreases from the first to the fourth trial. The decrease in the mean amount of 
force applied between the first and fourth trials was statistically significant (p = 
0.0019).   
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Figure 3.8: Mean maximum force applied to mitral valve tissue by and novices (n = 
9) during robotics-assisted mitral valve annuloplasty suturing decreases from the 
first to the fourth trial.  The decrease in the mean amount of force applied between 
the first and fourth trials was statistically significant (p = 0.0009).   
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Figure 3.9: The mean maximum force applied to mitral valve tissue by novices with 
and without visual force feedback during robotics-assisted mitral valve annuloplasty 
suturing was significantly lower than the mean maximum force applied to cardiac 
tissue by subjects without visual feedback during robotics-assisted suturing (p = 
0.018). 
3.3.3 The effect of direct force feedback on the amount of force 
applied during suturing by novices during robotics-assisted 
ex vivo mitral valve annuloplasty 
The mean maximum force applied to mitral valve tissue by novices with direct force 
feedback at the same, double, or half of the intensity of the actual force applied to tissue 
was 1.89 ± 1.01 N, 2.03 ± 1.10 N, and 2.63 ± 1.48 N, respectively.  This is significantly 
lower than the mean maximum force applied to cardiac tissue by subjects without direct 
force feedback (2.75 ± 1.69 N; p = 0.001; Figure 3.10).  Furthermore, the mean 
maximum force applied to mitral valve tissue with double the intensity of the actual force 
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applied to tissue was significantly lower than the mean maximum force applied to mitral 
valve tissue with half the intensity of actual force (p = 0.0028; Figure 3.10).  Direct force 
feedback denotes the same intensity of force applied to tissue is transmitted back to the 
subject.  High force feedback denotes that double the intensity of the actual force applied 
to tissue is transmitted back to the subject.  Low force feedback denotes that half the 
intensity of actual force applied to tissue is transmitted back to the subject.   
 
 
Figure 3.10: Main effects of different levels of direct force feedback on mean 
maximum force applied to mitral valve tissue by novices during robotics-assisted 
mitral valve annuloplasty suturing.  The mean maximum force applied to mitral 
valve tissue by novices with direct force feedback at the same (Direct), double 
(High), or half (Low) the intensity of the actual force applied to tissue was 
significantly lower than the mean maximum force applied to cardiac tissue by 
subjects without direct force feedback (Off, p = 0.001). 
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3.3.4 The effect of combined visual and direct force feedback on the 
amount of force applied during suturing by novices during 
robotics-assisted ex vivo mitral valve annuloplasty 
The groups examined all had 3D visualization with visual force feedback (ON) or 
without visual force feedback (OFF), and with or without (OFF) direct force feedback 
(Table 3.1).  When compared to no force feedback, the addition of either visual force 
feedback, direct force feedback, or both visual and direct force feedback decreased the 
maximum force applied to mitral valve tissue during robotics-assisted ex vivo mitral 
valve annuloplasty (p<0.05; Figure 3.11).  The lowest maximum force applied was seen 
with the addition of direct force feedback alone (1.62 ± 0.86 N) compared to no force 
feedback (3.34 ± 1.93 N; p<0.0001).  The addition of both visual and high direct force 
feedback (1.68 ± 0.99 N) also significantly decreased the amount of maximum force 
applied to cardiac tissue when compared to no force feedback (p<0.0001).  Both groups 
decreased the mean maximum force applied to mitral valve tissue by approximately 0.7 
N.  The addition of visual force feedback alone decreased the mean maximum force 
applied to mitral valve tissue by 0.5 N (p = 0.0001).   
It is also interesting to note that damaging forces above 6N were only applied when no 
force feedback was provided. The addition of any force feedback prevented the 
application of any damaging forces above 6 N.  However, the combination of both visual 
and direct force feedback did not result in an additive decrease in the amount force 
applied to cardiac tissue (Figure 3.12).   
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Table 3.1.   The amount of force (N) ± SD applied during suturing by novices during 
robotics-assisted ex vivo mitral valve annuloplasty. 
 
Direct Force Feedback 
 
Visual Force Feedback  
Force (N) ± SD 
OFF ON 
OFF 3.34 ± 1.93 2.16 ± 1.67 
LOW 2.53 ± 1.26 2.74 ± 1.68 
HIGH 2.39 ± 1.10 1.68 ± 0.99 
DIRECT 1.62 ± 0.86 2.15 ± 1.08 
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Figure 3.11: Mean maximum force applied to mitral valve tissue subjects with and 
without visual and direct force feedback during robotics-assisted mitral valve 
annuloplasty suturing.  When compared to no force feedback, the addition of either 
visual force feedback, direct force feedback, or both visual and direct force feedback 
decreased the maximum force applied to mitral valve tissue (p<0.05).  The lowest 
maximum force applied was seen with the addition of direct force feedback alone 
compared to no force feedback (p<0.0001).  Each point represents the force applied 
for one trial.   
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Figure 3.12: Mean maximum force applied to mitral valve tissue subjects with visual 
force feedback (green) and without visual force feedback (red) in combination with 
or without direct force feedback during robotics-assisted mitral valve annuloplasty 
suturing.   
3.3.5 Amount of maximum force applied during tying by novices and 
experts during robotics-assisted ex vivo mitral valve 
annuloplasty 
Figure 3.13 illustrates the variability in the maximum force (N) applied to mitral valve 
tissue by novices and experts during robotics-assisted tying.  Novices are Subjects 1–9 
and experts are Subjects 10–12.  
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Figure 3.13: Variability in maximum force (N) applied to mitral valve tissue by 
novices and experts during robotics-assisted tying.  
The dependent variable, maximum force applied to cardiac tissue, was right or positively 
skewed.  Therefore, a logarithmic transformation of maximum force score was applied to 
the data to bring the outlying data closer to the center in order to achieve a normal 
distribution for further statistical analysis.   
The mean maximum force applied to cardiac tissue by experts (n = 3) and novices (n = 9) 
during tying for all trials was 2.91 ± 2.31 N and 2.44 ± 1.94 N, respectively. There 
appeared to be a trend toward higher force applied by experts; however, likely due to the 
low number of experts included in the study, this difference was not statistically 
significant (p = 0.72; Figure 3.14).   
Interestingly, the mean amount of force applied by both experts and novices gradually 
decreased after each trial.  The mean amount of force applied by experts and novices 
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during tying for the first and second trials were 2.71 ± 2.29 N and 2.41 ± 1.77 N, 
respectively.  Nevertheless, this decrease was not statistically significant (p = 0.1635).  
This decrease was also seen in novices alone.  The mean amount of force applied by 
novices alone during tying for the first and second trials were 2.57 ± 2.16 N and 2.32 ± 
1.70 N, respectively.  However, the decrease was not statistically significant (p = 0.3331).       
 
 
Figure 3.14: Mean maximum force applied to mitral valve tissue by experts (n = 3) 
and novices (n = 9) during robotics-assisted mitral valve annuloplasty tying 
3.3.6 The effect of visual force feedback on the amount of force 
applied during tying by novices during robotics-assisted ex 
vivo mitral valve annuloplasty 
The mean maximum force applied to cardiac tissue by novices with visual force feedback 
(2.35 ± 1.79 N) was not significantly different from the mean maximum force applied to 
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cardiac tissue by subjects without visual feedback  (2.54 ± 2.10; p = 0.53; Figure 3.15).  
When the results from both experts and novices were combined, the mean maximum 
force applied to mitral valve tissue by all subjects with visual force feedback (2.48 ± 1.99 
N) was also not significantly different from the mean maximum force applied to cardiac 
tissue by subjects without visual feedback  (2.64 ± 2.10; p = 0.47; Figure 3.16).   
 
Figure 3.15: Mean maximum force applied to mitral valve tissue by novices with 
and without visual force feedback during robotics-assisted mitral valve annuloplasty 
tying (p = 0.53).   
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Figure 3.16: The mean maximum force applied to mitral valve tissue by novices and 
experts with and without visual force feedback during robotics-assisted tying was 
not significantly different (p = 0.47). 
3.3.7 The effect of direct force feedback on the amount of force 
applied during tying by novices during robotics-assisted ex 
vivo mitral valve annuloplasty 
The mean maximum force applied to mitral valve tissue by novices with direct force 
feedback at same, double, or half the intensity of the actual force applied to tissue was 
2.12 ± 1.30 N, 2.68 ± 2.06 N, and 2.14 ± 1.01 N, respectively.  This is not significantly 
different from the mean maximum force applied to cardiac tissue by subjects without 
direct force feedback (2.83 ± 2.84 N; p = 0.99; Figure 3.17).  When the results from both 
experts and novices were combined, the mean maximum force applied to mitral valve 
tissue by all subjects with direct force feedback at same, double, or half the intensity of 
the actual force applied to tissue was 2.02 ± 1.18 N, 2.70 ± 1.95 N, and 2.43 ± 1.62 N, 
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respectively.  This is also not significantly different from the mean maximum force 
applied to cardiac tissue by all subjects without direct force feedback (3.09 ± 2.92 N; p = 
0.44; Figure 3.18).  
 
Figure 3.17: The mean maximum force applied to cardiac tissue by novices with and 
without different levels of direct force feedback during robotics-assisted tying was 
not significantly different (p = 0.99). 
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Figure 3.18: The mean maximum force applied to cardiac tissue by novices and 
experts with and without different levels of direct force feedback during robotics-
assisted tying was not significantly different (p = 0.44). 
 
3.3.8 The effect of combined visual and direct force feedback on the 
amount of force applied during tying by novices during 
robotics-assisted ex vivo mitral valve annuloplasty 
The effect of direct and visual force feedback on the amount of force applied during tying 
by novices (Table 3.2) and both experts and novices (Table 3.3) are summarized below.  
When compared to no force feedback, the addition of either visual force feedback, direct 
force feedback, or both visual and direct force feedback did not significantly decrease the 
maximum force applied to mitral valve tissue during robotics-assisted ex vivo mitral 
valve annuloplasty in either novices alone (p = 0.16; Figure 3.19) or novices and experts 
combined (p = 0.19; Figure 3.20).  
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Table 3.2.   The amount of force (N) ± SD applied during tying by novices during 
robotics-assisted ex vivo mitral valve annuloplasty. 
 
Direct Force Feedback 
 
Visual Force Feedback  
Force (N) ± SD 
OFF ON 
OFF 3.39 ± 3.17 2.27 ± 2.43 
LOW 2.13 ± 1.09 2.16 ± 0.95 
HIGH 2.57 ± 1.83 2.79 ± 2.32 
DIRECT 2.08 ± 1.61 2.16 ± 0.94 
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Table 3.3.   The amount of force (N) ± SD applied during tying by novices and 
experts during robotics-assisted ex vivo mitral valve annuloplasty. 
 
Direct Force Feedback 
 
Visual Force Feedback  
Force (N) ± SD 
OFF ON 
OFF 3.23 ± 2.90 2.95 ± 2.99 
LOW 2.35 ± 1.91 2.51 ± 1.30 
HIGH 2.96 ± 1.81 2.44 ± 2.10 
DIRECT 2.02 ± 1.41 2.03 ± 0.93 
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Figure 3.19: When compared to no force feedback, the addition of either visual 
force feedback, direct force feedback, or both visual and direct force feedback did 
not significantly decrease the maximum force applied to mitral valve tissue during 
robotics-assisted tying by novices  (p = 0.16).  Each point represents the force 
applied for one trial.    
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Figure 3.20: When compared to no force feedback, the addition of either visual 
force feedback, direct force feedback, or both visual and direct force feedback did 
not significantly decrease the maximum force applied to mitral valve tissue during 
robotics-assisted tying by novices and experts combined (p = 0.19).  Each point 
represents the force applied for one trial.   
Furthermore, the combination of both visual and direct force feedback did not result in an 
additive decrease in the amount force applied to cardiac tissue (Tables 3.2, 3.3, and 
Figure 3.21).   
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Figure 3.21: Mean maximum force applied to mitral valve tissue by both experts 
and novices with visual force feedback (green) and without visual feedback (red) in 
combination with or without direct force feedback during robotics-assisted mitral 
valve annuloplasty tying.    
3.4 Discussion 
The objective of this study was to determine the effect of both direct force feedback and 
visual force feedback on the amount of force applied to mitral valve tissue during ex 
vivo mitral valve annuloplasty using robotics-assisted techniques.   
Previous studies using noncardiac robotics-assisted surgical models have found that force 
feedback [14, 15] and graphical displays of applied forces [16] could lower the 
magnitude of the force applied to tissue and increase the overall performance mostly for 
novice surgeons, respectively.  In this robotics-assisted model of ex vivo mitral valve 
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annuloplasty, we found that significantly less force was applied to cardiac tissue when all 
modes of force feedback were provided to the study subjects.  In particular, the use of 
direct force feedback during robotics-assisted mitral valve annuloplasty resulted in a 
greater decrease in forces applied to cardiac tissue when compared to visual force 
feedback.  These results suggest that when comparing robotics-assisted mitral valve 
annuloplasty with and without force feedback, use of the former mode results in 
significantly less force applied to cardiac tissue during robotics-assisted suturing.    
Previous work by Tholey, et al. [18] found that using both visual and force feedback led 
to better tissue characterization compared to each individual method.  However, we found 
that the addition of both visual and direct force feedback did not reduce the amount of 
force applied to mitral valve tissue in an additive fashion.  This may reflect subjects’ 
preference for one mode over the other.  During trials, the results suggest that subjects 
followed the feedback from either direct or visual force feedback, but not both at the 
same time.  
For the suture used, 4 N is sufficient to have a secure knot. If a subject applies forces 
greater than 6 N, he or she could damage the tissue or break the suture; therefore, this 
was set as the threshold of the red zone [19]. Previous studies of porcine tissue have 
reported visible tissue damage with the application of an 11 N force over an area of 2.4 
cm2 [1]. During the tying task, even without force feedback, no damaging forces were 
applied to the cardiac tissue.  The addition of either visual or direct force feedback did 
not significantly decrease the amount of force applied to cardiac tissue.          
In addition, our aim was to determine whether these effects are consistent between 
novices and experts in robotics-assisted cardiac surgery.  Although there appeared to be a 
trend toward higher force applied by experts, this difference was not statistically 
significant.  This refutes previous findings [26] and is most likely due to the low number 
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of experts included in the study.  Unfortunately, there are a limited number of surgeons 
with expertise in robotics-assisted cardiac surgery; therefore, a larger number could not 
be recruited for this study.  Furthermore, it could also be argued that the robotics-assisted 
cardiac surgery test bed doesn’t fully measure tissue forces, as some forces would be 
absorbed by the cardiac tissue itself and not detected by the sensor below.        
Importantly, the mean amount of force applied by both experts and novices gradually 
decreased after each trial.  This suggests that, with practice on robotics-assisted surgical 
systems, less damaging force may be applied to cardiac tissue.   
The implication of these findings is that in order to achieve better control of interaction 
forces on cardiac tissue during robotics-assisted mitral valve annuloplasty suturing, force 
feedback may be required.  Furthermore, direct force feedback has a significantly greater 
impact on force applied than visual force feedback.    
Force feedback has also been used to develop training simulators by some researchers 
[27-30].  Judkins, et al. [30] showed that using force feedback for training in MIS could 
cause novice surgeons to apply less force when performing surgery using the da Vinci 
surgical system in the absence of force feedback.   
In conclusion, we have shown that in order to achieve better control of interaction forces 
on cardiac tissue during robotics-assisted mitral valve annuloplasty suturing, force 
feedback may be required.  Direct force feedback may have a significantly greater impact 
on force applied than visual force feedback.  In addition, this force feedback-enabled 
robotics-assisted surgical system can be used to effectively train novices in mitral valve 
annuloplasty and to apply force feedback for safer and improved surgical performances.  
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Chapter 4  
4 Evaluating Performance and Improving Safety of a 
Novel Tool for Beating Heart Mitral Valve Repair 
New cardiovascular techniques for beating heart mitral valve repair using minimally 
invasive access avoid the risks associated with cardiopulmonary bypass; however, intra-
cardiac visualization is challenging due to the limitations of currently available medical 
imaging techniques.   As a result, novel imaging modalities are required for superior tool 
guidance and improved patient safety and outcomes.  One such guidance tool is 
augmented reality.  Augmented reality (AR) refers to the integration of  ‘real-world’ 
images, for example from video, endoscopic, or ultrasound, with a computer generated 
model [1, 2].  This may be used to add useful information to an image-guided surgical 
procedure.  Recently, a variety of AR systems have been developed for intracardiac 
surgery [3, 4].  The following chapter will outline the application of a novel AR guidance 
system for the minimally invasive mitral valve repair on a beating heart.   
____________________________________________________________________ 
This chapter is adapted from the following work: 
 Chu MW, Moore J, Peters T, Bainbridge D, McCarty D, Guiraudon GM, Wedlake 
C, Lang P, Rajchl M, Currie ME, Daly RC, Kiaii B.  Augmented reality image 
guidance improves navigation for beating heart mitral valve repair.  Innovations 
(Phila). 2012 Jul-Aug; 7(4): 274-81. 
 Moore JT, Chu MW, Kiaii B, Bainbridge D, Guiraudon G, Wedlake C, Currie M, 
Rajchl M, Patel RV, Peters TM.  A navigation platform for guidance of beating 
heart transapical mitral valve repair.  IEEE Trans Biomed Eng. 2013 Apr; 60(4): 
1034-40.  
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My contribution to these manuscripts involved organizing and conducting 
experiments.    
 
 Currie ME.  NeoChord Progress Report.  Safety and performance study of the 
NeoChord Suturing Device in subjects with degenerative mitral valve disease 
diagnosed with severe mitral regurgitation.  NeoChord.  September, 2013. 
My contribution to this report involved designing and conducting experiments and 
analyzing data.    
4.1 Introduction 
Conventional mitral valve repair requires aortic cross-clamping and cardiopulmonary 
bypass to remove blood from an arrested heart, to oxygenate the blood, and to maintain 
oxygenated blood circulation to the remainder of the body during cardiac surgery.   
However, cardiopulmonary bypass itself has been related to perioperative morbidity and 
mortality [5, 6] including postoperative blood loss and blood product transfusions [7-9], 
postoperative prolonged mechanical ventilation, pulmonary edema, or acute respiratory 
distress syndrome [6, 10, 11], and renal dysfunction [12].   Furthermore, the use of 
cardiopulmonary bypass has been linked to permanent neurologic dysfunction and 
postoperative decreases in cognition and motor abilities [13].  Elderly patients with 
multiple comorbidities are particularly vulnerable to cognitive deficits including stroke 
[14-20].  Therefore, a large proportion of elderly patients with multiple comorbidities 
and severe symptomatic mitral valve regurgitation are not referred for surgical repair.  
Clearly, new cardiovascular techniques must be tailored to address the unique 
requirements of high risk, elderly, surgical patients with mitral valve regurgitation.   
In order to avoid aortic cross-clamping and cardiopulmonary bypass, many novel 
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transcatheter valve techniques have been developed to enable beating heart mitral valve 
repair [21-31].  Emerging transcatheter valve therapies have introduced various mitral 
valve repair strategies on the beating heart, including edge-to-edge repair [22-24], 
coronary sinus cerclage [25, 26], transcatheter annuloplasty [28], and neochordal 
reconstruction [27, 29, 30, 32].  For example, the NeoChord DS1000 (NeoChord Inc., 
Eden Prairie, MN USA) is an off-pump device that uses transapical access to deliver 
expanded polytetrafluoroethylene (ePTFE) neochordae to flail segments of the mitral 
valve [29, 30, 32].  
Although these experimental techniques avoid the deleterious effects of cardiopulmonary 
bypass, they continue to be hampered by limited intraoperative visualization and 
suboptimal procedural accuracy.  At present, fluoroscopy and/or echocardiography are 
used for intraoperative guidance of these new beating heart mitral valve procedures.  
Intraoperative TEE provides good real-time visualization of mitral valve anatomy but 
provides inadequate navigation and guidance of surgical tools. Intraoperative fluoroscopy 
with and without contrast provides reasonable visualization of surgical tools, but often 
lacks three-dimensional context with only gross anatomic structures visible.  As a result, 
current imaging modalities provide limited intracardiac views that make transcatheter 
manipulation of the mitral valve challenging and can result in prolonged procedural 
times, additional device deployments, excessive radiation exposure, and most 
importantly, increased complication rates [32, 33].  Although many advances have 
occurred in transcatheter valve therapy designs, there remains great dependence on 
current imaging modalities and their known limitations [33].  Therefore, although these 
techniques have shown positive results in animal and human trials, beating heart valve 
implantation and repair is challenging due to the limitations of currently available 
medical imaging techniques.     
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The NeoChord DS1000 is introduced into the left ventricle and left atrium through 
transapical access.  Using the center thumb ring shaft (Figure 4.1), the surgeon opens the 
gripper at the distal end of the tool and then closes the gripper on the prolapsed portion of 
the mitral leaflet by releasing the thumb ring. Correct leaflet capture is verified using a 
fiber-optic-based detection mechanism.  After leaflet capture has been verified, a needle 
and an exchangeable cartridge for loading the neochord suture are installed within the 
tool.  The needle is used to puncture the leaflet and an ePTFE suture is pulled through the 
leaflet and the tool is retracted exterior to the apex of the heart with both ends of the 
suture.   The suture is fixed at the leaflet with a girth hitch knot, adjusted under Doppler 
ultrasound to ensure minimum mitral regurgitation and then secured at the apex using a 
pledget.  Multiple neochordae are typically used to ensure optimal valvular function. 
Use of the NeoChord DS1000 tool relies exclusively on TEE guidance in the form of 2D 
single plane, biplane, and 3D imaging for tool navigation and neochordae deployment 
[29].  The tool is identified in 2D biplane ultrasound (mitral valve commissural, 
midesophageal long-axis view), and navigated into the commissure of the mitral valve 
leaflets, while the surgeon and echocardiographer attempt to maintain tool tip, tool 
profile, and final target site in the ultrasound image planes at all times. Correct position 
and orientation of the grasping tool are then achieved using a 3D zoomed view. 
Returning to biplane ultrasound for higher temporal and spatial resolution, the prolapsing 
leaflet is grasped by the jaws of the NeoChord device.  
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Figure 4.1: Z-bar calibration block (top left) and NeoChord calibration block 
holding the DS1000 device. 
After extensive acute and chronic animal studies throughout Europe, Canada, and the 
United States, the NeoChord is undergoing human trials for the repair of degenerative 
mitral valve regurgitation [29-31].  Initial results confirm the safety and efficacy of this 
surgical tool for mitral valve repair in patients with degenerative mitral valve 
regurgitation.  In fact, analysis of initial echocardiographic parameters following 
NeoChord placement revealed a trend towards improved left ventricular dimensions 
following the procedure.  These results from the Transapical Artificial Chordae 
Tendineae (TACT) study in Europe (Tables 4.1, 4.2).  Nevertheless, limited data at this 
time preclude any firm conclusions regarding the efficacy of the NeoChord tool.  
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Table 4.1.  Comparison to baseline data in all patients with data from TACT: 
Matched data from TACT patient trials following paired two-tailed t-test. 
 N Mean ± SD Paired 
Difference from 
Baseline 
95% 
Confidence 
Interval 
p 
 
Left Ventricular Diastolic Diameter (cm) 
Baseline 15 4.9 ± 0.82   
Discharge 15 4.45 ± 0.84 0.21, 0.69 0.001 
30-day 13 4.54 ± 0.60 -0.27, 0.83 0.29 
6-month 8 4.26 ± 0.72 -0.36, 1.15 0.26 
 
Left Ventricular Systolic Diameter (cm) 
Baseline 15 3.1 ± 0.81   
Discharge 15 3.64 ± 0.42 -0.33, 0.51 0.66 
30-day 13 2.93 ± 0.52 -0.41, 0.60 0.70 
6-month 8 2.84 ± 0.66 -1.0, 1.05 0.95 
 
End Diastolic Volume (Teicholz formula, mL) 
Baseline 15 117.2 ± 45.92   
Discharge 15 94.66 ± 43.56 9.63, 35.5 0.002 
30-day 13 96.62 ± 29.02 -10.05, 42.30 0.20 
6-month 8 84.42 ± 33.62 -13.11, 56.21 0.19 
 
End Systolic Volume (Teicholz formula, mL) 
Baseline 15 41.79 ± 27.42   
Discharge 15 38.31 ± 22.13 -10.38, 17.35 0.60 
30-day 13 34.64 ± 14.10 -9.72, 18.98 0.50 
6-month 8 32.94 ± 18.21 -28.16, 31.39 0.90 
 
Table 4.2: Comparison to discharge data in all patients with data from TACT: 
Matched data from TACT patient trials following paired two-tailed t-test. 
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 N Mean ± SD Paired 
Difference 
from 
Discharge 
95% 
Confidence 
Interval 
p 
 
Left Ventricular Diastolic Diameter (cm) 
Discharge 21 4.51 ± 0.74   
30-day 21 4.56 ± 0.53 -0.34, 0.23 0.71 
6-month 11 4.40 ± 0.66 -0.09, 0.47 0.16 
 
Left Ventricular Systolic Diameter (cm) 
Discharge 21 3.08 ± 0.66   
30-day 21 2.96 ± 0.53 -0.19, 0.42 0.43 
6-month 11 2.77 ± 0.65 0.08, 0.82 0.02 
 
End Diastolic Volume (Teicholz formula, mL) 
Discharge 21 96.57 ± 38.42   
30-day 21 97.37 ± 25.91 -15.73, 14.13 0.91 
6-month 11 90.44 ± 30.99 -3.81, 21.60 0.15 
 
End Systolic Volume (Teicholz formula, mL) 
Discharge 21 39.83 ± 20.48   
30-day 21 35.48 ± 14.33 -4.89, 13.59 0.34 
6-month 11 31.25 ± 18.30 1.04, 23.2 0.04 
 
Furthermore, the limited visualization during tool navigation and neochord dehiscence, or 
tearing, from the mitral leaflet following deployment are ongoing challenges with this 
procedure.  This chapter outlines the development and use of a novel image guidance 
system for safer NeoChord tool navigation and identifies factors in neochord deployment 
that may prevent neochord dehiscence.   
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4.2 A Navigation Platform for Guidance of Beating 
Heart Transapical Mitral Valve Repair 
4.2.1 Motivation 
A major challenge in navigating the NeoChord device to the mitral valve target region is 
that ultrasound imaging must simultaneously keep the target region (mitral valve line of 
coaptation) and the tool tip in view.  While TEE has so far proven adequate for the final 
positioning of the tool and grasping the leaflet, there have been safety concerns relating 
to the navigation of the tool from the apex to the target mitral valve leaflet.  
Echocardiography lacks the spatial and temporal resolution to view intracardiac 
instruments and critical cardiac structures simultaneously; therefore, there is a risk of 
potential injury to intracardiac structures during instrument navigation.   TEE guidance is 
problematic since it is not always possible to maintain appropriate spatial and temporal 
resolution in 3D, and it is not always possible using 2D and 2D bi-plane views to 
simultaneously maintain both the tool tip and the target site in the field of view. The use 
of 2D ultrasound also makes it difficult to ensure that the tool tip itself is visualized, 
rather than an arbitrary cross section of the tool shaft that happens to be transecting the 
US plane.  Due to these navigation challenges, the tool can be caught in the subvalvar 
apparatus risking chordal rupture or leaflet perforation. Current clinical practice involves 
the use of highly trained surgical proctors who are expert in the use of this device. 
To overcome this challenge and to improve the overall safety of the navigation process, 
we have evaluated the efficacy of employing an AR technique capable of providing a 
robust 3D context for TEE image data [8]. We have adapted a visualization environment 
that uses tracking technology to locate both the tool and the TEE probe in 3D space, 
making it possible to represent the real-time ultrasound images with virtual geometric 
models of both devices and interactively defined anatomy within a common coordinate 
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system (Figure 4.2) defined by the Aurora (Northern Digital, Waterloo, Canada) 
magnetic tracking system.  In this real-time environment, the surgeon can easily and 
intuitively identify the tool, surgical targets, and high-risk areas, and view tool 
trajectories and orientations.  
 
 
Figure 4.2:  Real-time ultrasound image data integrated with geometric models 
representing aortic and mitral valve annuli (red and green, respectively), and 
tracked models of the NeoChord DS1000 and TEE probe. 
This study is a proof-of-concept validation from two animal studies involving six cardiac 
surgeons.  The purpose of this study was to compare navigation of the NeoChord DS1000 
in a porcine heart using either TEE guidance alone or TEE with the AR guidance system.   
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4.2.2 Methods 
4.2.2.1 Augmented Echocardiography 
Virtual geometric models of each device were created in VTK (Visualization Toolkit, 
Kitware Inc.).  VTK is an open-source, freely available software library of computer 
graphics and visualization algorithms for image processing and visualization [9].  The 
geometric representation of the TEE probe includes video image planes that can render 
real-time digital video capture of the dual ultrasound planes provided by the iE33 
ultrasound device (Philips, Inc.).  Real-time monitoring of rotation angles and depth 
settings makes it possible to properly represent the scale and orientation of the image 
planes in 3D. The geometric model of the NeoChord tool consists of the tip region only. 
Axes with 10 mm markings were projected from this virtual representation, indicating the 
forward trajectory of the tool and the direction of the opening jaws (Figure 4.2). This 
greatly facilitated the surgeons’ ability to plan their tool trajectory toward the desired 
target site. 
Magnetic tracking sensors are integrated into the tool and TEE probe, and appropriately 
calibrated, allowing geometric models of the tool and probe to be represented in the 
tracker coordinate reference frame. A six degrees of freedom (DOF) sensor was rigidly 
attached externally on the TEE probe of the Philips iE33 ultrasound (Figure 4.3).  
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Figure 4.3: NeoChord DS1000 outfitted with tracking sensors (left) and TEE probe 
with sensor on back (right and insert, top right).  Devices rest on the NDI Aurora 
tabletop magnetic field generator. 
 
Since the tip of the NeoChord device can open by over 20 mm (Figure 4.4), we required 
two tracked sensors to represent its real-time geometry. A 6DOF sensor was placed near 
the distal end of the fixed tool shaft to represent the pose of the tool as a whole, and a 
5DOF sensor was incorporated in the thumb ring shaft that controls the opening and 
closing of the distal tip that is used to grasp the flail mitral valve leaflet. The Euclidean 
distance between these two sensors was measured with the gripper closed. Subsequently, 
any increase in this distance could be used to accurately represent the opening of the 
distal end of the tool.  
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Figure 4.4: Geometric model of the open NeoChord tool, with trajectory axes.  
Insert: photograph of the device. 
The 6DOF sensor representing the rigid portion of the tool was calibrated using a custom-
built tracked calibration block designed to hold the NeoChord tool in a precise 
configuration (Figure 4.1). Using a CT image of the calibration block with a NeoChord 
tool attached, we were able to precisely define the tool and gripper geometry relative to 
the calibration block, making the calibration of the NeoChord  tools a trivial task.  The 
tracked TEE probe was calibrated using a Z-bar phantom [34].  A Z-bar calibration 
phantom comprises line fiducials in a known geometry.  Homologous points in both the 
phantom and the image coordinate space from different tracked probe positions are 
obtained and used to determine the transformation matrix mapping the ultrasound 
imaging coordinate system to the coordinate system defined by the tracking tool [34]. 
 
A valuable corollary to tracking the 2D ultrasound image data in 3D space is the ability to 
define anatomy of interest such as the target location (mitral valve line of coaptation), 
and regions to be avoided (mitral valve annulus and aortic valve annulus) for contextual 
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purposes.  For this application only the mitral and aortic valve annuli are required to 
safely complete the tool navigation task. These features are identified using tracked 
biplane ultrasound image data: four points defining the annular ring of each structure are 
defined in the image data and using these points, we define tubular splines and render 
them in the 3D scene in VTK (Figure 4.5). All features are identified in midsystole, since 
the mitral valve annular ring is closest to the apex at this point in the cardiac cycle. This 
in effect provides an indicator of the first danger zone to be avoided as the tool is moved 
into the left ventricle from the apex. 
 
 
Figure 4.5: (Left) Intraoperatively defined anatomy (mitral valve annulus). (Right) 
Planning entry trajectory in the operating room.  
Much of the difficulty associated with navigating the NeoChord device inside the beating 
heart stems from the use of intrinsically 2D image data to perform a 3D task. To address 
this limitation, our visualization platform consists of two views: a “bullseye” view as 
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seen from the apex of the heart toward the mitral valve annulus, and a side view 
orthogonal to the bullseye view, showing the mitral valve annulus and aortic valve 
annulus in profile (Figure 4.2).  With these two views, in concert with the tool trajectory 
axis, the surgeon is able to quickly and intuitively orient the device for a direct line path 
from the apex to the target region, safely avoiding the annular ring and valve apparatus. 
In addition, the side view provides a graphical representation of the tool tip distance to 
the mitral valve annular plane, ensuring that the tool tip avoids becoming caught under 
the valve leaflet apparatus, or passing too deeply into the left atrium. 
These views have the added benefit of simplifying the task of the echocardiographer who 
is otherwise required to maintain both the tool tip and mitral valve annulus in the image 
plane at all times.  However, during the navigation task it is not uncommon for the 
ultrasound image plane to obstruct the surgeon’s view of the tracked geometric models. 
In such circumstances, a balance must be struck between providing the surgeon with an 
unobstructed view (by adjusting the transparency of the ultrasound image data) and 
allowing the echocardiographer to ensure the accuracy of the geometric models relative 
to the real-time ultrasound data.  
4.2.2.2 Integration Into OR Workflow 
Our AR guidance system is designed to assist the surgeon with three related navigation 
tasks: planning the left ventricular apical access point and initial trajectory, maintaining a 
safe and direct entry through the mitral valve commisure into the left atrium, and 
establishing the correct tool orientation at the line of coaptation so that the NeoChord 
DS1000 device can grasp the flail leaflet. To achieve this, prior to making the apical 
entry incision, the echocardiographer identifies a minimal number of tie points along the 
pertinent anatomy (aortic valve annulus, mitral valve annulus, and line of coaptation) to 
represent this anatomy in our augmented ultrasound space. Next, the surgeon uses the 
  
 
 
 
 
219 
trajectory projection of the NeoChord DS1000 tool to plan the optimal entry point and 
orientation (Figure 4.5). After apical access, the surgeon simply orients and points the 
tool trajectory toward the desired target site and advances the tool, monitoring the 
geometric model representations as seen on the real-time ultrasound image data. By 
overlaying the geometric models on the real ultrasound image data, the surgeon is able to 
assess the accuracy and reliability of these representations in real time. If the features 
have moved, for example due to the introduction of the NeoChord tool, they can be 
redefined before proceeding. In future iterations, we plan to provide the surgeon with a 
view of the geometric models only, while the echocardiographer will have a separate 
monitor that includes the tracked ultrasound image data as well.  Once at the desired 
target location, the procedure returns to the standard workflow, with the navigation task 
completed. 
The technology associated with the AR navigation system can be easily integrated into 
the operating room. The Aurora tabletop magnetic field generator is specifically designed 
to work in the presence of various sources of metal. It has a large field of view, and easily 
fits on top of the OR table. Sensors attached to the TEE probe and surgical tools should 
not impede normal OR workflow. Furthermore, the cost associated with this technology 
is not prohibitive for most institutions. 
4.2.2.3 Proof of Concept: Animal Study 
Two porcine animal studies were performed to provide a proof-of-concept validation for 
the AR navigation system. All procedures were performed in compliance with standards 
of the Animal Use Subcommittee of Western University, London, ON, Canada.  
A total of six cardiovascular surgeons participated in the study, performing the 
neochordae image navigation tasks a total of 12 times with and without AR imaging 
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guidance in two porcine models.   All animals underwent general anesthesia with single-
lumen endotracheal tube intubation and monitoring using a right internal jugular venous 
line, femoral arterial line, three-lead electrocardiography, oxygen saturation probe, and 
end-tidal carbon dioxide monitoring.  A lower hemisternotomy was performed, and 
pericardial retention sutures were placed to expose the left ventricular apex. Two 
plegetted 2-0 Prolene purse-string sutures were placed around the left ventricular apex 
with Rummel tourniquets to secure the apical puncture site. The NeoChord DS1000 
device was introduced into left ventricular apex. The surgeon then used TEE guidance 
alone or AR imaging guidance to navigate the tool from the left ventricular apex across 
the mitral valve orifice to face the open tool jaw toward the predetermined intended 
mitral valve leaflet segment.  After the image guidance study, the targeted mitral valve 
leaflet segment was grasped by the jaws of the device. Correct leaflet capture was 
verified using the fiber optic Y based detection mechanism that is integrated into the 
NeoChord DS1000 tool. After leaflet capture was verified, an ePTFE suture was pulled 
through the leaflet and the tool was retracted out the left ventricular apex with both ends 
of the suture. The suture was fixed at the leaflet with a girth hitch knot, adjusted under 
real-time TEE guidance to the appropriate length, and then secured at the apex using a 
pledget. 
The primary goal of these studies was to compare navigation of the tool from apex to 
target region with and without AR assistance. In random order, the surgeons were asked 
to navigate the NeoChord tool from a starting point near the apex, up through the mitral 
valve line of coaptation, situating the distal end of the tool in the left atrium.  The 
NeoChord tool location was recorded every 0.5 seconds for all navigation attempts. Four 
metrics were used to assess the navigation task including (i) the total length the tool path 
followed; (ii) the distance error from tool locations to a direct line drawn from apex to 
final destination in the coaptation line; (iii) total task completion time; and finally, (iv) 
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the tool path data used to identify points of potential injury to neighboring intracardiac 
structures. 
The echocardiographer determined the successful end point of the task by identification 
of the tool facing the appropriate mitral valve leaflet segment, as indicated by the 3D 
short axis TEE.  In cases where the surgeon had to return to the apical region to reorient 
themselves, the attempt was defined as a fail and the task was started over.   
4.2.2.4 Statistical Analysis 
For purposes of data analysis, continuous variables were expressed as a mean +/- 
standard deviation and categorical variables were expressed as percentages.  
Statistical analysis was performed using paired t-test and Fisher exact test for 
dichotomous variables and a p-value of ≤0.05 was considered statistically significant. 
4.2.3 Results 
Successful tool navigation from left ventricular apex to mitral valve leaflet was achieved 
in 12 (100%) of 12 and 9 (75%) of 12 (P  = 0.2) attempts with AR imaging and TEE 
alone, respectively. The AR imaging guidance demonstrated significantly shorter 
distance errors from midline, total navigation times, and total path lengths traveled 
compared with TEE navigation alone (Table 4.3).  
 
Table 4.3: Navigation data in TEE-guided attempts (n = 12) and AR-guided 
attempts (n = 12) 
 
Navigation Data TEE Alone AR Guidance P 
 
Distance errors from midline, mm 
 
16.8 ± 10.9 
 
5.2 ± 2.4 
 
0.003 
  
 
 
 
 
222 
 
Total navigation times from  
left ventricular apex to mitral valve leaflet, 
s 
 
92.0 ± 84.5 
 
16.7 ± 8.0 
 
0.004 
 
Total path length, mm 
 
1128.9± 931.1 
 
225.2 ± 120.3 
 
0.003 
    
    
The AR imaging guidance allowed for more accurate tool navigation from left ventricular 
apex to the mitral valve leaflet with greater than threefold reduction in distance error 
from the intended midline trajectory (P  = 0.003) and greater than fourfold reduction in 
total tracked tool path lengths before reaching the intended mitral valve leaflet target (P  
= 0.003) when compared with TEE guidance alone. The total navigation times for the 
tool within the left ventricle was reduced fivefold with AR imaging compared with TEE 
alone (P  = 0.004). Figures 4.6 and 4.7 demonstrate the striking differences in the 
magnetically tracked tool paths taken by each surgeon (each surgeon represents a 
different color) when using TEE guidance alone versus AR imaging guidance.  
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FIGURE 4.6: Tracked tool paths demonstrating guidance with TEE alone (A) 
versus AR imaging (B) from experiment day 1. Each colored line represents a 
different surgeon trial, and the mitral (red) and aortic (blue) annuli are represented. 
 
FIGURE 4.7: Tracked tool paths demonstrating guidance with TEE alone (A) 
versus AR imaging (C) from experiment day 2. B, Three failed navigations with 
TEE alone. Each colored line represents a different surgeon trial, and the mitral 
(red) and aortic (blue) annuli are represented. 
We also analyzed these results by individual surgeon study, and Figure 4.8 demonstrates 
that even a surgeon with multiple NeoChord DS1000 human implants (one of the original 
inventors) can derive significantly improved tool navigation accuracy with AR guidance 
versus TEE alone. 
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FIGURE 4.8: Tracked tool paths of the most experienced surgeon with the 
NeoChord DS1000 tool, with TEE guidance alone (A) and AR guidance (B). Note 
the entry into the left ventricular outflow tract (LVOT) and aortic valve and getting 
caught under the posterior mitral valve leaflet (A) and the direct path taken with 
augmented image guidance (B). 
Although tool navigation accuracy is paramount, equally important is patient safety and 
prevention of iatrogenic injury to the aortic valve, anterior and posterior leaflets, left 
ventricular free wall, and left atrial roof.  
 
 
Table 4.4 demonstrates the number of times the tool traversed other intracardiac 
structures with TEE guidance alone versus AR imaging guidance. In total, there were 78 
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instances of potential injury using TEE alone compared with only 2 in the trials using the 
AR imaging guidance system, resulting in an approximate 40-fold decrease in risk of 
possible injurious events (P  = 0.008). 
Table 4.4: Potential injury to other intracardiac structures 
Intracardiac Structures TEE Alone AR Guidance P 
 
Aortic valve 
 
34 
 
0 
 
 
 
 
Anterior leaflet mitral valve 
 
 
20 
 
 
0 
 
 
    
Posterior leaflet mitral valve,  
Left ventricular free wall 
 
15 
 
2 
 
 
 
Left atrial roof  
 
 
6 
 
 
0 
 
 
 
Failed navigation 
 
 
Total 
 
 
3 
 
 
78 
 
 
0 
 
 
2 
 
 
 
 
 
0.008 
    
    
 
When comparing navigation outcomes between novices and experts (Table 4.5, Figure 
4.9), there were no statistically significant differences between the two groups. However, 
the confidence intervals narrow significantly with AR imaging versus TEE imaging 
alone, suggesting that AR imaging improves the reproducibility of the procedure and may 
help novice surgeons to more expeditiously overcome the steep learning curve associated 
with navigating the NeoChord DS1000 tool (Figure 4.9). 
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Table 4.5: Differences in tool navigation between novice and expert surgeons 
 
Navigation TEE Alone AR Guidance 
 
Distance errors from midline, mm 
      Novice 
      Expert 
      P 
 
 
25.12 ± 11.84 
10.85 ± 5.17 
0.43 
 
 
4.53 ± 2.00 
5.96 ± 2.64 
0.02 
 
Navigation time from Left ventricular 
apex to mitral valve leaflet, s 
 
 
 
 
 
 
      Novice 
      Expert 
      P 
110.4 ± 72.78 
78.86 ± 95.28 
0.53 
18.83 ± 2.84 
14.79 ± 10.11 
0.55 
 
Total path length, mm 
      Novice 
      Expert 
      P 
 
 
1337.13 ± 886.45 
980.08 ± 1001.85 
0.53 
 
 
216.00 ± 20.68 
228.35 ± 162.28 
0.90 
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FIGURE 4.9: Data graph demonstrating the distance errors from the intended 
midline trajectory comparing expert with novice study results. Although there are 
no statistically significant differences between the experts and novices, the 
confidence intervals narrow significantly with AR guidance, suggesting that it may 
improve the reproducibility of tool navigation and reduce the learning curve for 
novice surgeons. 
4.2.4 Discussion 
4.2.4.1 Advantages of AR Guidance  
A variety of AR imaging guidance systems have been developed to facilitate intracardiac 
beating heart surgery [3, 33-36].  We believe that our AR imaging platform 
demonstrated proof-of-concept with a robust three-dimensional context to enhance the 
TEE image guidance for beating heart mitral valve repair with the NeoChord DS1000 
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device. In this realtime environment, the surgeon easily and intuitively identified the 
surgical tool, relevant intracardiac anatomy, high-risk areas, and tool trajectories and 
orientations.  
Our results demonstrated that tool guidance from the left ventricular apex to the mitral 
valve leaflet target was always successful with AR guidance, and more importantly, tool 
navigation was much more accurate (more than threefold to fourfold) with significantly 
reduced total navigation times (more than fivefold shorter). We also demonstrated a 
dramatic reduction in the incidence of tool misguidance (and potential injury) into 
adjacent cardiac structures, such as the aortic valve or anterior leaflet of the mitral valve, 
thus enhancing patient safety with AR imaging. For example, with TEE guidance alone, 
the aortic valve was crossed with the tool in nearly all trials, whereas with AR guidance, 
the aortic valve was never touched at all.  
These studies also demonstrated the relatively poor tracking ability of two-dimensional 
echocardiography. Isolated three-dimensional TEE can be used for tracking tools in small 
spaces; however, it has a significant real-time delay and is often limited in the volume 
that it can display. As a result, three-dimensional TEE does not easily allow tracking of 
tools over long distances greater than 5 to 6 cm and cannot predict the optimal tool path 
for instrument navigation. 
When we examined the results by level of expertise, unfortunately, we had too small of a 
sample size to demonstrate any significant differences. Nonetheless, the confidence 
intervals of the tool accuracy measurements (distances from intended midline trajectory) 
were much narrower with AR imaging guidance than TEE alone, suggesting that AR 
imaging guidance may help improve the reproducibility of results in novice surgeons and 
shorten the procedural learning curve.  In addition, we believe that the AR imaging 
platform can still provide beneficial guidance to experts as well. Figure 4.8 demonstrates 
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the superior tool navigation paths with AR imaging compared with TEE alone performed 
by a surgeon experienced in numerous human implants with the NeoChord DS1000 
device.  
Overall, we believe that AR imaging guidance will shorten procedure times and 
significantly improve the safety of beating heart mitral valve repair with the NeoChord 
DS1000 device in both novices and experts. In addition, we believe that the improved 
image guidance provided by this AR navigation system could be easily adapted to other 
beating heart procedures. 
The infrastructure costs of most currently available intraoperative image guidance 
systems, including Dyna computed tomography, magnetic resonance imaging, and hybrid 
operating rooms, are in excess of several millions of dollars [33].  Our AR imaging 
guidance platform is much more cost-effective, with the magnetic tracking system 
retailing for approximately $18,000 USD and $250 USD for each single-use sensor. In 
addition, the AR system is portable, avoids irradiation, and does not impede normal 
operating room workflow. 
Beating heart mitral valve repair procedures, transcatheter aortic valve implantation, and 
atrial and ventricular septal defect device closure all rely on limited intraprocedural 
visualization that could be enhanced with this AR guidance system. Minimally invasive 
on-pump procedures, such as mini-thoracotomy mitral and aortic valve procedures, may 
also benefit from this assisted guidance to accurately place peripheral inserted cannulas 
centrally. 
4.2.4.2 Study Limitations  
Limitations in our study include the relatively small sample size, the porcine model, and 
misregistration errors related to aortic valve and mitral valve annular movement.  
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While this image guidance system provides sufficient accuracy for the procedure, it took 
up to 20 min to define the aortic valve annulus, mitral valve annulus, and line of 
coaptation in systole for these porcine studies. While the line of coaptation was 
particularly difficult to identify in healthy porcine hearts, we believe this feature to be 
much easier to define in humans, particularly when a prolapsed or flailing leaflet is 
present.  
 
4.2.4.3 Summary 
In summary, this proof-of-concept study demonstrated superior tool navigation accuracy, 
significantly shorter navigation times, and reduced potential for injury with AR enhanced 
intracardiac TEE navigation for off-pump transapical mitral valve repair with neochordae 
implantation.  
 
4.3 Predictors of Surgical Success in Beating Heart 
Mitral Valve Repair with Artificial Chordae 
4.3.1 Motivation   
The NeoChord device is currently undergoing human trials for the repair of degenerative 
mitral valve regurgitation.  Initial results confirm the safety and efficacy of this surgical 
tool for mitral valve repair [29-31]; however, clinical observations made during the 
conduct of the TACT study in Europe have highlighted key challenges with the 
procedure.  One challenge is Neochord suture dehiscence, or tearing, from the mitral 
valve leaflet following suture deployment.   
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The length of the neochord sutures is adjusted from outside of the left ventricular apex 
using echocardiographic guidance.  The left ventricular apex is used as the tethering point 
for neochords placed by the NeoChord tool.  This is not physiologic.  As previously 
described, natural chordae tendineae insert on the anterolateral and posteromedial 
papillary muscles.  Therefore, apical tethering of the neochordae may affect the dynamic 
relationship between the mitral valve leaflets and chordae. For example, a previous study 
reported that the variation in chordae tendineae length between systole and diastole is 
greater at the apex compared to the papillary muscles [37].  This may contribute to 
increased risk of prolapse or tearing of the repaired mitral leaflet when chordae are 
attached to the left ventricular apex. In fact, recent results in the TACT study would 
suggest a posterolateral left ventricular access site has yielded improved acute results.    
Furthermore, the NeoChord suture insertion site on the anterior or posterior leaflet may 
also affect risk of suture dehiscence.  In the normal mitral valve, the posterior leaflet and 
chordae are subject to much lower levels of tensile stress than the anterior leaflet and 
chordae.  Following neochord repair, there is an even higher stress concentration at the 
site of suture insertion, particularly at the suture close to the A2/P2 region.  
The purpose of this study was to determine if there was a difference in the amount of 
force required for suture dehiscence when comparing different suture insertion and 
tethering sites.  This information may indicate what factors in NeoChord suture 
placement determine successful NeoChord suture deployment on the mitral valve leaflet 
without suture dehiscence.   
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4.3.2 Methods 
4.3.2.1 Ex vivo Porcine NeoChord Suture Deployment 
Porcine hearts were obtained from a local abattoir.  The approximate mass of the hearts 
was 1 kg.  Only porcine hearts of similar size with intact mitral valve apparatus were 
selected for the study.  The left atrium was transected from the porcine heart.     
The NeoChord DS-1000 was used to deploy a 2-0 ePTFE suture (CV-4, W. L. Gore & 
Associates, Inc., Flagstaff, Arizona) at the anterior or posterior mitral valve leaflet of the 
porcine heart.  All sutures were deployed at the A2 or P2 location approximately 3 mm 
from the leading edge of the leaflet.  The order of NeoChord deployment to the anterior 
and posterior locations was randomized.  Each NeoChord suture was passed through 
either the apex or the base of a papillary muscle.  The order of NeoChord suture tethering 
to the apex or papillary muscle was randomized using Design-Expert statistical software 
(Stat-Ease, Inc., Minneapolis, MN). 
Following ex vivo NeoChord suture deployment in a porcine heart, the suture was placed 
between a custom plate and the surface of a nano force-torque sensor.  The force required 
for NeoChord suture dehiscence was measured using this nano force-torque sensor (ATI 
Industrial Automation, Apex, NC) mounted on a linear stage.  The tethered NeoChord 
suture was retracted by the linear stage at a rate of 2 mm/s.  The maximum net force 
required for NeoChord suture dehiscence from the leaflet was recorded.  From this data, a 
threshold of net maximum force required for chordal dehiscence was calculated and 
related to the location of NeoChord deployment and tethering. 
Next, the amount of force on the NeoChord suture between systole and diastole was 
measured in vivo in a porcine model.  Following in vivo NeoChord suture deployment at 
P2 in a porcine heart, the suture was passed through the apex of the left ventricle and 
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placed between a custom plate and the surface of a nano force-torque sensor mounted on 
a linear stage.  The tethered NeoChord suture was retracted by the linear stage at a rate of 
2 mm/s until the suture was taught during systole.  The forces on the NeoChord suture 
were recorded firstly during systole, when the suture is taught and forces are highest [38], 
and secondly during diastole, when the suture is lax and forces are lowest.  
4.3.2.2 Statistical Analysis 
There were four groups for this study:  A2 to apex, A2 to anterolateral papillary muscle, 
P2 to apex, and P2 to posteromedial papillary muscle.  The number of trials required for 
each group was determined by the resource equation, as this method does not require 
estimates of the effect size or standard deviation.  Six trials per group were calculated as 
an acceptable number each of the four groups to be tested.  Nevertheless, 22 trials were 
completed for each of the four groups.   
Continuous variables were expressed as a mean ± standard deviation (SD), and 
categorical variables were expressed as percentages.  The Shapiro-Wilk test for normality 
was performed on all four dehiscence trial data sets and confirmed a p ≥ 0.05 for each 
data set, indicating a normal distribution.  Statistical analysis was performed using two-
tailed paired t-test with bootstrapping and a value of 0.05 was considered statistically 
significant. 
 
4.3.3 Results 
The mean maximum force required for NeoChord suture dehiscence from the anterior 
mitral valve leaflet to the apex (5.09 ± 0.36 N) was significantly lower than the mean 
maximum force required for NeoChord suture dehiscence from the anterior mitral valve 
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leaflet to the anterolateral papillary muscle (10.01 ± 0.95 N, Table 4.6).   
The mean maximum force required for NeoChord suture dehiscence from the posterior 
mitral valve leaflet to the apex (4.07 ± 0.41 N) was significantly lower than the mean 
maximum force required for NeoChord suture dehiscence from the posterior mitral valve 
leaflet to the posteromedial papillary muscle (7.21 ± 0.77 N, Table 4.6).   
The mean maximum force required for NeoChord suture dehiscence from the posterior 
mitral valve leaflet to the apex (4.07 ± 0.41 N) was lower than the mean maximum force 
required for NeoChord suture dehiscence from the anterior mitral valve leaflet to the apex 
(5.09 ± 0.36 N, Table 4.7).  However, this difference was not statistically significant.     
The mean maximum force required for NeoChord suture dehiscence from the posterior 
mitral valve leaflet to the posteromedial papillary muscle (7.21 ± 0.77 N) was 
significantly lower than the mean maximum force required for NeoChord suture 
dehiscence from the posterior mitral valve leaflet to the posteromedial papillary muscle 
(10.01 ± 0.95 N, Table 4.7).   
The mean force measured from the NeoChord suture in vivo during systole was 0.151 ± 
0.005 N.  The range between of force measured from the NeoChord suture was 0.016 to 
0.285 N during systole.  
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Table 4.6:  Mean maximum force (N) required for neochord suture dehiscence for 
different attachment and tethering locations 
 
Neochord Suture Attachment and 
Tethering Locations 
 
Number of trials Maximum Force (N) 
Mean ± SD 
 
Anterior Leaflet to Apex 
 
22 
 
5.09 ± 0.36 
 
Anterior Leaflet to Anterolateral 
Papillary Muscle 
 
22 
 
10.01 ± 0.95 
 
Posterior Leaflet to Apex 
 
22 
 
4.07 ± 0.41 
 
Posterior Leaflet to Posteromedial 
Papillary Muscle 
 
22 
 
7.21 ± 0.77 
   
Table 4.7:  Comparison of mean maximum force (N) required for neochord suture 
dehiscence for different attachment and tethering locations 
 
Comparison 
Paired difference 
Mean ± SD 
 
95% Confidence 
Interval 
 
Significance  
(p-value) 
Anterior Leaflet to Apex – 
Anterior Leaflet to 
Anterolateral Papillary Muscle 
 
-4.92 ± 1.03 
 
-7.06, -2.78 
 
<0.001 
 
Posterior Leaflet to Apex – 
Posterior Leaflet to 
Posteromedial Papillary Muscle 
 
 
-3.14 ± 0.74 
 
 
-4.67, -1.60 
 
 
<0.001 
 
Anterior Leaflet to Apex – 
Posterior Leaflet to Apex 
 
 
1.02 ± 0.59 
 
 
-0.21, 2.25 
 
 
0.1 
Anterior Leaflet to  
 
Anterolateral Papillary Muscle– 
Posterior Leaflet to 
Posteromedial Papillary Muscle 
 
 
 
2.80 ± 1.06 
 
 
 
0.61, 5.00 
 
 
 
0.02 
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4.3.4 Discussion 
Initial results from the TACT trial of beating heart NeoChord repair in patients with 
mitral valve regurgitation revealed favourable outcomes.  However, one complication of 
NeoChord suture placement is postoperative suture dehiscence, or tearing, from the 
mitral valve leaflet.  NeoChord sutures are synthetic, nonabsorbable monofilament 
sutures made of ePTFE and they are more extensible than natural chordae tendineae.  
Whereas, natural chordae tendineae are extensible and may change up to 10-15% in 
length when higher load levels are applied, ePTFE sutures may change less than 2% 
under the application of higher loads [38].  Furthermore, once stretched, ePTFE does not 
have the ability of natural chordae tendineae to return to the original length.  These 
differences may alter the conditions and forces on the mitral valve leaflets following 
NeoChord suture placement.  The purpose of this study was to determine if there was a 
difference in the amount of force required for NeoChord suture dehiscence from the 
mitral valve leaflet when comparing different suture insertion and tethering sites.   
We found that the mean maximum force required for NeoChord suture dehiscence from 
the anterior or posterior mitral valve leaflet to the apex was significantly lower than the 
mean maximum force required for NeoChord suture dehiscence from the anterior or 
posterior mitral valve leaflet to the anterolateral or posteromedial papillary muscle, 
respectively.  Furthermore, the mean maximum force required for NeoChord suture 
dehiscence from the posterior mitral valve leaflet was lower than the mean maximum 
force required for NeoChord suture dehiscence from the anterior mitral valve leaflet.  
Therefore, there may be a lower threshold of force required for dehiscence when 
NeoChord sutures from either mitral valve leaflet are tethered at the left ventricular apex.  
NeoChord sutures inserted in the posterior mitral valve leaflet may be more vulnerable to 
dehiscence.  Our results data follow from previous studies that found that in the normal 
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mitral valve, the posterior mitral valve leaflet is subject to much lower levels of tensile 
stress than the anterior leaflet.  Therefore, tissues of the posterior mitral valve leaflet may 
be more vulnerable to the application of force through NeoChord sutures.   
In addition, previous studies have found that the area of ePTFE suture attachment to the 
leaflet had higher stress concentrations, particularly at the suture closest to the midline.  
Therefore, differences in locations within the mitral valve leaflets may also play a role in 
NeoChord suture dehiscence.  For example, NeoChord sutures placed closer to the 
leading edge or the midline (P2) of the mitral valve leaflet may dehisce more readily than 
NeoChord sutures placed further from the leading edge or the midline of the mitral valve 
leaflet.  The force required for NeoChord suture dehiscence from locations within the 
anterior and posterior mitral valve leaflets including different A1, A3, P1, P3 segments 
and different distances from the leaflet edge were not explored in this study.   
The mean force measured from the NeoChord suture in vivo during systole was much 
lower than the force required for dehiscence measured ex vivo. Therefore, the location of 
NeoChord suture placement and tethering is not the only factor that affects NeoChord 
suture dehiscence.  Potential additional factors they may contribute to NeoChord suture 
dehiscence include individual patient and mitral valve characteristics.  For example, a 
NeoChord suture in a thin myxomatous mitral valve leaflet would be more likely to 
dehisce than a NeoChord suture in a thickened rheumatic mitral valve leaflet.  Therefore, 
as part of this study, the preoperative, intraoperative, and postoperative patient data and 
ultrasound images from patients who have undergone mitral valve repair using the 
NeoChord were requested from NeoChord, Inc.  We had originally intended to correlate 
porcine ex vivo data with patient TEE data from the TACT trial.  However, patient data 
was not available from the study centres across Europe and a standard TEE protocol was 
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not employed at all TACT study centres.  Consequently, the requisite three-dimensional 
TEE volumes were not obtained for analysis. 
 Despite the limitations of this study, we were able to ascertain one potential influence on 
NeoChord suture dehiscence.  Although the location of NeoChord suture placement and 
tethering may not be the only contributor to suture dehiscence, careful consideration of 
this factor when placing NeoChord sutures may prevent suture dehiscence in mitral valve 
leaflets, particularly in patients more vulnerable to this unfortunate complication.  
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Chapter 5  
5 Augmented Reality System for Ultrasound Guidance of 
Transcatheter Aortic Valve Implantation 
Transcatheter aortic valve implantation (TAVI) relies on fluoroscopy and nephrotoxic 
contrast medium for valve deployment. We propose an alternative guidance system using 
augmented reality (AR) and transesophogeal echocardiography (TEE) to guide TAVI 
deployment. The goals of this study were to determine how consistently the aortic valve 
annulus is defined from TEE using different aortic valve landmarks, and to compare AR 
guidance to fluoroscopic guidance of TAVI deployment in an aortic root model.  We 
found that aortic valve commissures can be identified more reliably than cuspal nadirs 
from TEE.  Furthermore, the AR guidance system achieved similar deployment accuracy 
to fluoroscopy while eliminating the use and consequences of nephrotoxic contrast and 
radiation.   
____________________________________________________________________ 
This chapter is adapted from the following work: 
 McLeod AJ, Currie ME, Moore JT, et al. Phantom study of an ultrasound 
guidance system for transcatheter aortic valve implantation. Comput Med Imaging 
Graphics. 2014  Dec 15. 
 Currie ME, McLeod AJ, Moore JT, Chu MWA, Patel R, Kiaii B, Peters T.  
Augmented Reality System for Ultrasound Guidance of Transcatheter Aortic 
Valve Implantation.  Innovations (Phila). Accepted 2015.   
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My contribution to this chapter involved designing and conducting experiments and 
analyzing data.    
 
5.1 Introduction 
Transcatheter aortic valve implantation (TAVI) is a growing technology that provides an 
alternative surgical option for patients with severe aortic stenosis [1, 2]. Optimal 
positioning and safe deployment of TAVI valved-stent is integral to the success of the 
procedure.  Implantation of the valved-stent too far above the aortic valve annulus may 
result in its embolism or coronary occlusion by the valved-stent; whereas, positioning the 
valved-stent too far below the aortic valve annulus may cause atrioventricular block 
requiring a permanent pacemaker or retrograde embolization [3].  
Navigation and deployment of the valved-stent during TAVI relies largely on single-
plane fluoroscopy; however, this imaging modality has several limitations.  Fluoroscopic 
images are only able to display gross anatomic structures; therefore, to improve 
visualization, nephrotoxic contrast medium is required to obtain contrast-enhanced 
images.  However, the use of multiple contrast fluoroscopic images can increase a 
patient’s risk of acute kidney injury [4-7].  Many TAVI patients have underlying renal 
dysfunction and are therefore more vulnerable to acute kidney injury.  The reported 
incidence of acute kidney injury following TAVI is between 12 and 57% [4-5, 7-8].  One 
registry of TAVI patients reported that up to 6.7% of patients required acute hemodialysis 
was required in the post-procedural period [9].  Furthermore, the development of acute 
kidney injury is an independent predictor of prolonged hospital stay and impaired early 
survival following cardiac surgery [7, 10, 11].  In fact, one study reported an 11.7% 
incidence of acute kidney injury following TAVI and a greater than four-fold increase in 
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the risk of postoperative mortality among those patients [7].  Finally, fluoroscopic 
imaging exposes both patients and health care professionals to ionizing radiation.   
Transesophageal echocardiography (TEE) has been successfully employed as an 
alternative primary imaging modality for TAVI guidance, albeit in a limited number of 
centres.  However, TEE alone has limited resolution and does not provide satisfactory 
imaging of the TAVI catheter [12, 13].  Integrating AR with TEE would enable virtual 
representations of both the TAVI valved-stent and critical aortic valve anatomy to be 
registered to biplane TEE.  In fact, previous work using AR and TEE for beating heart 
mitral valve repair has found that simply defining the valve annuli from tracked TEE is 
sufficient for image guidance [14, 15]. This eliminates the need for complex preoperative 
models and registrations with associated errors [16, 17].   
We have adapted this AR and TEE guidance system for TAVI deployment.  The location 
of the magnetically tracked TAVI catheter and TEE in 3D space along with interactively 
defined aortic valve anatomy can be represented by virtual geometric models and 
overlaid onto real time TEE images, all within a common coordinate system.  This 
enables the surgeon to assess the accuracy and reliability of the geometric models as 
compared to the underlying real ultrasound image data.  Furthermore, augmenting the 
real-time TEE image data with virtual models of the critical anatomy required for 
accurate TAVI deployment may facilitate TAVI deployment that achieves similar 
deployment accuracy to the current standard of care, fluoroscopy, while eliminating the 
use of nephrotoxic contrast and ionizing radiation. The accuracy of TAVI deployment 
using this AR guidance system depends on the accuracy of the magnetic tracking system 
and on the accuracy of the location of the aortic valve annulus defined from TEE.   
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The goals of this study were to determine how consistently the aortic valve annulus is 
defined from TEE using different aortic valve landmarks, and to compare AR guidance to 
fluoroscopic guidance of TAVI valved-stent deployment in an aortic root model.    
5.2 Methods 
5.2.1 AR Guidance System Design 
This guidance system was designed to assist the surgeon to establish the correct location 
for deployment of the TAVI valved-stent within the aortic annulus without using 
fluoroscopy. To accomplish this goal, real-time TEE images were augmented with the 
location of the magnetically tracked valved-stent and intra-operatively defined aortic 
valve anatomy.  
Real-time tracking of the TEE and TAVI catheter was accomplished using the Aurora 
tabletop magnetic tracking system (Northern Digital, Waterloo, Ontario).  A six degree of 
freedom (DOF) magnetic tracking sensor was attached to the Ascendra TAVI catheter 
(Edwards Life Sciences, Irvine, California) and integrated into a custom made cap that 
attaches to the x7-2t TEE probe (Philips Healthcare, Andover, Massachusetts).  Virtual 
geometric models of the TEE probe and the TAVI valved-stent were created in VTK 
(Visualization Toolkit, Kitware Inc., Clifton Park, New York). The geometric 
representation of the TEE probe included video image planes that rendered real-time 
digital video capture of the TEE.  The tracked TEE probe was calibrated using a standard 
Z-bar calibration technique [18].  Once the valve was crimped on to the catheter, a 
calibration was performed using a custom-built tracked calibration block designed to hold 
the catheter shaft and valve in a precise configuration (Figure 5.1). This allowed the 
crimped prosthetic valve to be magnetically tracked. 
 
  
 
 
 
 
249 
 
Figure 5.1:  Calibration block for magnetic tracking of the transcatheter aortic 
valve on the catheter. 
5.2.2 Surgical Workflow 
Incorporation of this system into the operating room first involved identification of aortic 
valve landmarks from biplane TEE images.  Our intention is for this task to be completed 
by the echocardiographer during rapid pacing prior to advancement of the TAVI catheter.  
Rapid pacing is routinely performed at this point in the procedure to test the leads.  Based 
on the identification of clear aortic valve landmarks, virtual geometric models of the 
aortic annulus were displayed in the AR guidance system.  Using the location of aortic 
annulus models superimposed on the live biplane TEE, the surgeon determined the ideal 
valved-stent deployment depth relative to the aortic valve annulus.  The target 
deployment depth marks the ideal distance from an aortic valve landmark at which the 
leading edge of the valved-stent should be deployed.  During navigation of the valved-
stent to the target deployment depth or target depth, the remaining distance from the 
catheter to this plane was displayed numerically and the target plane changed color to 
indicate when the target deployment depth was reached (Figure 5.2).   
  
 
 
 
 
250 
 
Figure 5.2:  AR guidance system showing the catheter approach the target 
deployment depth (5.0 mm) marked by target plane.  As the catheter reaches the 
target deployment depth, the target plane changes from red to green. 
5.2.3 Localization of Aortic Valve Landmarks from Human Three 
Dimensional TEE Images 
Defining the aortic valve annulus can be challenging, and it is essential that the 
landmarks used to delineate the valve annulus be well defined with minimal variability in 
identification.  Aortic valve commissures and aortic valve cuspal nadirs were used as 
potential landmarks to define the aortic valve from TEE.  Commissures of the aortic 
valve are stationary hinge points; therefore, the guidance system may use these points to 
determine the ideal valved-stent deployment depth.  The nadirs of the aortic valve cusps 
have also been used as landmarks for determining the ideal fluoroscopic angle for TAVI 
deployment [19-25].  
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To assess the interoperator variability in identifying these landmarks, three subjects 
identified three commissures and three cuspal nadirs in ten full volume TEE images of 
the aortic root in diastole (Figure 5.3).  The images provided were consistent with 
standard intraoperative TEE imaging (Figure 5.4).  Furthermore, they provided a view 
similar to that of rapid pacing.  To assess intraoperator variability, a cardiac surgery 
resident repeated the identification of aortic valve landmarks on ten volumes five times, 
each on separate days. 
Feature localization error was calculated from the average overall standard deviation in 
commissure and nadir localization.  The standard deviation in commissure and nadir 
localization in the direction parallel to the aortic annular plane was used as the in plane 
error.  The standard deviation in commissure and nadir localization in the direction 
perpendicular to the aortic annular plane was used as the out of plane error.   
 
 
Figure 5.3: Human full volume cardiac images with aortic commissures labeled 
green and aortic cuspal nadirs labeled red.   
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Figure 5.4: Long and short axis views from all 10 volumes used for the 
intraoperator variability experiment. Image quality is typical for diagnostic 
volumes.  
5.2.4 Intraoperative Localization using Aortic Annulus Model 
To assess the intraoperator variability in identifying the aortic commissures during TAVI 
deployment, a single subject identified the three commissures from a live TEE image of 
an aortic root model.  This was repeated ten times by the same subject.  The Euclidean 
distance from mean location of each identified commissure was measured.  The feature 
localization error was calculated from the overall, in- plane, and out- of- plane standard 
deviation.   
5.2.5 TAVI Deployment with Fluoroscopic or AR guidance 
5.2.5.1 Aortic Root Model 
To compare AR guidance of TAVI valved-stent deployment to fluoroscopic guidance, a 
model of the aortic root was used.  This model consisted of a left ventricle, an atrial 
reservoir, a mitral valve, an aortic valve, and an actuator system. The ventricle had an 
apical access port for transapical TAVI. The model was constructed from soft silicone 
(Shore A 30 durometer).  Water was used to simulate blood, and the inner diameter 
across the aortic valve was 23 mm at the commissures.  Experiments were performed in a 
  
 
 
 
 
253 
static model to simulate rapid pacing (Figure 5.5).  A static model of the aortic root was 
chosen for this experiment in order to maintain consistent distances between anatomic 
landmarks and a consistent aortic valve diameter for each trial.  
 
 
Figure 5.5: Static silicone cardiac model with aortic and mitral valves.  Aortic valve 
(AV). 
5.2.5.2 Surrogate TAVI Stent 
As the balloon-inflated TAVI valved-stents are single use, a surrogate stent was used for 
the experiments, permitting a larger number of trials to be performed without consuming 
valuable valved-stents. The surrogate stent was made from an elastic material with 
radiopaque markers simulating the struts of the stent, and had a similar appearance in 
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both fluoroscopy and TEE to an actual valved-stent (Figure 5.6).  The surrogate stent was 
reused without significant wear and collapsed as soon as the balloon was deflated.  For 
this reason, all measurements were acquired while the balloon was still inflated.   
 
 
Figure 5.6:Transcatheter aortic valve (a) deployed using fluoroscopy (b).  Surrogate 
transcatheter aortic valve shown under fluoroscopy (c).   
5.2.5.3 Fluoroscopic TAVI Guidance 
A cardiac surgery resident deployed the surrogate TAVI valved-stent ten times in the 
aortic root model using each of the two guidance systems.   For conventional contrast-
enhanced fluoroscopic guidance, a qualitative target was used to guide the target 
deployment depth.  The subject strived to achieve a consistent deployment depth.   First, 
a guide wire was inserted through the apex and passed through the ventricle and aortic 
valve, terminating in the aortic reservoir. A pigtail catheter was deployed through the 
aortic reservoir and rested under one of the aortic cusps. The valved-stent delivery 
catheter was inserted onto the guidewire and into the left ventricle of the model. Prior to 
a     b                 c 
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each trial, contrast was injected into the aortic root so that the valve, including 
commissures and nadir were visible in the fluoroscopic image.  The valved-stent was 
positioned using fluoroscopic video so that it appeared that half the valved-stent lay on 
either side of the valve (Figure 5.6).  Before deployment, the pigtail catheter was 
withdrawn to ensure that it would not become caged by the valved-stent. As the current 
standard of care is to deploy the valved-stent using the fluoroscopy images qualitatively 
without any quantitative target, it is difficult to give an exact deployment error or location 
for ideal deployment. In this experiment, the user was instructed to strive to achieve 
consistent deployment in all ten trials.  
After each deployment, a camera assembly was positioned over the aortic root model to 
photograph the valved-stent inside the aorta from a fixed position. A reference 
checkerboard was mounted beside the aorta at the same depth as the two commissures 
visible from the camera’s position. The distance between the commissure plane and the 
furthest visible stent strut was measured from photographs acquired immediately after 
deployment (Figure 5.7).  The variability of target deployment depths gave an estimate of 
the minimum error achieved in fluoroscopic guidance. 
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Figure 5.7:Camera jig for measurement of true distance of deployed transcatheter 
aortic valve from the aortic valve commissures. 
5.2.5.4 AR TAVI Guidance 
For AR guidance of TAVI deployment, a target depth 5 mm beyond the commissural 
plane was used. As in fluoroscopy, a guidewire was passed through the aortic valve. The 
surrogate stent was placed on the modified valved-stent delivery catheter and the position 
of the stent was determined using the calibration block. After the delivery catheter was 
inserted into the left ventricle, all three aortic commissures were identified in the TEE 
image. The target plane was created 5 mm behind the commissural plane, and the valved-
stent was deployed at this location using the AR guidance system.  In practice, the target 
deployment depth would depend on the patient’s anatomy and the profile of the 
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prosthetic valved-stent to ensure the coronary ostia are not obstructed by the valved-stent. 
The aortic valve and stent calibration were repeated for each trial so that variability in 
these steps was included in the stent deployment.   
After each deployment, the camera was positioned over the aortic root model to 
photograph the stent as previously described for fluoroscopic guidance.  In addition to the 
photographic measurements, the target deployment depth reported by the AR system was 
also recorded. 
5.3 Results 
5.3.1 Comparison of Aortic Valve Commissure and Aortic Cuspal 
Nadir Localization Error  
Errors in localizing commissures and nadirs from full volume human cardiac TEE images 
were compared.  The error in feature-based localization was calculated using an unbiased 
estimate of variance of feature positions.  Feature localization error was reported for 
every image and for the entire dataset and was broken down into both the in-plane and 
out-of-plane directions.  In-plane errors indicate how difficult the feature was to localize 
on the valve plane.  Out-of-plane errors indicate difficulty in finding the depth of the 
valve.  While both errors contribute to deployment error, out-of-plane errors are more 
serious because achieving the correct depth is critical.   
In examining interoperator variability, we found that the overall error for commissure 
localization was 2.2 mm.  The errors in commissure and nadir localizations are shown in 
Table 5.1, where the in-plane commissure localization error was 1.4 mm, and the out-of-
plane commissure localization error was 1.7 mm.  The overall error for aortic valve 
cuspal nadir localization was 3.8 mm.  The nadir localization error was 3.4 mm in-plane, 
and 1.5 mm out-of-plane.  
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Table 5.1.   Interobserver feature localization error for each point.  Error was 
calculated using the standard deviation of commissure and nadir positions in full 
volume TEE cardiac images. 
 
Trial 1 2 3 4 5 6 7 8 9 10 
Overall 
Error 
Commissures 2.5 3.7 1.6 2.1 1.6 2.0 1.4 1.4 2.2 3.8 2.2 
     in-plane 1.9 3.2 0.8 1.4 1.1 0.7 0.9 0.8 1.3 1.7 1.4 
     out-of-plane 1.7 1.8 1.4 1.6 1.1 1.9 1.1 1.2 1.8 3.4 1.7 
Nadir 2.3 3.5 3.0 5.2 5.2 4.1 3.4 2.9 4.2 4.2 3.8 
     in-plane 2.0 3.4 2.9 4.8 5.0 3.6 3.0 2.7 2.9 4.0 3.4 
     out-of-plane 1.1 0.8 1.0 1.8 1.3 2.1 1.4 1.2 3.0 1.1 1.5 
For intra-operator variability, the overall error for commissure localization was 2.2 mm.    
The individual errors in commissure and nadir localizations are shown in Table 5.2.  The 
in-plane commissure localization and out-of-plane commissure localization errors were 
1.2 mm and 1.9 mm respectively.  The overall error for aortic valve cuspal nadir 
localization was 4.7 mm, with in-plane nadir and out of plane errors being 4.2 mm and 
2.1 mm respectively. The largest error of 3.8 mm for commissures and 8.2 mm for nadir 
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occurred in image two, which had the worst image quality in the dataset. 
 
 
 
Table 5.2.   Intraobserver feature localization error for each point.  Error was 
calculated using of the standard deviation of commissure and nadir positions in full 
volume TEE cardiac images. 
 
Trial 1 2 3 4 5 6 7 8 9 10 
Overall 
Error 
Commissures 1.4 3.8 2.3 1.7 2.6 1.9 1.9 1.3 2.3 2.1 2.2 
     in-plane 0.8 2.1 0.9 1.2 1.0 0.7 0.7 0.9 0.9 1.8 1.2 
     out-of-plane 1.1 3.2 2.1 1.2 2.4 1.8 1.8 1.0 2.1 1.0 1.9 
Nadir 2.8 8.2 2.6 5.4 5.6 3.7 3.8 3.2 4.7 3.7 4.7 
     in-plane 2.6 6.5 2.5 5.0 5.4 3.3 3.6 3.1 4.2 3.6 4.2 
     out-of-plane 0.9 5.0 0.8 2.0 1.3 1.8 1.2 0.9 2.3 0.8 2.1 
 
5.3.2 Localization of Aortic Valve Commissures from Live TEE 
Biplane Images in an Aortic Root Model 
To examine the intraoperator localization error for identification of aortic valve 
commissures during the TAVI procedure, live biplane TEE images of the aortic root 
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model were used.  Only commissures were considered for this experiment, as their 
localization was more consistent. The overall commissure localization error was 2.0 mm.  
Both the in-plane and out-of-plane commissure localization errors were 1.4 mm.  The 
individual errors in commissure localizations are shown in Figure 5.8.         
  
Figure 5.8:  Short (left) and long (right) axis views of the ten live biplane definitions 
of the aortic valve. 
5.3.3 TAVI deployment with Fluoroscopic or AR guidance 
The TAVI deployment depths using either fluoroscopic or AR guidance systems are 
shown in Table 5.3.  Fluoroscopic guidance of TAVI deployment achieved an average 
deployment depth of 6.3  3.4 mm (mean  standard deviation) for ten deployment trials.     
AR guidance of TAVI deployment resulted in a deployment depth of 7.0  2.9 mm as 
recorded by the photographic measurements, while the AR system reported a mean 
deployment depth of 5.03  0.03 mm. Therefore, the stent was deployed an average 2 
mm beyond the target depth displayed by the AR guidance system (5.0 mm).  The 
variability in deployment depth was 2.9 mm. The root mean square (RMS) error of 
deployment using AR guidance was 3.4 mm.  This error takes into account the variability 
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in both the deployment depth and the distance from the intended target, A comparison of 
deployment depths using either AR or fluoroscopic guidance is shown in Figure 5.8.   
The overlapping lines showing standard deviation reveal that both methods have a 
comparable accuracy in deployment depth.  In addition, the standard deviation of 
deployment was slightly smaller using the AR guidance system indicating improved 
precision of deployment.  Therefore, our proposed AR guidance system may achieve 
similar or better results than contrast enhanced fluoroscopy while eliminating the use of 
nephrotoxic contrast and ionizing radiation.   
 
 
Figure 5.9: Mean distance of the transcatheter aortic valve from the commissures 
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following deployment with either fluoroscopic or AR guidance. 
The TAVI deployment depths using either fluoroscopic or AR guidance systems are 
shown in both Table 5.3 and Figure 5.9.  Fluoroscopic guidance of TAVI deployment 
achieved an average deployment depth of 6.3  3.4 mm for ten deployment trials while 
the AR guidance of TAVI deployment resulted in a deployment depth of 7.0  2.9 mm.  
While the AR guidance system had slightly better precision in our experiments this 
difference was not statistically significant. As fluoroscopic deployment was performed 
using live video without a quantitative target, only the precision could be assessed of this 
guidance system could be assessed. However, the AR guidance system had a specified 
target at 5 mm superior to the AV annulus. The RMS error of deployment using AR 
guidance was 3.4 mm. This error measures the overall accuracy of the system and takes 
into account both precision and bias in deployment depths. These results suggest that the 
errors associated with using AR guidance are within the variability in deployment depth 
that occurs with conventional contrast enhanced fluoroscopy. 
Table 5.3.   Deployment depths (distance from commissures to leading edge of TAVI 
valved-stent) achieved using each of the guidance systems.  The overall mean and 
standard deviation (SD) of the deployment depths are summarized in the last 
column. The differences in the mean and variance of the deployment depth were not 
statistically significant. 
Trial 1 2 3 4 5 6 7 8 9 10 Overall 
Mean (SD) 
Fluoroscopy 7.0 1.3 0.6 6.0 9.3 11.1 7.3 9.4 6.0 4.9 6.3 (2.5) 
AR 9.8 7.8 3.0 7.7 6.8 6.6 7.9 10.0 9.2 0.8 7.0 (2.1) 
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The actual deployment of the TAVI valve under both fluoroscopic and AR guidance was 
very fast, taking approximately a minute to complete under both guidance platforms. The 
TAVI procedure did require a more elaborate setup including, calibrating the TAVI valve 
and starting the guidance software. In addition, the valve commissures were manually 
defined from TEE before each deployment. While this would be performed before the 
TAVI catheter enters the heart, it may contribute slightly to longer procedure time. We 
observed a median time between trials of 8 minutes for the fluoroscopic guidance and 18 
minutes for the AR system. This time included everything from resetting the experiments 
to taking photographs for measuring valve position. The extra 10 minutes required for the 
AR system were mostly due to the more elaborate setup required. In a clinical context, an 
extra 10 minutes of preparation in the OR before the procedure would not impede current 
workflow. 
 
5.4 Discussion 
Adequate and safe deployment of TAVI valved-stents is integral to the success of the 
procedure. The 2013 Society of Thoracic Surgeons Guidelines recommends 
intraoperative fluoroscopy as the standard of care for guidance of TAVI deployment [21].  
However, fluoroscopy necessitates the use of nephrotoxic contrast medium, which is of 
concern in the TAVI patient cohort, as many are elderly, high-risk surgical patients with 
underlying renal dysfunction.  The incidence of acute kidney injury following TAVI is 
reported as high as over 50% [4-5, 7-8].  Furthermore, the development of acute kidney 
injury is an independent predictor of postoperative mortality [7]. 
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This study presents a TEE and AR guidance system for TAVI placement to visualize both 
the TAVI valved-stent and the critical aortic anatomy without exposure to contrast 
medium and ionizing radiation.   
There have been several alternatives to single plane fluoroscopy that aim to improve 
valved-stent placement and reduce or eliminate the use of nephrotoxic contrast and 
ionizing radiation, including rotational angiography, magnetic resonance imaging (MRI), 
and TEE guidance. 
In rotational angiography, an intraoperative cone beam computer tomography (CT) 
volume is acquired by rotating the C-arm around the patient during rapid ventricular 
pacing.  This reduces the amount of contrast delivered and also minimizes motion 
artifacts. Subsequently, the image volume generated can be superimposed on the real-
time fluoroscopic image to provide more anatomical context for aortic valved-stent 
implantation and to select the ideal fluoroscopic imaging plane.   The optimal C-arm 
angle for TAVI deployment occurs when the nadir of all three aortic cusps are aligned, 
suggesting the aortic root is perpendicular to the imaging beam [19-25].  It has previously 
been shown that use of an optimal C-arm angle for TAVI deployment is associated with 
decreased rates of postprocedural paravalvular leak and reduces the number of contrast 
enhanced images [16].  Nevertheless, this image guidance technique employs 
fluoroscopic guidance that exposes the patient to both nephrotoxic contrast medium and 
ionizing radiation.  Increased use of contrast medium results in increased risk of renal 
dysfunction [4-6]. 
Other investigators have used intraoperative MRI to guide placement of the valved-stent, 
resulting in successful implantation in animal studies [27].  Although this technique 
eliminates radiation and contrast medium exposure to the patients, such intraoperative 3D 
imaging is not widely available and is very expensive [28]. 
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In comparison to cone-beam CT and MRI based imaging systems, TEE provides a more 
attractive modality for image guidance and does not require nephrotoxic contrast agents 
or ionizing radiation.  In addition, TEE is already an integral part of the pre-, intra-, and 
postoperative valve assessment in both conventional aortic valve surgery and TAVI [29, 
30].  Investigators have previously proposed the use of three dimensional (3D) TEE for 
TAVI guidance; however, visualization of both the aortic valve and TAVI valved-stent 
would not be possible given the limited spatial and temporal resolution of 3D TEE [30, 
31].  Intraoperative guidance using only TEE and TEE with fluoroscopy but without 
contrast agents has been previously reported [12, 13].  However, TEE does not provide 
satisfactory imaging of the catheter or surrounding tissue due to the highly reflective 
surface of the catheter and resulting shadowing artifacts [12, 13].  For this reason, TEE 
has been proposed as a bridging modality allowing preoperative models to be registered 
into the intraoperative environment.  Lang et al. [3], proposed using TEE to register 
preoperative CT models to fluoroscopy to improve image guidance without requiring 
rotational angiography. Luo et al. [17] proposed a system using magnetic tracking of the 
TEE and catheter to eliminate the need for fluoroscopy entirely.  In this system, a 
preoperative model of the aortic root was registered to the tracked TEE.  The tracked 
catheter could then be visualized in relation to the aortic model so that the valved-stent 
could be deployed at the desired depth.  One challenge of these techniques is that the 
registration between TEE and preoperative CT is difficult resulting in a target registration 
error of 5.9 ± 3.2 mm and 3.3 ± 1.6 mm, respectively. In addition, both of these methods 
used a manual segmentation of the aorta from preoperative CT which is time consuming 
and difficult to integrate into clinical workflow.  
We have also used magnetic tracking systems to display both real-time TEE data with 
virtual representations of the cardiovascular anatomy and surgical tools in an AR 
guidance system.  Through the use of this guidance system for mitral valve repair, we 
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found that simply defining the valve annuli from tracked TEE was sufficient for image 
guidance and eliminated the need for complex preoperative models and registrations with 
associated errors [14, 15].  Using this guidance system, the surgeon can easily and 
intuitively identify the tool, surgical targets, and high-risk areas.  
The accuracy of TAVI deployment using this AR guidance system depends on the 
accuracy of the magnetic tracking system and on the accuracy of the location of the aortic 
valve annulus defined from TEE.  The latter depends on the operator’s ability to 
consistently identify aortic valve landmarks.  The first objective of this study was to 
determine how consistently the aortic valve annulus could be defined from either full 
volume TEE images or live biplane TEE images. We have shown that the aortic valve 
commissures can be identified more reliably than aortic valve cuspal nadirs from 3D full 
volume TEE images obtained from patients with aortic valve stenosis.  Furthermore, 
there was a low variability in the identification of aortic valve commissures from an 
aortic valve root model intraoperatively.   
The second objective of this study was to compare the accuracy of TAVI deployment 
using an AR guidance system to the accuracy of the current standard of care, fluoroscopy. 
In fluoroscopy, the error in deployment is generally determined by the visual appearance 
of the valve and its location with respect to gross anatomic structures.  New fluoroscopic 
based image guidance systems with CT image overlays report the error in overlay 
between their own model and real time fluoroscopy. While not the same as a true 
targeting error, these studies provide a baseline for clinically acceptable errors.  For 
example, the error in overlay of DynaCT on real-time fluoroscopy has been reported 
between 1.9±1.5 mm and 3.9±3.1 mm [16, 32].  Generally, errors in positioning less than 
5 mm are clinically accepted.   
We have shown that this guidance system may achieve similar or better deployment 
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results than contrast enhanced fluoroscopy while eliminating the use of nephrotoxic 
contrast and ionizing radiation.  In the aortic root model study, the errors reported by the 
guidance system were very low, with a standard deviation of 2.9 mm from the desired 
deployment location indicating that good valved-stent positioning could be achieved 
using the AR system.   
This AR guidance system for TAVI can be easily integrated into the operating room. The 
portable magnetic field generator is designed to fit on top of an operating room table and 
to work effectively in the presence of various metals.  The customized cap with magnetic 
sensors for the TEE probe has been approved for use in humans by Health Canada.  
Addition of single use magnetic sensors to the deployment catheter for TAVI valves 
should not impede the usual operative flow due to their small size.  Furthermore, the cost 
associated with this technology is not prohibitive for most institutions.  The magnetic 
tracking system retails for approximately $18 000 USD and each single use sensor is 
$250 USD [3].  This is less than the infrastructure costs of most currently available 
intraoperative image guidance systems including Dyna CT, MRI and hybrid operating 
rooms. 
The first limitation of this study was the use of a single TAVI catheter model for 
transapical deployment only.  We plan to expand this system to include the use of 
additional transcatheter TAVI models.   
The second limitation of this study is that it may not be applicable to the use of local 
anesthesia for transcatheter valve implantation.  Studies have reported the use of sedation 
and local anesthetic for transfemoral aortic valve implantation in patients who are 
considered too high risk for a general anesthetic.  Nonrandomized trials have shown 
several potential benefits of this approach including less patient hemodynamic instability, 
shorter procedure duration and shorter stay in hospital compared to patients who 
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underwent general anesthesia [33-35].  TEE may be used for TAVI with conscious 
sedation and local anesthetic [36-37]; however, TEE was not used in most studies 
reporting the benefits of TAVI under local anesthetic due to its potential for increased 
nociceptive stimulation [34, 37]. 
The third limitation of this study is the use of a rigidly defined aortic annulus from an 
aortic root model at the time of the procedure.  Uniformity in anatomic landmarks and 
distances was particularly important for this trial because these distances were used to 
determine localization errors associated with the guidance system, while eliminating 
errors that may be associated with variation in anatomic features between hearts if an 
animal model were used.  However, in the future, we hope to integrate real-time updates 
on the location of the aortic valve annulus using feature-based registration in a beating 
heart animal model.  Further animal trials will be necessary to evaluate the safety and 
efficacy of this device prior to its implementation in the cardiac surgery operating room.     
In conclusion, this study reveals that aortic valve commissures can be identified more 
reliably than aortic valve cuspal nadirs from TEE images and that our proposed AR 
guidance system may achieve similar or better results than contrast enhanced fluoroscopy 
while eliminating the use of nephrotoxic contrast and ionizing radiation.   
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Chapter 6  
6 Closing Remarks 
Both mitral valve regurgitation and aortic valve stenosis are increasing in prevalence.  In 
fact, they are the most common valvular heart diseases in the world [1-4].  Mitral valve 
repair and aortic valve replacement are the main surgical options for mitral valve 
regurgitation and aortic valve stenosis, respectively. Both mitral valve repair and aortic 
valve replacement demonstrate excellent outcomes [5-14].  
However, despite these favorable outcomes, many elderly patients with indications for 
valve surgery receive no operation [15-16].  Patients are either not referred for surgery or 
denied surgery due to the perceived risk of conventional valve surgery involving median 
sternotomy for surgical access and cardiopulmonary bypass for exposure of the surgical 
site [15-16].  Both procedures are associated with risk of longer recovery periods, which 
may not be as well tolerated in elderly patients with multiple co-morbidities.  
Consequently, new cardiovascular techniques must be tailored to address the unique 
requirements of high risk, elderly, surgical patients with heart valve disease.  These 
techniques must overcome the two main challenges of conventional cardiac surgery:  
sternotomy incision for surgical access and cardiopulmonary bypass for exposure of the 
surgical site.   
6.1 Robotics-assisted minimally invasive mitral valve 
repair and challenges 
Minimally invasive cardiac surgery encompasses a spectrum of new operative techniques 
that aim to minimize surgical trauma by avoiding sternotomy and reducing incision size 
[3].  These smaller incisions require advanced visualization systems and customized 
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instruments for surgery, but the surgery is dependent on cardiopulmonary bypass.    
Simultaneous advances in biomedical engineering have facilitated the use of minimally 
invasive access for mitral valve repair.  Furthermore, favorable outcomes of patients 
undergoing minimally invasive techniques, including robotics-assisted mitral valve 
repair, have been reported.  For example, reduced mortality in high risk patients, reduced 
blood loss, reduced need for reoperation for bleeding, reduced pain, reduced ventilation 
time, improved postoperative respiratory function, decreased patients post operative stay 
in hospital and ICU, more rapid return to functional activity, increased levels of 
satisfaction, reduction in health care costs [17-21].   
However, robotics-assisted mitral valve repair does have unique challenges.  In 
conventional or open surgery, sensory input is derived from both vision and haptic 
feedback [22, 23].  For a complete depiction of haptic interactions between surgical 
instruments and tissue kinesthetic, tactile, and proprioception feedback must be acquired 
[24-26].  The currently used minimally invasive surgical robotic system, the da Vinci 
from Intuitive Surgical Inc., was developed with a very high quality three-dimensional 
(3D) stereoscopic visualization system to enhance the performance of robotics-assisted 
surgical procedures [27-29].  However, the master-slave configuration and the absence of 
haptic feedback of the da Vinci system prevent the transmission of tool-tissue interaction 
forces to the surgeon [3].  This may be particularly deleterious in dexterous fine 
movements such as intracorporeal suturing and knot tying, which require accurate control 
of applied forces and instrument positions. Without haptic feedback, excessive forces 
may be applied to tissue leading to increased trauma and damage to tissue [3, 24]. This 
could be particularly important in robotics-assisted mitral valve repair, which requires 
fine motor skills to suture an annuloplasty band to the cardiac tissue along the mitral 
valve annulus.  Without tactile and force information, surgeons must rely on visual cues 
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to estimate the force being applied [22-24, 30].  
In addition to absence of haptic feedback, robotic-assisted minimally invasive techniques 
are technically more challenging and report steep learning curves of surgeons [31, 32].  
Furthermore, compared to conventional surgery, minimally invasive surgeries have more 
prolonged cardiopulmonary bypass, cross-clamp and operative times [33-35].   
To address these challenges, we propose that improved training methods and reduced 
operative time in robotics-assisted minimally invasive procedures can potentially be 
achieved by improving sensory input from both visualization and tissue manipulation 
with the addition of force feedback.  We also propose the examination and development 
of an enhanced imaging modality that can provide superior tool guidance for the 
performance of robotics-assisted minimally invasive techniques for beating heart surgery. 
With this enhanced modality, avoidance of cardiopulmonary bypass and aortic cross-
clamping can potentially be achieved and improved patient safety and outcomes can be 
attained during robotics-assisted minimally invasive beating heart surgery.  
6.2 3D Visualization  
Firstly, we examined the effect of three-dimensional visualization on the amount of force 
applied to mitral valve tissue and the time to perform ex vivo mitral valve annuloplasty 
using robotics-assisted and conventional techniques.  In addition, we determined whether 
these effects are consistent between novices and experts in robotics-assisted cardiac 
surgery.  Finally, to add further clinical relevance, we compared these results with those 
of conventional open mitral valve annuloplasty to examine differences in forces applied 
and times required to complete surgical tasks between robotics-assisted and conventional 
open surgery. 
This study demonstrated that although 3D visualization may provide more information 
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regarding object depth to facilitate complex tissue grasping, 3D visualization may not 
provide adequate visual cues to reflect the force applied to cardiac tissue. Despite high 
quality binocular images, both experts and novices applied significantly more force to 
cardiac tissue during 3D robotics-assisted mitral valve annuloplasty than during 
conventional open mitral valve annuloplasty.   The highest forces applied by experts were 
still less than the force required to inflict any damage on the cardiac tissue; however, 
novices applied potentially damaging force to the cardiac tissue using robotics-assisted 
techniques.  This finding suggests that 3D visualization does not fully compensate for the 
absence of haptic feedback in robotics-assisted cardiac surgery, particularly for novices.   
Furthermore, these findings imply that haptic feedback may be required to achieve better 
control of the interaction forces on cardiac tissue.  
6.3 Force feedback  
Secondly, our objective was to determine the effects of force feedback on the amount of 
force applied to cardiac tissue during robotics-assisted cardiac surgery and to determine if 
these effects are consistent between novices and experts in robotics-assisted cardiac 
surgery. Our results show that consistently less force was applied to cardiac tissue when 
all modes of force feedback were used.  In particular, the use of direct force feedback 
during robotics-assisted mitral valve annuloplasty resulted in a greater decrease in forces 
applied to cardiac tissue when compared to visual force feedback alone.  There was no 
significant difference in the amount of force applied to mitral valve tissue between 
experts and novices.  Therefore, in order to achieve better control of interaction forces on 
cardiac tissue during robotics-assisted mitral valve annuloplasty, direct or visual force 
feedback may be required.   
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6.4 NeoNav: An Augmented Reality Guidance System  
Thirdly, we evaluated the use of an augmented reality (AR) guidance system for 
minimally invasive beating heart surgery. This is an emerging field of transcatheter mitral 
valve repair that avoids the risks of cardiopulmonary bypass and cross-clamp used in 
conventional surgery, and it potentially offers hopes of beating heart mitral valve 
reconstruction. However, concerns relating to the navigation of the tool from the apex to 
the target mitral valve leaflet have been raised. 
The NeoChord DS-1000 (NeoChord, Minnetonka, MN) is a device capable of performing 
off-pump, mitral valve repair for certain forms of degenerative mitral valve disease [36]. 
Currently, this procedure relies exclusively on transesophageal echocardiography (TEE) 
guidance.  Due to the navigational challenges of TEE, the tool can be caught in the  
 
subvalvar apparatus risking chordal rupture or leaflet perforation [37, 38].  Current 
clinical practice involves the use of highly trained surgical proctors who are expert in the 
use of this device.   
To improve the overall safety of the navigation process in the NeoChord procedure, we 
have evaluated the efficacy of employing an AR technique capable of providing a robust 
3D context for TEE image data.  In this real-time environment, the surgeon can easily 
and intuitively identify the tool, surgical targets, and high-risk areas, and view tool 
trajectories and orientations. 
6.5 AR Guidance for Transcatheter Aortic Valve 
Implantation  
Finally, we designed a study to determine how consistently the aortic valve annulus is 
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defined from TEE using different aortic valve landmarks, and to compare AR guidance to 
fluoroscopic guidance of transcatheter aortic valve implantation (TAVI) deployment in 
an aortic root model.  TAVI is a growing technology that provides an alternative surgical 
option for patients with aortic stenosis.  Navigation and deployment of the valve during 
TAVI relies largely on single-plane fluoroscopy, which has several limitations [38].   
We have adapted the NeoNav guidance system for TAVI deployment to achieve similar 
deployment accuracy to the current standard of care, while eliminating the use of 
nephrotoxic contrast and ionizing radiation used in fluoroscopy.  TEE is essential for 
accessing valve function in both conventional aortic valve surgery and TAVI.       
Through the use of the AR guidance system, we simply defined the valve annulus from 
tracked TEE for image guidance and eliminated the need for complex preoperative 
models and registrations with associated errors.  Using this guidance system, the surgeon 
can easily and intuitively identify the tool, surgical targets, and high-risk areas.  We have 
shown that the aortic valve commissures can be identified more reliably than aortic valve 
leaflet nadirs from 3D full volume TEE images obtained from patients with aortic valve 
stenosis.  Furthermore, there was a low variability in the identification of aortic valve 
commissures from an aortic valve root model intraoperatively.   In the aortic root model 
study, the errors reported by the guidance system were very low. 
In conclusion, the following findings are the results of our primary objectives to evaluate 
the usefulness of three-dimensional visualization, force feedback, and AR technologies to 
surgeons as they are applied in a clinical settings:   
   We determined that although 3D visualization may provide more information 
regarding object depth to facilitate complex tissue grasping during robotics-assisted 
minimially invasive surgery, 3D visualization may not provide adequate visual cues 
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to reflect the force applied to cardiac tissue.  This suggests that 3D visualization does 
not fully compensate for the absence of haptic feedback in robotics-assisted cardiac 
surgery. 
  We determined that novices applied potentially damaging force to the cardiac tissue 
using robotics-assisted techniques; and, therefore, we propose that a simulation 
system providing force feedback may improve both expert and trainee performance 
using robotics-assisted techniques.  
   We learned that the addition of either direct or visual force feedback significantly 
decreased the amount of force applied to cardiac tissue during robotics-assisted mitral 
valve annuloplasty. 
   We presented NeoNav, AR-enhanced echocardiograpy intracardiac navigation for the 
NeoChord off pump mitral valve repair procedure.  Using ultrasound guidance alone 
compared to AR navigation, six cardiac surgeons used the NeoChord device to 
navigate the tool from entry at the apex of the heart to a point at the line of coaptation 
in the MV.  Tracked path results clearly show improved safety and time using AR 
navigation. 
 We proposed our NeoNav integrated AR and TEE as a safe and inexpensive 
alternative imaging modality for TAVI guidance.  Through the use of the NeoNav 
guidance system for mitral valve repair, we simply defined the valve annuli from 
tracked TEE for image guidance and eliminated the need for complex preoperative 
models and registrations with associated errors.  Using this guidance system, the 
surgeon can easily and intuitively identify the tool, surgical targets, and high-risk 
areas.   
6.6 Future Directions 
With a rapidly expanding elderly population, the complexity of cardiac surgery continues 
  
 
 
 
 
282 
to evolve.  Innovative strategies to treat pathology and also improve quality of life in this 
high risk population are in high demand.  Minimally invasive and beating heart surgery 
provide both improved postoperative morbidity and quality of life; however, they are 
technically demanding and require additional surgical training and expertise.  Therefore, 
these techniques are limited to few centres with specialized cardiac surgeons.  This thesis 
has proposed innovative strategies to make these technologies more facile and safe.  
Hopefully, these force feedback and AR guidance systems will be utilized by cardiac 
surgeons so that robotics-assisted and beating heart mitral valve repair may be available 
to a broader population.  Furthermore, the use of both force feedback and AR guidance 
may be applied to additional minimally invasive techniques in cardiac surgery including 
the MitraClip and other beating heart valve procedures in development.   
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